filename,arm_name,intervention_type,screening_window,1_month,3_months,6_months,9_months,12_months,core_treatment_screening_window,core_treatment_1_month,core_treatment_3_months,core_treatment_6_months,core_treatment_9_months,core_treatment_12_months,imaging_diagnostics_screening_window,imaging_diagnostics_1_month,imaging_diagnostics_3_months,imaging_diagnostics_6_months,imaging_diagnostics_9_months,imaging_diagnostics_12_months,labs_screening_window,labs_1_month,labs_3_months,labs_6_months,labs_9_months,labs_12_months,clinic_visits_screening_window,clinic_visits_1_month,clinic_visits_3_months,clinic_visits_6_months,clinic_visits_9_months,clinic_visits_12_months,cycle_length_days,treatment_duration_rule,visit_pattern,assumptions
30516102,Arm A: Trastuzumab emtansine,intervention,1,2,6,11,16,21,0,2,5,9,13,14,1,0,1,2,3,6,0,0,0,0,0,0,0,0,0,0,0,1,21,"14 cycles, followed by long-term follow-up until Year 10 from randomization.","1 screening day. Treatment consists of 14 cycles, each 21 days long. Day 1 of each cycle involves drug administration and general assessments. ECHO/MUGA is performed during Day 14-21 of Cycles 2, 6, 10, and 14. A Study Drug Completion Visit (SDCV) occurs approximately 30 days after the last treatment dose. Follow-up includes disease status assessments and ECHO/MUGA at specified intervals.","All screening assessments (informed consent, patient numbers, tumor tissue submission, medical history, physical exam, height, vital signs, ECOG, concomitant meds, AE reporting, 12-lead ECG, ECHO/MUGA, HBV/HCV serology, hematology, biochemistry, INR/aPTT, pregnancy test, bilateral mammogram, PRO) are consolidated into 1 contact day during the screening window (Day -28 to Day -1). The highest priority procedure on this day is 'imaging_diagnostics' due to tumor tissue submission, ECG, ECHO/MUGA, and mammogram.; PK/ATA samples (detailed in Appendix 2) are considered optional for individual patients based on footnote 'a' in Appendix 2 and 'u' in Appendix 1, and thus do not add mandatory contact days.; Radiotherapy and hormonal therapy are considered standard of care treatments, not trial-mandated visits for all patients, and are therefore excluded from contact day counts.; Disease status assessments (footnote 'f') in the follow-up period, when not coinciding with a higher-priority procedure, are counted as in-person 'clinic_visits'.; The Study Drug Completion Visit (SDCV) is assumed to occur on Day 303 (Day 273 + 30 days).; The follow-up Disease Status assessment (Day 360) and the 12-month follow-up ECHO/MUGA (Day 365) are counted as distinct in-person days, as no explicit instruction for consolidation was provided for visits on different nominal dates.; For days with multiple procedures, the highest priority category is assigned: core_treatment > imaging_diagnostics > labs > clinic_visits."
30516102,Arm B: Trastuzumab,control,1,2,6,11,16,21,0,2,5,9,13,14,1,0,1,2,3,6,0,0,0,0,0,0,0,0,0,0,0,1,21,"14 cycles, followed by long-term follow-up until Year 10 from randomization.","1 screening day. Treatment consists of 14 cycles, each 21 days long. Day 1 of each cycle involves drug administration and general assessments. ECHO/MUGA is performed during Day 14-21 of Cycles 2, 6, 10, and 14. A Study Drug Completion Visit (SDCV) occurs approximately 30 days after the last treatment dose. Follow-up includes disease status assessments and ECHO/MUGA at specified intervals.","All screening assessments (informed consent, patient numbers, tumor tissue submission, medical history, physical exam, height, vital signs, ECOG, concomitant meds, AE reporting, 12-lead ECG, ECHO/MUGA, HBV/HCV serology, hematology, biochemistry, INR/aPTT, pregnancy test, bilateral mammogram, PRO) are consolidated into 1 contact day during the screening window (Day -28 to Day -1). The highest priority procedure on this day is 'imaging_diagnostics' due to tumor tissue submission, ECG, ECHO/MUGA, and mammogram.; PK/ATA samples (detailed in Appendix 2) are considered optional for individual patients based on footnote 'a' in Appendix 2 and 'u' in Appendix 1, and thus do not add mandatory contact days.; Radiotherapy and hormonal therapy are considered standard of care treatments, not trial-mandated visits for all patients, and are therefore excluded from contact day counts.; Disease status assessments (footnote 'f') in the follow-up period, when not coinciding with a higher-priority procedure, are counted as in-person 'clinic_visits'.; The Study Drug Completion Visit (SDCV) is assumed to occur on Day 303 (Day 273 + 30 days).; The follow-up Disease Status assessment (Day 360) and the 12-month follow-up ECHO/MUGA (Day 365) are counted as distinct in-person days, as no explicit instruction for consolidation was provided for visits on different nominal dates.; For days with multiple procedures, the highest priority category is assigned: core_treatment > imaging_diagnostics > labs > clinic_visits."
35660812,Arm A: Conventional dose treatment (RVD) followed by lenalidomide maintenance,intervention,1,7,15,30,41,48,0,7,15,30,35,35,1,0,0,0,0,0,0,0,0,0,6,13,0,0,0,0,0,0,21,until disease progression,"Screening (Day -28). Initial RVD (C1-C3): Day 0, 4, 8, 11 per 21-day cycle. PBSC Mobilization (Cyclophosphamide IV: 1 day, PBSC Collection: 2 days) after C3. Consolidation RVD (C4-C8): Day 1, 4, 8, 11 per 21-day cycle. Maintenance Lenalidomide: weekly for 2 months, then bi-weekly for 2 months, then monthly until progression.","Screening is assumed to be a single day (Day -28).; PBSC collection (apheresis) is assumed to be 2 days, as it is a significant interventional procedure.; Lenalidomide maintenance visits for labs (Hematology, Serum Chemistry, Pregnancy Test, M-protein quantification, 24hr urine, FreeLite Testing) are based on the most frequent schedule mentioned in Note 3 (page 225): weekly for the first 2 months, then bi-weekly for the next 2 months, then monthly thereafter. This schedule dictates the contact days for maintenance.; Filgrastim/G-CSF administration is assumed to be self-administered, and only monitoring visits for blood counts (already covered by lab schedule) are considered contact days.; Oral medications (Lenalidomide, Dexamethasone) are assumed to be self-administered at home and do not count as contact days unless explicitly tied to an in-person visit for dispensing or monitoring.; QOL/Pharmacoeconomic assessments are considered clinic_visits."
35660812,"Arm B: RVD plus high-dose treatment with peripheral stem cell transplant (PBSCT), also followed by lenalidomide maintenance",intervention,1,7,18,31,42,46,0,7,18,25,26,26,1,0,0,0,0,0,0,0,0,0,10,14,0,0,0,6,6,6,21,until disease progression,"Screening (Day -28). Initial RVD (C1-C3): Day 0, 4, 8, 11 per 21-day cycle. PBSC Mobilization (Cyclophosphamide IV: 1 day, PBSC Collection: 2 days) after C3. PBSC Transplant (Melphalan: 2 days, Reinfusion: 1 day, Inpatient monitoring: 5 days). Consolidation RVD (C4-C5): Day 1, 4, 8, 11 per 21-day cycle. Maintenance Lenalidomide: weekly for 2 months, then bi-weekly for 2 months, then monthly until progression.","Screening is assumed to be a single day (Day -28).; PBSC collection (apheresis) is assumed to be 2 days, as it is a significant interventional procedure.; Melphalan conditioning is assumed to be 2 days (Day -2 and Day -1 relative to transplant Day 0).; PBSC reinfusion is assumed to be 1 day (Day 0).; The 'Inpatient PBSCT Period' is assumed to cover Day +1 to Day +5 (5 days) for post-reinfusion monitoring and supportive care, classified as clinic_visits.; Lenalidomide maintenance visits for labs (Hematology, Serum Chemistry, Pregnancy Test, M-protein quantification, 24hr urine, FreeLite Testing) are based on the most frequent schedule mentioned in Note 3 (page 225): weekly for the first 2 months, then bi-weekly for the next 2 months, then monthly thereafter. This schedule dictates the contact days for maintenance.; Filgrastim/G-CSF administration is assumed to be self-administered, and only monitoring visits for blood counts (already covered by lab schedule) are considered contact days.; Oral medications (Lenalidomide, Dexamethasone) are assumed to be self-administered at home and do not count as contact days unless explicitly tied to an in-person visit for dispensing or monitoring.; QOL/Pharmacoeconomic assessments are considered clinic_visits."
35704479,Active Monitoring Arm,control,1,1,1,2,2,3,0,0,0,0,0,0,1,1,1,2,2,3,0,0,0,0,0,0,0,0,0,0,0,0,,up to 5 years after enrollment,"Screening (Visit 0), Randomization/Baseline (Visit 1, Day 0), then regular 6-month follow-up visits (Visits 2, 3, etc.)","Information Visit is not a separate contact day; if screening procedures are performed, they are considered part of Visit 0.; Visit 0 (Screening) and Visit 1 (Randomization/Day 0) are always distinct in-person contact days.; For the Active Monitoring arm, anal biopsies are performed at Visit 0, Visit 1, and then annually (Visit 3, 5, 7, 9, 11). Visit 2 does not include a biopsy.; HIV viral load and CD4 count results are generally assumed to be obtained from routine medical care and not to require a separate study contact day, except for venipuncture at Visit 1.; Optional visits (e.g., Visit 1B at 16 weeks for Imiquimod/5-FU) are not counted."
35704479,Treatment Arm (Imiquimod or 5-Fluorouracil Cream),intervention,1,1,2,3,3,4,0,1,1,2,2,3,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,,until progression,"Screening (Visit 0), Randomization/Baseline (Visit 1, Day 0), 8-week interim visit (Visit 1A), then regular 6-month follow-up visits (Visits 2, 3, etc.)","Information Visit is not a separate contact day; if screening procedures are performed, they are considered part of Visit 0.; Visit 0 (Screening) and Visit 1 (Randomization/Day 0) are always distinct in-person contact days.; For the Imiquimod or 5-Fluorouracil Cream arm, the 'first application of treatment' at Visit 1 (Day 0) is a core_treatment activity.; Visit 1A (8 weeks, Day +56) is a mandated clinic_visit for toxicity/tolerability assessment.; Subsequent 6-month visits (Visit 2, 3, etc.) are counted as core_treatment days, assuming treatment is initiated/continued due to persistent HSIL as per protocol guidance.; HIV viral load and CD4 count results are generally assumed to be obtained from routine medical care and not to require a separate study contact day, except for venipuncture at Visit 1.; Optional visits (e.g., Visit 1B at 16 weeks for Imiquimod/5-FU) are not counted."
35704479,Treatment Arm (TCA),intervention,1,2,5,6,6,7,0,2,5,6,6,7,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,,until progression,"Screening (Visit 0), Randomization/Baseline (Visit 1, Day 0), up to 4 interim TCA application visits (Visits 1A, 1B, 1C), then regular 6-month follow-up visits (Visits 2, 3, etc.)","Information Visit is not a separate contact day; if screening procedures are performed, they are considered part of Visit 0.; Visit 0 (Screening) and Visit 1 (Randomization/Day 0) are always distinct in-person contact days.; For the TCA arm, the 'initial study treatment' at Visit 1 (Day 0) is a core_treatment activity.; Four clinician-applied TCA treatments are assumed within the first 12 weeks (Day +21, +42, +63, +84), each counted as a core_treatment day.; Subsequent 6-month visits (Visit 2, 3, etc.) are counted as core_treatment days, assuming treatment is initiated/continued due to persistent HSIL as per protocol guidance.; HIV viral load and CD4 count results are generally assumed to be obtained from routine medical care and not to require a separate study contact day, except for venipuncture at Visit 1.; Optional visits are not counted."
35704479,"Treatment Arm (IRC, Hyfrecation or Laser)",intervention,1,1,2,3,4,5,0,1,2,2,3,3,1,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,,until progression,"Screening (Visit 0), Randomization/Baseline (Visit 1, Day 0), 8-week interim treatment visit (Visit 1A), then regular 6-month follow-up assessment visits (Visits 2, 3, etc.) with potential separate re-treatment visits.","Information Visit is not a separate contact day; if screening procedures are performed, they are considered part of Visit 0.; Visit 0 (Screening) and Visit 1 (Randomization/Day 0) are always distinct in-person contact days.; For the IRC, Hyfrecation or Laser arm, the 'initial study treatment' at Visit 1 (Day 0) is a core_treatment activity.; One 'staged ablative procedure' is assumed at 8 weeks (Day +56) as a core_treatment day.; Regular 6-month follow-up visits (Visit 2, 3, etc.) are primarily for assessment (imaging_diagnostics).; If HSIL is present at a 6-month assessment visit, a separate 're-treatment' visit is assumed to occur within 4 weeks (e.g., Day +181, Day +366), counted as a core_treatment day.; HIV viral load and CD4 count results are generally assumed to be obtained from routine medical care and not to require a separate study contact day, except for venipuncture at Visit 1.; Optional visits are not counted."
35704479,Treatment Arm (Surgery - TUA),intervention,1,1,2,4,4,5,0,0,1,2,2,3,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,,until progression,"Screening (Visit 0), Randomization/Baseline (Visit 1, Day 0), Surgery (Day +60), Post-surgery re-evaluation (Day +116), then regular 6-month follow-up visits (Visits 2, 3, etc.)","Information Visit is not a separate contact day; if screening procedures are performed, they are considered part of Visit 0.; Visit 0 (Screening) and Visit 1 (Randomization/Day 0) are always distinct in-person contact days.; For the Surgery (TUA) arm, Visit 1 (Day 0) includes surgery planning, but the surgery itself is a separate core_treatment day, assumed at Day +60 (within 2 months of Visit 1).; A re-evaluation visit is mandated 8-12 weeks post-surgery, assumed at Day +116 (8 weeks after Day +60) as a clinic_visit.; Subsequent 6-month visits (Visit 2, 3, etc.) are counted as core_treatment days, assuming new treatment is initiated/continued due to persistent HSIL as per protocol guidance.; HIV viral load and CD4 count results are generally assumed to be obtained from routine medical care and not to require a separate study contact day, except for venipuncture at Visit 1.; Optional visits are not counted."
35759733,Regimen I: CT-2103 (135mg/m²),intervention,2,3,7,14,20,25,0,2,4,7,10,12,1,0,0,0,0,0,0,1,3,7,10,13,1,0,0,0,0,0,28,12 monthly cycles,"Screening (2 days); 12 cycles of treatment, each with an infusion day (Day 1 of cycle) and a nadir lab day (Day 8 of cycle). Specific imaging and QOL assessments are integrated into these cycle visits. One post-treatment lab visit.","Screening procedures are consolidated into two in-person visits: Day -28 for EKG and CT scan (imaging_diagnostics), and Day -1 for History, Physical Exam, QOL, labs (CBC & Diff, Platelets, Serum Creatinine, Bilirubin/SGOT/ALP, CA-125, Negative serum pregnancy test), and Chest X-Ray (clinic_visits).; For 'Prior to Each Course or Monthly During 1st Year' column: History, Physical Exam, CBC & Diff, Platelets, Serum Creatinine, Bilirubin/SGOT/ALP, and CA-125 are assumed to occur at C1D1, C2D1, ..., C12D1 (Day 0, 28, 56, 84, 112, 140, 168, 196, 224, 252, 280, 308).; Chest X-Ray (listed as '1' in the 'Prior to Each Course' column) is assumed to occur once at C1D1 (Day 0).; CT scan of abdomen/pelvis (listed as '6' in the 'Prior to Each Course' column) is assumed to occur at C1D1, C3D1, C5D1, C7D1, C9D1, C11D1 (Day 0, 56, 112, 168, 224, 280).; QOL assessments (listed as '7' in the 'Prior to Each Course' column) occur at Baseline (Day -1), C3D1 (Day 56), C5D1 (Day 112), C7D1 (Day 168), and C12D1 (Day 308).; Nadir labs (CBC & Diff, Platelets) are assumed to occur on Day 7 of each cycle (Day 7, 35, 63, 91, 119, 147, 175, 203, 231, 259, 287, 315).; Coagulation Profile is excluded from routine contact days based on Footnote 8, which states it's only for patients with baseline abnormal parameters or on anti-coagulant treatment.; Post-treatment CA-125 (Footnote 10) is included at Day 360.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits. Infusion days are categorized as core_treatment. Days with CT/EKG are imaging_diagnostics unless core_treatment is present. Days with H&P/QOL are clinic_visits unless imaging_diagnostics or core_treatment is present. Days with only labs are labs."
35759733,Regimen II: Paclitaxel (135mg/m²),intervention,2,3,7,14,20,25,0,2,4,7,10,12,1,0,0,0,0,0,0,1,3,7,10,13,1,0,0,0,0,0,28,12 monthly cycles,"Screening (2 days); 12 cycles of treatment, each with an infusion day (Day 1 of cycle) and a nadir lab day (Day 8 of cycle). Specific imaging and QOL assessments are integrated into these cycle visits. One post-treatment lab visit.","Screening procedures are consolidated into two in-person visits: Day -28 for EKG and CT scan (imaging_diagnostics), and Day -1 for History, Physical Exam, QOL, labs (CBC & Diff, Platelets, Serum Creatinine, Bilirubin/SGOT/ALP, CA-125, Negative serum pregnancy test), and Chest X-Ray (clinic_visits).; For 'Prior to Each Course or Monthly During 1st Year' column: History, Physical Exam, CBC & Diff, Platelets, Serum Creatinine, Bilirubin/SGOT/ALP, and CA-125 are assumed to occur at C1D1, C2D1, ..., C12D1 (Day 0, 28, 56, 84, 112, 140, 168, 196, 224, 252, 280, 308).; Chest X-Ray (listed as '1' in the 'Prior to Each Course' column) is assumed to occur once at C1D1 (Day 0).; CT scan of abdomen/pelvis (listed as '6' in the 'Prior to Each Course' column) is assumed to occur at C1D1, C3D1, C5D1, C7D1, C9D1, C11D1 (Day 0, 56, 112, 168, 224, 280).; QOL assessments (listed as '7' in the 'Prior to Each Course' column) occur at Baseline (Day -1), C3D1 (Day 56), C5D1 (Day 112), C7D1 (Day 168), and C12D1 (Day 308).; Nadir labs (CBC & Diff, Platelets) are assumed to occur on Day 7 of each cycle (Day 7, 35, 63, 91, 119, 147, 175, 203, 231, 259, 287, 315).; Coagulation Profile is excluded from routine contact days based on Footnote 8, which states it's only for patients with baseline abnormal parameters or on anti-coagulant treatment.; Post-treatment CA-125 (Footnote 10) is included at Day 360.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits. Infusion days are categorized as core_treatment. Days with CT/EKG are imaging_diagnostics unless core_treatment is present. Days with H&P/QOL are clinic_visits unless imaging_diagnostics or core_treatment is present. Days with only labs are labs."
35759733,Regimen III: No anti-cancer treatment until evidence of disease progression,control,2,2,4,7,10,13,0,0,0,0,0,0,1,1,2,4,5,6,0,0,0,0,0,0,1,1,2,3,5,7,30,until disease progression,Screening (2 days); 12 monthly surveillance visits. Specific imaging and QOL assessments are integrated into these monthly visits. One post-treatment QOL/lab visit.,"Screening procedures are consolidated into two in-person visits: Day -28 for EKG and CT scan (imaging_diagnostics), and Day -1 for History, Physical Exam, QOL, labs (CBC & Diff, Platelets, Serum Creatinine, Bilirubin/SGOT/ALP, CA-125, Negative serum pregnancy test), and Chest X-Ray (clinic_visits).; For 'Prior to Each Course or Monthly During 1st Year' column (interpreted as 'Monthly During 1st Year' for Regimen III): History, Physical Exam, CBC & Diff, Platelets, Serum Creatinine, Bilirubin/SGOT/ALP, and CA-125 are assumed to occur monthly for 12 months (Day 0, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330).; Chest X-Ray (listed as '1' in the 'Monthly During 1st Year' column) is assumed to occur once at Day 0.; CT scan of abdomen/pelvis (listed as '6' in the 'Monthly During 1st Year' column) is assumed to occur at Day 0, 60, 120, 180, 240, 300.; QOL assessments (listed as '7' in the 'Monthly During 1st Year' column) occur at Baseline (Day -1), Day 60 (2 months), Day 120 (4 months), Day 180 (6 months), and Day 360 (12 months).; Coagulation Profile is excluded from routine contact days based on Footnote 8, which states it's only for patients with baseline abnormal parameters or on anti-coagulant treatment.; Post-treatment CA-125 (Footnote 10) is included at Day 360.; Category precedence: core_treatment > imaging_diagnostics > labs > clinic_visits. Days with CT/EKG are imaging_diagnostics. Days with H&P/QOL are clinic_visits unless imaging_diagnostics is present. Days with only labs are labs."
35763704,Atezolizumab + ddAC-PacHP,intervention,2,3,9,19,23,27,0,3,9,19,23,27,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Cycles 1-4: 14 days; Cycles 5-21: 21 days,"Chemotherapy has fixed cycles (ddAC for 4 cycles, Paclitaxel for 12 weeks). HER2-targeted therapy (Atezolizumab/Placebo, Trastuzumab, Pertuzumab) continues for a total duration of 52 weeks from the first dose of HER2-targeted therapy (C5D1).","Screening: 2 days (biopsy, main screening). Neoadjuvant Phase (Cycles 1-4, 14-day cycles): Day 1 of each cycle (4 visits). Neoadjuvant Phase (Cycles 5-8, 21-day cycles): Day 1, Day 8, Day 15 of each cycle (12 visits). Surgery: 1 day. Adjuvant Phase (Cycles 9-21, 21-day cycles): Day 1 of each cycle (13 visits within 12 months).","Assumed two distinct screening days: one for the baseline tumor biopsy (imaging_diagnostics) and one for the main screening visit with all other baseline assessments. The main screening visit is categorized as imaging_diagnostics due to the presence of highest priority procedures like ECHO/MUGA, ECG, mammogram, and disease status assessment.; Assumed Day 0 is Cycle 1 Day 1 (C1D1), the first treatment day.; Assumed Paclitaxel weekly infusions (C5D8, C5D15, C6D8, C6D15, C7D8, C7D15, C8D8, C8D15) are distinct contact days. Basic safety assessments (vital signs, weight, limited physical exam, labs, concomitant medications, adverse events) are assumed to be performed on these days, categorizing them as core_treatment due to the infusion.; Assumed surgery occurs on a representative day (Day 147) within the allowed window (at least 14 days after the last neoadjuvant infusion, C8D15 on Day 133, and no later than 6 weeks after the last infusion). Surgery is categorized as core_treatment.; Assumed C9D1 (first adjuvant treatment) occurs 14 days post-surgery (Day 161).; Assumed HER2-targeted therapy (Atezolizumab/Placebo, Trastuzumab, Pertuzumab) duration is 52 weeks from C5D1 (Day 56), ending on Day 419. This results in 4 neoadjuvant and 13 adjuvant cycles of HER2-targeted therapy within the 12-month window.; ECHO/MUGA scans, TSH, and PROs scheduled on Day 1 of cycles are considered part of the core_treatment day if an infusion occurs.; All treatment days involving infusions are categorized as core_treatment due to the highest priority rule.; ""As clinically indicated"" visits are not counted."
35763704,Placebo + ddAC-PacHP,control,2,3,9,19,23,27,0,3,9,19,23,27,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,Cycles 1-4: 14 days; Cycles 5-21: 21 days,"Chemotherapy has fixed cycles (ddAC for 4 cycles, Paclitaxel for 12 weeks). HER2-targeted therapy (Atezolizumab/Placebo, Trastuzumab, Pertuzumab) continues for a total duration of 52 weeks from the first dose of HER2-targeted therapy (C5D1).","Screening: 2 days (biopsy, main screening). Neoadjuvant Phase (Cycles 1-4, 14-day cycles): Day 1 of each cycle (4 visits). Neoadjuvant Phase (Cycles 5-8, 21-day cycles): Day 1, Day 8, Day 15 of each cycle (12 visits). Surgery: 1 day. Adjuvant Phase (Cycles 9-21, 21-day cycles): Day 1 of each cycle (13 visits within 12 months).","Assumed two distinct screening days: one for the baseline tumor biopsy (imaging_diagnostics) and one for the main screening visit with all other baseline assessments. The main screening visit is categorized as imaging_diagnostics due to the presence of highest priority procedures like ECHO/MUGA, ECG, mammogram, and disease status assessment.; Assumed Day 0 is Cycle 1 Day 1 (C1D1), the first treatment day.; Assumed Paclitaxel weekly infusions (C5D8, C5D15, C6D8, C6D15, C7D8, C7D15, C8D8, C8D15) are distinct contact days. Basic safety assessments (vital signs, weight, limited physical exam, labs, concomitant medications, adverse events) are assumed to be performed on these days, categorizing them as core_treatment due to the infusion.; Assumed surgery occurs on a representative day (Day 147) within the allowed window (at least 14 days after the last neoadjuvant infusion, C8D15 on Day 133, and no later than 6 weeks after the last infusion). Surgery is categorized as core_treatment.; Assumed C9D1 (first adjuvant treatment) occurs 14 days post-surgery (Day 161).; Assumed HER2-targeted therapy (Atezolizumab/Placebo, Trastuzumab, Pertuzumab) duration is 52 weeks from C5D1 (Day 56), ending on Day 419. This results in 4 neoadjuvant and 13 adjuvant cycles of HER2-targeted therapy within the 12-month window.; ECHO/MUGA scans, TSH, and PROs scheduled on Day 1 of cycles are considered part of the core_treatment day if an infusion occurs.; All treatment days involving infusions are categorized as core_treatment due to the highest priority rule.; ""As clinically indicated"" visits are not counted."
35922251,Cemiplimab (Experimental / Extension Phase),experimental,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,up to 96 weeks,"Screening (1 day). Treatment visits every 21 days (Day 0, 21, 42, etc.) for up to 96 weeks. All treatment days include Cemiplimab infusion and other assessments (CT/MRI, labs, clinic visits).","The Cemiplimab Extension Phase (Table 3) is used for all cemiplimab patients, including those initially randomized to cemiplimab and those crossing over from IC chemotherapy. This schedule supersedes Table 1 for cemiplimab treatment.; Screening for the Extension Phase is counted as one in-person day, categorized as imaging_diagnostics due to CT/MRI/ECG/biopsy.; Cemiplimab is administered on Day 1 of each 21-day cycle (Day 0, 21, 42, etc.). All assessments (including CT/MRI, labs, and clinic visits) occurring on these days are overridden by core_treatment due to drug infusion.; Treatment duration is assumed to be up to 96 weeks (Day 672).; Follow-up visits are explicitly stated as 'no longer required' as of Amendment 7 (Section 7.1.4, Page 17) for patients entering the cemiplimab Extension Phase, therefore no follow-up visits are counted."
35922251,IC Chemotherapy: Pemetrexed,control,1,5,10,22,32,44,0,2,4,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,3,6,13,19,26,42,up to 96 weeks,"Screening (1 day). Treatment visits every 6 weeks (Day 0, 7, 14, 21, 28, 42, then repeating). Pemetrexed infusion on Day 0 and Day 21 of each 6-week cycle. Imaging on Day 42 of specific cycles.","Table 1 is the primary source for the IC chemotherapy schedule. The 'Cycles 1 through 16 (cycle length = 6 weeks)' header implies that the listed 'Day' columns (Day 1, 8, 15, 22, 29, 42) repeat as fixed days within each 6-week cycle (e.g., C1D1=Day 0, C1D8=Day 7, C2D1=Day 42, C2D8=Day 49).; Pemetrexed is administered on Day 1 and Day 22 of each 6-week cycle (Day 0, 21, 42, 63, etc.). These days are categorized as core_treatment.; Imaging (CT/MRI) is scheduled for Day 42 of cycles 1-4, 6, 8, 10, 12, 14, and 16. Since Day 42 is also C2D1 (a drug administration day), these imaging days are overridden by core_treatment.; General assessments (physical exams, vitals, weight, QOL, concomitant meds) and labs (hematology, blood chemistry, pregnancy test, urinalysis) are performed as per Table 1. Labs take precedence over clinic_visits.; Treatment duration is assumed to be up to 96 weeks (Day 672).; Follow-up visits are explicitly stated as 'no longer required' as of Amendment 7 (Section 7.1.4, Page 17), therefore no follow-up visits are counted."
35922251,IC Chemotherapy: Topotecan,control,1,9,19,42,58,76,0,5,11,25,35,45,1,0,0,0,0,0,0,1,2,4,5,7,0,3,6,13,18,24,42,up to 96 weeks,"Screening (1 day). Treatment visits every 6 weeks (Day 0-4, 7, 14, 21, 28, 42, then repeating). Topotecan infusion on Day 0-4 of each 6-week cycle. Imaging on Day 42 of specific cycles.","Table 1 is the primary source for the IC chemotherapy schedule. The 'Cycles 1 through 16 (cycle length = 6 weeks)' header implies that the listed 'Day' columns (Day 1, 8, 15, 22, 29, 42) repeat as fixed days within each 6-week cycle (e.g., C1D1=Day 0, C1D8=Day 7, C2D1=Day 42, C2D8=Day 49).; Topotecan is administered on Day 1-5 of each 6-week cycle (Day 0-4, 42-46, 84-88, etc.). These days are categorized as core_treatment.; Imaging (CT/MRI) is scheduled for Day 42 of cycles 1-4, 6, 8, 10, 12, 14, and 16. Since Day 42 is also C2D1 (a drug administration day), these imaging days are overridden by core_treatment.; General assessments (physical exams, vitals, weight, QOL, concomitant meds) and labs (hematology, blood chemistry, pregnancy test, urinalysis) are performed as per Table 1. Labs take precedence over clinic_visits.; Treatment duration is assumed to be up to 96 weeks (Day 672).; Follow-up visits are explicitly stated as 'no longer required' as of Amendment 7 (Section 7.1.4, Page 17), therefore no follow-up visits are counted."
35922251,IC Chemotherapy: Irinotecan,control,1,5,10,24,33,37,0,4,9,19,27,31,1,0,0,0,0,0,0,0,0,0,0,0,0,1,2,4,6,6,42,up to 96 weeks,"Screening (1 day). Treatment visits every 6 weeks (Day 0, 7, 14, 21, 28, 42, then repeating). Irinotecan infusion on Day 0, 7, 14, 21 of each 6-week cycle. Imaging on Day 42 of specific cycles.","Table 1 is the primary source for the IC chemotherapy schedule. The 'Cycles 1 through 16 (cycle length = 6 weeks)' header implies that the listed 'Day' columns (Day 1, 8, 15, 22, 29, 42) repeat as fixed days within each 6-week cycle (e.g., C1D1=Day 0, C1D8=Day 7, C2D1=Day 42, C2D8=Day 49).; Irinotecan is administered on Day 1, 8, 15, and 22 of each 6-week cycle (Day 0, 7, 14, 21, 42, 49, 56, 63, etc.). These days are categorized as core_treatment.; Imaging (CT/MRI) is scheduled for Day 42 of cycles 1-4, 6, 8, 10, 12, 14, and 16. Since Day 42 is also C2D1 (a drug administration day), these imaging days are overridden by core_treatment.; General assessments (physical exams, vitals, weight, QOL, concomitant meds) and labs (hematology, blood chemistry, pregnancy test, urinalysis) are performed as per Table 1. Labs take precedence over clinic_visits.; Treatment duration is assumed to be up to 96 weeks (Day 672).; Follow-up visits are explicitly stated as 'no longer required' as of Amendment 7 (Section 7.1.4, Page 17), therefore no follow-up visits are counted."
35922251,IC Chemotherapy: Gemcitabine,control,1,5,10,22,32,45,0,2,4,9,14,19,1,0,0,0,0,0,0,1,2,4,5,7,0,2,4,9,13,19,42,up to 96 weeks,"Screening (1 day). Treatment visits every 6 weeks (Day 0, 7, 14, 21, 28, 42, then repeating). Gemcitabine infusion on Day 0 and Day 7 of each 6-week cycle. Imaging on Day 42 of specific cycles.","Table 1 is the primary source for the IC chemotherapy schedule. The 'Cycles 1 through 16 (cycle length = 6 weeks)' header implies that the listed 'Day' columns (Day 1, 8, 15, 22, 29, 42) repeat as fixed days within each 6-week cycle (e.g., C1D1=Day 0, C1D8=Day 7, C2D1=Day 42, C2D8=Day 49).; Gemcitabine is administered on Day 1 and Day 8 of each 6-week cycle (Day 0, 7, 42, 49, etc.). These days are categorized as core_treatment.; Imaging (CT/MRI) is scheduled for Day 42 of cycles 1-4, 6, 8, 10, 12, 14, and 16. Since Day 42 is also C2D1 (a drug administration day), these imaging days are overridden by core_treatment.; General assessments (physical exams, vitals, weight, QOL, concomitant meds) and labs (hematology, blood chemistry, pregnancy test, urinalysis) are performed as per Table 1. Labs take precedence over clinic_visits.; Treatment duration is assumed to be up to 96 weeks (Day 672).; Follow-up visits are explicitly stated as 'no longer required' as of Amendment 7 (Section 7.1.4, Page 17), therefore no follow-up visits are counted."
35922251,IC Chemotherapy: Vinorelbine,control,1,5,10,22,32,45,0,2,4,9,14,19,1,0,0,0,0,0,0,1,2,4,5,7,0,2,4,9,13,19,42,up to 96 weeks,"Screening (1 day). Treatment visits every 6 weeks (Day 0, 7, 14, 21, 28, 42, then repeating). Vinorelbine infusion on Day 0 and Day 7 of each 6-week cycle. Imaging on Day 42 of specific cycles.","Table 1 is the primary source for the IC chemotherapy schedule. The 'Cycles 1 through 16 (cycle length = 6 weeks)' header implies that the listed 'Day' columns (Day 1, 8, 15, 22, 29, 42) repeat as fixed days within each 6-week cycle (e.g., C1D1=Day 0, C1D8=Day 7, C2D1=Day 42, C2D8=Day 49).; Vinorelbine is administered on Day 1 and Day 8 of each 6-week cycle (Day 0, 7, 42, 49, etc.). These days are categorized as core_treatment.; Imaging (CT/MRI) is scheduled for Day 42 of cycles 1-4, 6, 8, 10, 12, 14, and 16. Since Day 42 is also C2D1 (a drug administration day), these imaging days are overridden by core_treatment.; General assessments (physical exams, vitals, weight, QOL, concomitant meds) and labs (hematology, blood chemistry, pregnancy test, urinalysis) are performed as per Table 1. Labs take precedence over clinic_visits.; Treatment duration is assumed to be up to 96 weeks (Day 672).; Follow-up visits are explicitly stated as 'no longer required' as of Amendment 7 (Section 7.1.4, Page 17), therefore no follow-up visits are counted."
36108662,Pembrolizumab,intervention,4,2,5,9,13,18,0,2,5,9,13,18,2,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,21,until 18 infusions completed,"4 screening days, followed by 18 infusions every 3 weeks. All assessments on infusion days are consolidated into the infusion day count.","The two treatment arms (Pembrolizumab and Placebo) follow identical schedules for all assessments and visits.; Screening procedures occurring 'Any time after surgery or during adjuvant chemotherapy', 'Within 12 weeks prior to randomization', 'Within 10 days prior to treatment initiation', 'Within 72 hours prior to treatment initiation', and 'Within 24 hours prior to treatment initiation' are consolidated into 4 distinct in-person contact days within the screening window:;   1. Registration/Main Study Consent/Initial Bloods (clinic_visits, due to consent).;   2. PD-L1 Sample Submission (imaging_diagnostics, for tumor assessment).;   3. Comprehensive Screening (Physical Exam, ECOG PS, 12-lead ECG, Disease Evaluation CT/MRI, HRQoL, Urinalysis, Thyroid function) (imaging_diagnostics, due to imaging/ECG).;   4. Pre-Treatment Labs (Hematology, Serum Chemistry, Pregnancy Test, PK/ADA samples, Correlative Bloods) (labs, due to multiple lab draws).; Visits or procedures explicitly stated as 'optional' or 'if clinically indicated' (e.g., Serology HIV, HBV, HCV during screening, Thyroid function after year 1 follow-up) are excluded from contact day counts.; All 18 infusions are considered in-person core_treatment days. Any other assessments (PE, labs, imaging, HRQoL) scheduled on the same day as an infusion are absorbed into the 'core_treatment' category due to precedence.; The 'At week 12' translational research samples (Serum, PBMC, Whole Blood DNA/RNA) listed in Table 6 fall on Infusion 5 day (Day 84), which is already a core_treatment day, and thus do not add new contact days.; The End of Treatment (EoT) visit (Day 385) and subsequent follow-up visits fall outside the 12-month window and are not included in these counts."
36108662,Placebo,control,4,2,5,9,13,18,0,2,5,9,13,18,2,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,21,until 18 infusions completed,"4 screening days, followed by 18 infusions every 3 weeks. All assessments on infusion days are consolidated into the infusion day count.","The two treatment arms (Pembrolizumab and Placebo) follow identical schedules for all assessments and visits.; Screening procedures occurring 'Any time after surgery or during adjuvant chemotherapy', 'Within 12 weeks prior to randomization', 'Within 10 days prior to treatment initiation', 'Within 72 hours prior to treatment initiation', and 'Within 24 hours prior to treatment initiation' are consolidated into 4 distinct in-person contact days within the screening window:;   1. Registration/Main Study Consent/Initial Bloods (clinic_visits, due to consent).;   2. PD-L1 Sample Submission (imaging_diagnostics, for tumor assessment).;   3. Comprehensive Screening (Physical Exam, ECOG PS, 12-lead ECG, Disease Evaluation CT/MRI, HRQoL, Urinalysis, Thyroid function) (imaging_diagnostics, due to imaging/ECG).;   4. Pre-Treatment Labs (Hematology, Serum Chemistry, Pregnancy Test, PK/ADA samples, Correlative Bloods) (labs, due to multiple lab draws).; Visits or procedures explicitly stated as 'optional' or 'if clinically indicated' (e.g., Serology HIV, HBV, HCV during screening, Thyroid function after year 1 follow-up) are excluded from contact day counts.; All 18 infusions are considered in-person core_treatment days. Any other assessments (PE, labs, imaging, HRQoL) scheduled on the same day as an infusion are absorbed into the 'core_treatment' category due to precedence.; The 'At week 12' translational research samples (Serum, PBMC, Whole Blood DNA/RNA) listed in Table 6 fall on Infusion 5 day (Day 84), which is already a core_treatment day, and thus do not add new contact days.; The End of Treatment (EoT) visit (Day 385) and subsequent follow-up visits fall outside the 12-month window and are not included in these counts."
36155117,Arm A: Palbociclib + Letrozole,intervention,1,4,8,11,14,18,0,0,0,0,0,0,1,0,1,2,3,4,0,3,5,5,5,5,0,1,2,4,6,9,28,"until disease progression, unacceptable toxicity, death, or withdrawal","Screening (Day -7). Cycle 1: Day 1, Day 14, Day 21. Cycle 2: Day 1, Day 14, Day 21. Subsequent Cycles (C>=3): Day 1. Additional assessments (imaging, ophthalmic, HgbA1C, QoL) occur at fixed intervals from randomization, often coinciding with cycle Day 1 visits.","Screening is counted as one contact day (Day -7) for all screening procedures, categorized as imaging_diagnostics due to multiple imaging assessments and potential biopsy.; Randomization (C1D1) is considered a separate contact day (Day 0) from screening.; For Cycles >=3, only 'Day 1' is explicitly listed in the Schedule of Activities. It is assumed that Day 14 and Day 21 visits do not occur in subsequent cycles unless specifically indicated for a procedure (e.g., disease assessments, ophthalmic exams, HgbA1C, QoL).; Monthly monitoring of complete blood count on Day 1 of each cycle is assumed to continue beyond Cycle 6 as 'clinically indicated' for the purpose of counting contact days up to 12 months.; End of Treatment/Withdrawal and Post-Treatment Follow-up visits are not included in the fixed interval counts, as treatment continues 'until progression' and follow-up is often telephonic.; Tumor Tissue for Biomarker (biopsy) is assumed to be an in-person procedure at screening if required, contributing to a contact day.; All procedures listed for a given day are assumed to occur on that single contact day."
36155117,Arm B: Placebo + Letrozole,control,1,4,8,11,14,18,0,0,0,0,0,0,1,0,1,2,3,4,0,3,5,5,5,5,0,1,2,4,6,9,28,"until disease progression, unacceptable toxicity, death, or withdrawal","Screening (Day -7). Cycle 1: Day 1, Day 14, Day 21. Cycle 2: Day 1, Day 14, Day 21. Subsequent Cycles (C>=3): Day 1. Additional assessments (imaging, ophthalmic, HgbA1C, QoL) occur at fixed intervals from randomization, often coinciding with cycle Day 1 visits.","Screening is counted as one contact day (Day -7) for all screening procedures, categorized as imaging_diagnostics due to multiple imaging assessments and potential biopsy.; Randomization (C1D1) is considered a separate contact day (Day 0) from screening.; For Cycles >=3, only 'Day 1' is explicitly listed in the Schedule of Activities. It is assumed that Day 14 and Day 21 visits do not occur in subsequent cycles unless specifically indicated for a procedure (e.g., disease assessments, ophthalmic exams, HgbA1C, QoL).; Monthly monitoring of complete blood count on Day 1 of each cycle is assumed to continue beyond Cycle 6 as 'clinically indicated' for the purpose of counting contact days up to 12 months.; End of Treatment/Withdrawal and Post-Treatment Follow-up visits are not included in the fixed interval counts, as treatment continues 'until progression' and follow-up is often telephonic.; Tumor Tissue for Biomarker (biopsy) is assumed to be an in-person procedure at screening if required, contributing to a contact day.; All procedures listed for a given day are assumed to occur on that single contact day."
36162037,Arm A: nivolumab 240 mg IV every 2 weeks + ipilimumab 1 mg/kg IV every 6 weeks,intervention,1,3,7,13,19,26,0,3,7,13,19,26,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,maximum of 1 year,"One screening visit, followed by in-person visits every 2 weeks for 1 year for drug administration and concurrent assessments.","Arm C was excluded as randomization into this arm was discontinued.; All on-treatment assessments (safety, labs, biomarkers, efficacy, outcome research, HCRU) occurring on drug administration days are subsumed under 'core_treatment' due to precedence.; The screening visit is counted as one in-person day, with the highest priority procedure determining its category.; Treatment is assumed to continue for the maximum duration of 1 year (365 days) for calculation purposes."
36162037,Arm B: nivolumab 480 mg IV every 4 weeks,intervention,1,3,7,13,19,26,0,3,7,13,19,26,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,maximum of 1 year,"One screening visit, followed by in-person visits every 2 weeks for 1 year for drug/placebo administration and concurrent assessments.","Arm C was excluded as randomization into this arm was discontinued.; Placebo administration days (for nivolumab and ipilimumab) are considered in-person healthcare-contact days and categorized as 'core_treatment' to maintain blinding and align with the active drug administration process.; All on-treatment assessments (safety, labs, biomarkers, efficacy, outcome research, HCRU) occurring on drug/placebo administration days are subsumed under 'core_treatment' due to precedence.; The screening visit is counted as one in-person day, with the highest priority procedure determining its category.; Treatment is assumed to continue for the maximum duration of 1 year (365 days) for calculation purposes."
36265504,Period 1 - Open Label Enzalutamide,intervention,1,2,3,4,5,6,1,2,3,4,5,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"N/A (daily drug, visits at fixed weeks)","until disease progression, intolerable toxicity, subject withdrawal, or death","Screening (Day -X), then Day 1, Day 29 (Week 5), Day 85 (Week 13), Day 169 (Week 25), Day 253 (Week 37), Day 337 (Week 49). Enzalutamide is administered daily.","Screening visit is counted as 1 day, with enzalutamide dispensing making it a core_treatment day.; Optional biomarker sub-study visits and unscheduled visits are excluded.; Extension Period 1 visits are excluded as they are described as 'standard of care' and not strictly trial-mandated in-person contact days.; The 30-day safety follow-up visit after the last dose of IMP (Day 337 + 30 = Day 367) falls outside the 12-month window."
36265504,Enzalutamide + Docetaxel + Prednisolone,intervention,1,5,12,21,24,26,0,2,5,9,11,12,1,0,0,0,0,0,0,3,7,12,13,14,0,0,0,0,0,0,21,"Docetaxel for up to 10 cycles; Enzalutamide until disease progression, intolerable toxicity, subject withdrawal, or death","Eligibility Assessment (Day -X), then Docetaxel administration (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189). Nadir labs (Day 7, 28, 49, 70, 91, 112, 133, 154, 175, 196). Additional labs (Day 14, 35, 56). Post-docetaxel IMP continuation visits (Day 227, 311). Follow-up (Day 341).","Period 2 Eligibility Assessment is counted as 1 day, with radiographic assessments and ECG making it an imaging_diagnostics day.; Docetaxel is administered every 3 weeks for up to 10 cycles. Each administration day is a core_treatment day.; Footnote (h) on page 19 indicates additional in-person lab visits for nadir counts (approx. 1 week after docetaxel in all cycles) and additional hematology (approx. 2 weeks after docetaxel in first 3 cycles). These are counted as separate 'labs' days.; The 'Additional' column (Varies q3wk cycles) in the Period 2 schedule is not counted as distinct visits, assuming its procedures are covered by docetaxel administration days or specific lab visits.; Ongoing Double-Blind Treatment visits (Day 227, Day 311) are counted as core_treatment days due to IMP dispensing.; The 30-day safety follow-up visit after the last dose of IMP (Day 311 + 30 = Day 341) falls within the 12-month window and is categorized as a labs day."
36265504,Placebo + Docetaxel + Prednisolone,control,1,5,12,21,24,26,0,2,5,9,11,12,1,0,0,0,0,0,0,3,7,12,13,14,0,0,0,0,0,0,21,"Docetaxel for up to 10 cycles; Placebo until disease progression, intolerable toxicity, subject withdrawal, or death","Eligibility Assessment (Day -X), then Docetaxel administration (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189). Nadir labs (Day 7, 28, 49, 70, 91, 112, 133, 154, 175, 196). Additional labs (Day 14, 35, 56). Post-docetaxel IMP continuation visits (Day 227, 311). Follow-up (Day 341).","Period 2 Eligibility Assessment is counted as 1 day, with radiographic assessments and ECG making it an imaging_diagnostics day.; Docetaxel is administered every 3 weeks for up to 10 cycles. Each administration day is a core_treatment day.; Footnote (h) on page 19 indicates additional in-person lab visits for nadir counts (approx. 1 week after docetaxel in all cycles) and additional hematology (approx. 2 weeks after docetaxel in first 3 cycles). These are counted as separate 'labs' days.; The 'Additional' column (Varies q3wk cycles) in the Period 2 schedule is not counted as distinct visits, assuming its procedures are covered by docetaxel administration days or specific lab visits.; Ongoing Double-Blind Treatment visits (Day 227, Day 311) are counted as core_treatment days due to IMP dispensing.; The 30-day safety follow-up visit after the last dose of IMP (Day 311 + 30 = Day 341) falls within the 12-month window and is categorized as a labs day."
36308441,Arm A: PledOx (5 µmol/kg) + mFOLFOX6 chemotherapy,intervention,2,9,22,39,40,41,0,3,7,12,12,12,2,0,0,1,2,3,0,0,0,0,0,0,0,6,15,26,26,26,14,up to 24 weeks (6 months),"Screening (Day -28, Day -7); Treatment Cycles (Day 0, Day 1, Day 2 of each 14-day cycle for 12 cycles); Assessment Visits (Month 3 (Day 90), EoT (Day 168), Month 6 (Day 180), Month 9 (Day 270), Month 12 (Day 365)).","Both Arm A and Arm B have identical in-person healthcare contact days as the Schedule of Assessments does not differentiate between them for procedures, and IMP administration (PledOx or Placebo) is an in-person infusion for both.; The 'W-1' column in the Schedule of Assessments (Day -7) is considered a contact day, as it lists multiple procedures and is not explicitly marked 'not a patient visit' like the 'Randomization' column.; The 'Cold Sensitivity Patient Questionnaire (Paper Diary)' marked for 'before IMP* infusion and Days 1, 2, 3 after IMP and mFOLFOX6 infusion at Day 1' implies 3 distinct contact days per cycle (Day 0, Day 1, Day 2 of each cycle). Day 0 is categorized as core_treatment due to IMP/mFOLFOX6 infusion, and Day 1 and Day 2 are categorized as clinic_visits.; The End of Treatment (EoT) visit (Day 168) and Month 6 Assessment visit (Day 180) are counted as separate contact days, as they appear in distinct columns in the Schedule of Assessments and are not explicitly mandated to be combined.; Procedures marked with '(X)10' for 'Brain MRI and Blood Mn incl. Neurological Exam' are considered conditional based on Footnote 10 and are therefore not counted as mandatory contact days for all patients."
36308441,Arm B: Placebo + mFOLFOX6 chemotherapy,control,2,9,22,39,40,41,0,3,7,12,12,12,2,0,0,1,2,3,0,0,0,0,0,0,0,6,15,26,26,26,14,up to 24 weeks (6 months),"Screening (Day -28, Day -7); Treatment Cycles (Day 0, Day 1, Day 2 of each 14-day cycle for 12 cycles); Assessment Visits (Month 3 (Day 90), EoT (Day 168), Month 6 (Day 180), Month 9 (Day 270), Month 12 (Day 365)).","Both Arm A and Arm B have identical in-person healthcare contact days as the Schedule of Assessments does not differentiate between them for procedures, and IMP administration (PledOx or Placebo) is an in-person infusion for both.; The 'W-1' column in the Schedule of Assessments (Day -7) is considered a contact day, as it lists multiple procedures and is not explicitly marked 'not a patient visit' like the 'Randomization' column.; The 'Cold Sensitivity Patient Questionnaire (Paper Diary)' marked for 'before IMP* infusion and Days 1, 2, 3 after IMP and mFOLFOX6 infusion at Day 1' implies 3 distinct contact days per cycle (Day 0, Day 1, Day 2 of each cycle). Day 0 is categorized as core_treatment due to IMP/mFOLFOX6 infusion, and Day 1 and Day 2 are categorized as clinic_visits.; The End of Treatment (EoT) visit (Day 168) and Month 6 Assessment visit (Day 180) are counted as separate contact days, as they appear in distinct columns in the Schedule of Assessments and are not explicitly mandated to be combined.; Procedures marked with '(X)10' for 'Brain MRI and Blood Mn incl. Neurological Exam' are considered conditional based on Footnote 10 and are therefore not counted as mandatory contact days for all patients."
36322844,Standard Arm (ABVE-PC),control,4,17,41,58,60,61,0,16,39,54,54,54,2,1,2,3,4,5,1,0,0,1,2,2,1,0,0,0,0,0,21,5 cycles of chemotherapy + response-adapted ISRT until progression (assumed to complete full course for calculation),"5 cycles of 21-day chemotherapy, followed by 14 days of radiation therapy, then follow-up visits.","All patients complete 5 cycles of chemotherapy and receive Involved Site Radiation Therapy (ISRT). ISRT is assumed for all patients to provide an upper bound on contact days, starting on Day 147 (6 weeks after the end of Cycle 5).; ISRT consists of 14 treatment days, administered 5 days per week over approximately 3 weeks (Day 147-151, Day 154-158, Day 161-164).; G-CSF administration is not counted as an in-person healthcare contact day unless it coincides with another scheduled clinic visit, as it is often self-administered or administered by family.; Baseline procedures (biopsies, imaging, labs, clinic visits) are spread over 4 distinct days in the screening window (Day -28, -27, -26, -25) to account for different types of procedures.; Routine H&P and labs 'Prior to each cycle' are assumed to occur on Day 1 of each cycle and are subsumed under the core_treatment category due to chemotherapy administration on those days.; Biology blood draws are collected on scheduled days. If they coincide with chemotherapy (core_treatment) or major imaging (imaging_diagnostics), they are subsumed under the higher priority category. If they are standalone, they are counted as 'labs'. Standalone biology blood draws are assumed on Day 104 (end of C5) and Day 164 (end of RT).; Follow-up visits are scheduled at 3 and 6 months after the end of all therapy (Day 164), occurring on Day 254 and Day 344 respectively."
36322844,Experimental Arm (Bv-AVEPC),intervention,4,17,43,61,63,64,0,16,39,54,54,54,2,1,2,3,4,5,1,0,2,4,5,5,1,0,0,0,0,0,21,5 cycles of chemotherapy + response-adapted ISRT until progression (assumed to complete full course for calculation),"5 cycles of 21-day chemotherapy, followed by 14 days of radiation therapy, then follow-up visits with additional PK sampling during cycles 4 and 5.","All patients complete 5 cycles of chemotherapy and receive Involved Site Radiation Therapy (ISRT). ISRT is assumed for all patients to provide an upper bound on contact days, starting on Day 147 (6 weeks after the end of Cycle 5).; ISRT consists of 14 treatment days, administered 5 days per week over approximately 3 weeks (Day 147-151, Day 154-158, Day 161-164).; G-CSF administration is not counted as an in-person healthcare contact day unless it coincides with another scheduled clinic visit, as it is often self-administered or administered by family.; Baseline procedures (biopsies, imaging, labs, clinic visits) are spread over 4 distinct days in the screening window (Day -28, -27, -26, -25) to account for different types of procedures.; Routine H&P and labs 'Prior to each cycle' are assumed to occur on Day 1 of each cycle and are subsumed under the core_treatment category due to chemotherapy administration on those days.; Biology blood draws and PK samples are collected on scheduled days. If they coincide with chemotherapy (core_treatment) or major imaging (imaging_diagnostics), they are subsumed under the higher priority category. If they are standalone, they are counted as 'labs'. Standalone biology blood draws are assumed on Day 104 (end of C5) and Day 164 (end of RT).; Follow-up visits are scheduled at 3 and 6 months after the end of all therapy (Day 164), occurring on Day 254 and Day 344 respectively."
36327426,Treatment Arm 1: durvalumab + tremelimumab combination therapy + SoC chemotherapy,intervention,1,5,13,16,19,23,0,5,13,16,19,23,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"21 days (chemotherapy), 28 days (post-chemotherapy)",until progression,"Screening (1 day); During chemotherapy (4 cycles, q3w): Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78; Post-chemotherapy (q4w until PD): Day 85, 113 (with additional tremelimumab), 141, 169, 197, 225, 253, 281, 309, 337, 365. Tumor evaluations on Day -X, 43, 85, 141, 197, 253, 309, 365. PROs on Day -X, 43, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365.","Screening is assumed to occur on a single day within the screening window.; For SoC chemotherapy, the Abraxane + Carboplatin regimen (Days 1, 8, 15 of each 21-day cycle for Abraxane; Day 1 for Carboplatin) was assumed to maximize contact days during the initial 4 cycles.; Pemetrexed maintenance therapy was assumed for non-squamous patients, administered q4w in the post-chemotherapy phase.; Treatment is assumed to continue until objective disease progression, calculated up to Day +365.; All assessments listed in Table 2 (physical exams, vital signs, ECG, labs, tumor evaluations, PROs, PK samples, drug accountability) are assumed to require an in-person visit on the specified day.; Tumor evaluation (CT/MRI) and PRO assessments are assumed to coincide with infusion days, thus not adding new contact days but contributing to the highest priority category present on that day.; PK samples are assumed to be collected on infusion days and do not add new contact days.; The additional dose of durvalumab + tremelimumab at Week 16 is included."
36327426,Treatment Arm 2: durvalumab monotherapy + SoC chemotherapy,intervention,1,5,13,16,19,23,0,5,13,16,19,23,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"21 days (chemotherapy), 28 days (post-chemotherapy)",until progression,"Screening (1 day); During chemotherapy (4 cycles, q3w): Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78; Post-chemotherapy (q4w until PD): Day 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365. Tumor evaluations on Day -X, 43, 85, 141, 197, 253, 309, 365. PROs on Day -X, 43, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365.","Screening is assumed to occur on a single day within the screening window.; For SoC chemotherapy, the Abraxane + Carboplatin regimen (Days 1, 8, 15 of each 21-day cycle for Abraxane; Day 1 for Carboplatin) was assumed to maximize contact days during the initial 4 cycles.; Pemetrexed maintenance therapy was assumed for non-squamous patients, administered q4w in the post-chemotherapy phase.; Treatment is assumed to continue until objective disease progression, calculated up to Day +365.; All assessments listed in Table 2 (physical exams, vital signs, ECG, labs, tumor evaluations, PROs, PK samples, drug accountability) are assumed to require an in-person visit on the specified day.; Tumor evaluation (CT/MRI) and PRO assessments are assumed to coincide with infusion days, thus not adding new contact days but contributing to the highest priority category present on that day.; PK samples are assumed to be collected on infusion days and do not add new contact days."
36327426,Treatment Arm 3: SoC chemotherapy alone,control,1,5,13,22,27,34,0,5,13,21,25,30,1,0,0,1,2,4,0,0,0,0,0,0,0,0,0,0,0,0,"21 days (chemotherapy), 21 days (post-chemotherapy)",until progression,"Screening (1 day); During chemotherapy (4 cycles, q3w): Day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78; Post-chemotherapy (q3w until PD): Day 85, 92, 99, 106, 113, 120, 127, 141 (imaging only), 148, 169, 190, 197 (imaging only), 211, 232, 253, 274, 295, 309 (imaging only), 316, 337, 358, 365 (imaging only). Tumor evaluations on Day -X, 43, 85, 141, 197, 253, 309, 365. PROs on Day -X, 43, 85, 106, 127, 148, 169, 190, 211, 232, 253, 274, 295, 316, 337, 358.","Screening is assumed to occur on a single day within the screening window.; For SoC chemotherapy, the Abraxane + Carboplatin regimen (Days 1, 8, 15 of each 21-day cycle for Abraxane; Day 1 for Carboplatin) was assumed to maximize contact days during the initial 4 cycles.; The optional additional 2 cycles of SoC chemotherapy at Weeks 12 and 15 (q3w) were assumed to be taken to maximize contact days.; Pemetrexed maintenance therapy was assumed for non-squamous patients, administered q3w in the post-chemotherapy phase to align with the optional SoC chemotherapy schedule and maximize contact days.; Treatment is assumed to continue until objective disease progression, calculated up to Day +365.; All assessments listed in Table 2 (physical exams, vital signs, ECG, labs, tumor evaluations, PROs, PK samples, drug accountability) are assumed to require an in-person visit on the specified day.; Tumor evaluation (CT/MRI) and PRO assessments are assumed to coincide with infusion days where possible. If no infusion is scheduled, a separate visit for tumor evaluation is counted as an 'imaging_diagnostics' day.; PK samples are assumed to be collected on infusion days and do not add new contact days."
36346687,Capecitabine x 8,intervention,1,2,5,8,9,10,0,0,0,0,0,0,1,0,0,0,0,0,0,2,5,8,9,10,0,0,0,0,0,0,21,"8 cycles (24 weeks) of capecitabine, followed by 5 years clinical follow-up.","1 screening visit, 1 randomization/C1D1 visit, 7 subsequent cycle Day 1 visits (every 21 days), followed by 3-monthly follow-up visits for the first 2 years (with annual imaging), then 6-monthly follow-up visits for years 3-5 (with annual imaging).","The 'Pre-rd' column in the Schedule of Events (SoE) table is considered a single in-person contact day during the screening window. Procedures on this day include imaging (Mammography, Chest X-ray, Abdominal ultrasound or CT), labs (Hematology, Biochemistry, Pharmacogenetics, Blood or urine test, Pregnancy test, Hormone receptor status, HER2 status), and clinic visits (Informed consent, History, Physical examination, Adverse events, Evaluation of amenorrhea, Menopausal status). Per tie-breaker rules, this day is categorized as 'imaging_diagnostics'.; The '0=Rd day' column in the SoE table is considered a single in-person contact day (Day 0). Procedures on this day include labs (Hematology, Biochemistry, Pharmacogenetics, Blood or urine test, Pregnancy test) and clinic visits (Informed consent, History, Physical examination, Adverse events, Evaluation of amenorrhea, Menopausal status). Per tie-breaker rules, this day is categorized as 'labs'.; For Arm A, 'During CT (Day 1 or day -1 of each cycle)' is interpreted as a mandatory visit on Day 1 of each cycle (C2D1 through C8D1). These visits include Physical examination, Hematology, Biochemistry, Adverse events, Evaluation of amenorrhea, and Menopausal status. Per tie-breaker rules, these days are categorized as 'labs'. C1D1 is covered by '0=Rd day'.; The 'Day 1 or day -1 of cycle 4' column for Pharmacogenetics is combined with the C4D1 visit and does not add an additional contact day.; Capecitabine administration is oral and taken at home; therefore, it does not constitute a 'core_treatment' contact day. Clinic visits for drug dispensing are not considered 'core_treatment' but rather 'clinic_visits' or 'labs' if other procedures are performed.; Follow-up visits for Arm A begin after the 24-week (168-day) treatment period. The follow-up schedule is: every 3 months for the first 2 years (Physical examination, Hematology, Biochemistry, Adverse events, Amenorrhea, Menopausal status) and every 12 months for Mammography and Chest X-ray. When imaging coincides with a 3-month visit, the day is categorized as 'imaging_diagnostics'. Otherwise, it's 'labs'.; For calculation purposes, 1 month is approximated as 30.4375 days."
36346687,Observation,control,1,1,1,2,3,5,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,2,3,4,0,0,0,0,0,0,,"Observation, followed by 5 years clinical follow-up.","1 screening visit, 1 randomization visit, followed by 3-monthly follow-up visits for the first 2 years (with annual imaging), then 6-monthly follow-up visits for years 3-5 (with annual imaging).","The 'Pre-rd' column in the Schedule of Events (SoE) table is considered a single in-person contact day during the screening window. Procedures on this day include imaging (Mammography, Chest X-ray, Abdominal ultrasound or CT), labs (Hematology, Biochemistry, Pharmacogenetics, Blood or urine test, Pregnancy test, Hormone receptor status, HER2 status), and clinic visits (Informed consent, History, Physical examination, Adverse events, Evaluation of amenorrhea, Menopausal status). Per tie-breaker rules, this day is categorized as 'imaging_diagnostics'.; The '0=Rd day' column in the SoE table is considered a single in-person contact day (Day 0). Procedures on this day include labs (Hematology, Biochemistry, Pharmacogenetics, Blood or urine test, Pregnancy test) and clinic visits (Informed consent, History, Physical examination, Adverse events, Evaluation of amenorrhea, Menopausal status). Per tie-breaker rules, this day is categorized as 'labs'.; For Arm B (Observation), there are no cycle-specific treatment visits. Follow-up visits begin after Day 0. The follow-up schedule is: every 3 months for the first 2 years (Physical examination, Hematology, Biochemistry, Adverse events, Amenorrhea, Menopausal status) and every 12 months for Mammography and Chest X-ray. When imaging coincides with a 3-month visit, the day is categorized as 'imaging_diagnostics'. Otherwise, it's 'labs'.; For calculation purposes, 1 month is approximated as 30.4375 days."
36455168,Pembrolizumab plus Best Supportive Care (BSC),intervention,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression (assumed to continue for 12 months for calculation),"One screening visit, followed by 3-week (21-day) treatment cycles. Each cycle includes study drug administration, clinical assessments, and labs. Imaging and specific serologies occur at predefined intervals.","Screening procedures, despite having varying windows (7, 21, 28 days), are consolidated into a single in-person contact day. The highest priority procedure (tumor imaging and ECG) dictates the category for the screening day.; Patient Reported Outcomes (PROs) listed under screening in the table are overridden by footnote 'f' on page 36, which specifies their schedule starting from Cycle 1 Day 1.; Treatment is assumed to continue for the full 12-month duration for calculation purposes, encompassing 17 full cycles and the first day of Cycle 18 (Day 357).; All procedures marked with 'X' in the cycle columns occur on Day 1 of that respective cycle.; The 'Pembrolizumab/placebo administration' is an in-person intravenous infusion, categorizing any day it occurs as a 'core_treatment' day. This category takes precedence over all other activities on the same day.; Best Supportive Care (BSC) is considered local standard of care and is not explicitly detailed as trial-mandated in-person visits in the Schedule of Events, therefore, no additional contact days are counted for BSC.; The 'Second Course Treatment' phase is not included in the 12-month calculation as it is conditional on retreatment after disease progression and is not part of the initial treatment phase."
36455168,Placebo plus Best Supportive Care (BSC),intervention,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression (assumed to continue for 12 months for calculation),"One screening visit, followed by 3-week (21-day) treatment cycles. Each cycle includes study drug administration, clinical assessments, and labs. Imaging and specific serologies occur at predefined intervals.","Screening procedures, despite having varying windows (7, 21, 28 days), are consolidated into a single in-person contact day. The highest priority procedure (tumor imaging and ECG) dictates the category for the screening day.; Patient Reported Outcomes (PROs) listed under screening in the table are overridden by footnote 'f' on page 36, which specifies their schedule starting from Cycle 1 Day 1.; Treatment is assumed to continue for the full 12-month duration for calculation purposes, encompassing 17 full cycles and the first day of Cycle 18 (Day 357).; All procedures marked with 'X' in the cycle columns occur on Day 1 of that respective cycle.; The 'Pembrolizumab/placebo administration' is an in-person intravenous infusion, categorizing any day it occurs as a 'core_treatment' day. This category takes precedence over all other activities on the same day.; Best Supportive Care (BSC) is considered local standard of care and is not explicitly detailed as trial-mandated in-person visits in the Schedule of Events, therefore, no additional contact days are counted for BSC.; The 'Second Course Treatment' phase is not included in the 12-month calculation as it is conditional on retreatment after disease progression and is not part of the initial treatment phase."
36473143,Arm A: Nivolumab + Ipilimumab Arm,intervention,2,3,7,13,20,28,0,3,5,9,14,19,2,0,2,4,6,9,0,0,0,0,0,0,0,0,0,0,0,0,42,"until progression, unacceptable toxicity, or a maximum of 24 months from first nivolumab treatment","Screening (2 days). Treatment: Nivolumab every 2 weeks, Ipilimumab every 6 weeks. Routine safety/labs/PK/biomarkers on infusion days. Tumor assessments (CT/MRI) every 6 weeks for first 48 weeks, then every 12 weeks. Week 7 biopsy and progression biopsy.","Treatment duration is assumed to continue for the full 12-month period for calculation purposes, or until progression if a progression biopsy is assumed.; Screening procedures are consolidated into two in-person days: one for imaging (CT/MRI) and biopsy (if needed), and another for labs (blood, urine, pregnancy), ECG, physical exam, consent, and other routine assessments. The day with ECG is categorized as 'imaging_diagnostics' due to precedence.; Optional visits, such as the Week 7 biopsy and progression biopsy, are assumed to occur.; Patient-reported outcomes (FACT-H&N, EQ-5D-3L) are assumed to be collected via phone and are not counted as in-person contact days.; Progression biopsy is assumed to occur once within the 12-month window (e.g., Day 300) and is counted as an 'imaging_diagnostics' day."
36473143,Arm B: EXTREME regimen Arm,control,2,11,28,44,57,72,0,10,20,34,45,57,2,1,8,10,12,15,0,0,0,0,0,0,0,0,0,0,0,0,21,"maximum of 6 cycles of combination, followed by maintenance Cetuximab weekly until disease progression or unacceptable toxicity","Screening (2 days). Initial 6 cycles (3 weeks/cycle): Cetuximab weekly, Cisplatin/Carboplatin + 5-FU (4 days) on Day 1 of each cycle. Maintenance: Cetuximab weekly. Routine safety/labs on infusion days. Tumor assessments (CT/MRI) every 6 weeks for first 48 weeks, then every 12 weeks. Week 7 biopsy and progression biopsy.","Treatment duration is assumed to continue for the full 12-month period for calculation purposes, or until progression if a progression biopsy is assumed.; Screening procedures are consolidated into two in-person days: one for imaging (CT/MRI) and biopsy (if needed), and another for labs (blood, urine, pregnancy), ECG, physical exam, consent, and other routine assessments. The day with ECG is categorized as 'imaging_diagnostics' due to precedence.; Optional visits, such as the Week 7 biopsy and progression biopsy, are assumed to occur.; Patient-reported outcomes (FACT-H&N, EQ-5D-3L) are assumed to be collected via phone and are not counted as in-person contact days.; For maintenance, Cetuximab is assumed to be administered weekly, as per the primary description, including routine safety assessments and labs on these days.; Progression biopsy is assumed to occur once within the 12-month window (e.g., Day 300) and is counted as an 'imaging_diagnostics' day."
36503738,Arm 1 (BBI-608 plus biweekly FOLFIRI),intervention,5,3,7,13,20,27,0,3,7,13,20,27,2,0,0,0,0,0,2,0,0,0,0,0,1,0,0,0,0,0,14,until progression,"Screening visits at Day -28, -21, -14, -5, -2 (Arm 1 only). Treatment visits on Day 1 of every 14-day cycle (Day 0, 14, 28, ... 364). Specific assessments (imaging, PK, correlative labs, QoL, pregnancy tests) occur on various cycle Day 1s.","Cycle length is 14 days.; Treatment continues until progression, so calculations are made up to Day +365.; For Arm 1, 'Run-in Day 1' is assumed to be Day -2 (2 days prior to C1D1) and is a contact day for clinic visits. 'Run-in Day 2' is for phone assessment only and is not counted as a contact day.; Baseline CT/MRI is considered a screening visit on Day -21.; Baseline ECG is considered a screening visit on Day -28.; Baseline labs (Hematology, Biochemistry, Urinalysis, Blood sample for correlative studies, Pregnancy test) and clinic visits (H&P, Vitals, Weight, ECOG, Clinical tumor measurements, RAS testing, Concurrent meds, AE, QoL) are consolidated to Day -14 for the main screening visit, and Day -5 for pregnancy test.; On-treatment CT/MRI scans are scheduled for Day 56 (C5D1), Day 112 (C9D1), Day 168 (C13D1), Day 252 (C19D1), Day 336 (C25D1).; On-treatment ECG is only performed on C1D1 (Day 0) and as clinically indicated thereafter (not counted unless explicitly scheduled).; Sparse PK collection for Arm 1 is on Day 14 (C2D1) and Day 28 (C3D1).; Blood collection for correlative studies for both arms is on Day 28 (C3D1).; Quality of Life assessments for both arms are on Day 28 (C3D1), Day 56 (C5D1), Day 84 (C7D1), Day 112 (C9D1), Day 168 (C13D1).; Serum or urine pregnancy tests for both arms are on Day 14 (C2D1), Day 42 (C4D1), Day 70 (C6D1), Day 98 (C8D1), Day 126 (C10D1), Day 154 (C12D1), Day 182 (C14D1), Day 210 (C16D1), Day 238 (C18D1), Day 266 (C20D1), Day 294 (C22D1), Day 322 (C24D1), Day 350 (C26D1).; All visits on Day 1 of each cycle (C1D1, C2D1, etc.) include FOLFIRI infusion, making them 'core_treatment' days due to precedence."
36503738,Arm 2 (biweekly FOLFIRI alone),control,4,3,7,13,20,27,0,3,7,13,20,27,2,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,14,until progression,"Screening visits at Day -28, -21, -14, -5. Treatment visits on Day 1 of every 14-day cycle (Day 0, 14, 28, ... 364). Specific assessments (imaging, correlative labs, QoL, pregnancy tests) occur on various cycle Day 1s.","Cycle length is 14 days.; Treatment continues until progression, so calculations are made up to Day +365.; No BBI-608 run-in days for Arm 2.; Baseline CT/MRI is considered a screening visit on Day -21.; Baseline ECG is considered a screening visit on Day -28.; Baseline labs (Hematology, Biochemistry, Urinalysis, Blood sample for correlative studies, Pregnancy test) and clinic visits (H&P, Vitals, Weight, ECOG, Clinical tumor measurements, RAS testing, Concurrent meds, AE, QoL) are consolidated to Day -14 for the main screening visit, and Day -5 for pregnancy test.; On-treatment CT/MRI scans are scheduled for Day 56 (C5D1), Day 112 (C9D1), Day 168 (C13D1), Day 252 (C19D1), Day 336 (C25D1).; On-treatment ECG is only performed on C1D1 (Day 0) and as clinically indicated thereafter (not counted unless explicitly scheduled).; Sparse PK collection is not applicable for Arm 2.; Blood collection for correlative studies for both arms is on Day 28 (C3D1).; Quality of Life assessments for both arms are on Day 28 (C3D1), Day 56 (C5D1), Day 84 (C7D1), Day 112 (C9D1), Day 168 (C13D1).; Serum or urine pregnancy tests for both arms are on Day 14 (C2D1), Day 42 (C4D1), Day 70 (C6D1), Day 98 (C8D1), Day 126 (C10D1), Day 154 (C12D1), Day 182 (C14D1), Day 210 (C16D1), Day 238 (C18D1), Day 266 (C20D1), Day 294 (C22D1), Day 322 (C24D1), Day 350 (C26D1).; All visits on Day 1 of each cycle (C1D1, C2D1, etc.) include FOLFIRI infusion, making them 'core_treatment' days due to precedence."
36521097,Arm A: nab-Paclitaxel + Gemcitabine,intervention,1,4,10,20,21,22,0,4,10,18,18,18,1,0,0,1,2,3,0,0,0,1,1,1,0,0,0,0,0,0,28,"6 cycles (168 days), followed by imaging until disease recurrence.","Screening (1 day); Cycle 1-6 Day 1, 8, 15 (18 days); Week 24 CT/MRI (1 day); End of Treatment Visit (1 day); Follow-up CT/MRI at Week 36, 48 (2 days).","Screening and Randomization are considered one contact day, as randomization occurs on a screening day (Day -X).; The screening visit is considered a distinct day from Cycle 1 Day 1, despite the possibility of overlap mentioned in footnote 'c'.; The End of Treatment (EOT) visit is assumed to occur on Day 169, as it is specified to be 'as soon as possible after end of Cycle 6 (ie, after Cycle 6 Day 28), but no later than 14 days after Cycle 6 Day 28'. This makes it distinct from the last treatment day (C6D15 on Day 154) and the Week 24 CT/MRI (Day 168).; CT/MRI scans and other assessments (e.g., CA19-9, Quality of Life) scheduled on the same day are counted as one contact day.; When multiple activities occur on the same day, the tie-breaker precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) is applied.; Treatment is assumed to continue for the full 6 cycles (168 days).; Follow-up imaging is assumed to continue as scheduled within the 12-month window, as the protocol states it continues 'until disease recurrence'.; Collection of mandatory surgical primary pancreatic tumor sample and normal sample at screening are considered diagnostic biopsies, categorized under imaging_diagnostics.; Biomarker blood sample and Pregnancy Test at screening are considered lab procedures.; ECG (12 lead) is considered an imaging_diagnostics procedure.; QoL questionnaires are considered clinic_visits."
36521097,Arm B: Gemcitabine alone,control,1,4,10,20,21,22,0,4,10,18,18,18,1,0,0,1,2,3,0,0,0,1,1,1,0,0,0,0,0,0,28,"6 cycles (168 days), followed by imaging until disease recurrence.","Screening (1 day); Cycle 1-6 Day 1, 8, 15 (18 days); Week 24 CT/MRI (1 day); End of Treatment Visit (1 day); Follow-up CT/MRI at Week 36, 48 (2 days).","Screening and Randomization are considered one contact day, as randomization occurs on a screening day (Day -X).; The screening visit is considered a distinct day from Cycle 1 Day 1, despite the possibility of overlap mentioned in footnote 'c'.; The End of Treatment (EOT) visit is assumed to occur on Day 169, as it is specified to be 'as soon as possible after end of Cycle 6 (ie, after Cycle 6 Day 28), but no later than 14 days after Cycle 6 Day 28'. This makes it distinct from the last treatment day (C6D15 on Day 154) and the Week 24 CT/MRI (Day 168).; CT/MRI scans and other assessments (e.g., CA19-9, Quality of Life) scheduled on the same day are counted as one contact day.; When multiple activities occur on the same day, the tie-breaker precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) is applied.; Treatment is assumed to continue for the full 6 cycles (168 days).; Follow-up imaging is assumed to continue as scheduled within the 12-month window, as the protocol states it continues 'until disease recurrence'.; Collection of mandatory surgical primary pancreatic tumor sample and normal sample at screening are considered diagnostic biopsies, categorized under imaging_diagnostics.; Biomarker blood sample and Pregnancy Test at screening are considered lab procedures.; ECG (12 lead) is considered an imaging_diagnostics procedure.; QoL questionnaires are considered clinic_visits."
36535566,Pembrolizumab (MK-3475) Monotherapy,intervention,2,4,7,11,15,19,0,2,5,9,13,17,1,0,0,0,0,0,1,2,2,2,2,2,0,0,0,0,0,0,21,until progression or up to 35 administrations (approx. 2 years),"Screening (Day -28, Day -1), then Day 1 of each 21-day cycle, plus Day 7 and Day 14 for C1 EBV DNA collection.","Screening is comprised of two distinct in-person visits: Day -28 for initial comprehensive screening procedures and Day -1 for pre-treatment labs and assessments to meet 'within 10 days' or 'within 72/24 hours' requirements.; Treatment duration is assumed to be 12 months (365 days) or until progression, whichever is earlier. For counting purposes, visits are included up to Day +365.; Cycle length for all treatments is 21 days.; Plasma EBV DNA collection occurs weekly during Cycle 1 (Day 0, Day 7, Day 14) and then pre-dose on Day 1 of all subsequent cycles.; Tumor imaging is performed every 6 weeks (every 2 cycles) for the first year (C1, C3, C5, C7, C9, C11, C13, C15, C17).; Urinalysis and Thyroid labs (T3/FT3/FT4/TSH) are performed every other cycle after Cycle 1 (C2, C4, C6, C8, C10, C12, C14, C16).; Pharmacokinetics (PK) and Anti-Pembrolizumab Antibodies (ADA) are collected on Day 1 of C1, C2, C4, C6, C8, C12, C16 (every 4 cycles after C8).; Patient-Reported Outcomes (EQ 5D) are collected on Day 1 of C1, C2, C3, C5, C7, C9, C11, C13, C15, C17 (every 2 cycles after C3 up to 1 year).; Newly obtained tissue biopsies for EBV and PD-L1 biomarker analysis at screening are categorized as imaging_diagnostics.; Oral administration of Capecitabine is not considered an in-person healthcare contact day for drug delivery."
36535566,Standard Chemotherapy - Capecitabine,control,2,4,7,11,15,19,0,0,0,0,0,0,1,1,3,5,7,9,1,3,4,6,8,10,0,0,0,0,0,0,21,until progression,"Screening (Day -28, Day -1), then Day 1 of each 21-day cycle, plus Day 7 and Day 14 for C1 EBV DNA collection.","Screening is comprised of two distinct in-person visits: Day -28 for initial comprehensive screening procedures and Day -1 for pre-treatment labs and assessments to meet 'within 10 days' or 'within 72/24 hours' requirements.; Treatment duration is assumed to be 12 months (365 days) or until progression, whichever is earlier. For counting purposes, visits are included up to Day +365.; Cycle length for all treatments is 21 days.; Plasma EBV DNA collection occurs weekly during Cycle 1 (Day 0, Day 7, Day 14) and then pre-dose on Day 1 of all subsequent cycles.; Tumor imaging is performed every 6 weeks (every 2 cycles) for the first year (C1, C3, C5, C7, C9, C11, C13, C15, C17).; Urinalysis and Thyroid labs (T3/FT3/FT4/TSH) are performed every other cycle after Cycle 1 (C2, C4, C6, C8, C10, C12, C14, C16).; Patient-Reported Outcomes (EQ 5D) are collected on Day 1 of C1, C2, C3, C5, C7, C9, C11, C13, C15, C17 (every 2 cycles after C3 up to 1 year).; Newly obtained tissue biopsies for EBV and PD-L1 biomarker analysis at screening are categorized as imaging_diagnostics.; Oral administration of Capecitabine is not considered an in-person healthcare contact day for drug delivery."
36535566,Standard Chemotherapy - Gemcitabine,control,2,5,10,19,27,35,0,4,9,18,26,34,1,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,21,until progression,"Screening (Day -28, Day -1), then Day 1 and Day 8 of each 21-day cycle, plus Day 14 for C1 EBV DNA collection.","Screening is comprised of two distinct in-person visits: Day -28 for initial comprehensive screening procedures and Day -1 for pre-treatment labs and assessments to meet 'within 10 days' or 'within 72/24 hours' requirements.; Treatment duration is assumed to be 12 months (365 days) or until progression, whichever is earlier. For counting purposes, visits are included up to Day +365.; Cycle length for all treatments is 21 days.; Plasma EBV DNA collection occurs weekly during Cycle 1 (Day 0, Day 7, Day 14) and then pre-dose on Day 1 of all subsequent cycles.; Tumor imaging is performed every 6 weeks (every 2 cycles) for the first year (C1, C3, C5, C7, C9, C11, C13, C15, C17).; Urinalysis and Thyroid labs (T3/FT3/FT4/TSH) are performed every other cycle after Cycle 1 (C2, C4, C6, C8, C10, C12, C14, C16).; Patient-Reported Outcomes (EQ 5D) are collected on Day 1 of C1, C2, C3, C5, C7, C9, C11, C13, C15, C17 (every 2 cycles after C3 up to 1 year).; Newly obtained tissue biopsies for EBV and PD-L1 biomarker analysis at screening are categorized as imaging_diagnostics.; Gemcitabine is administered via IV infusion on Day 1 and Day 8 of each 21-day cycle, making both days in-person contact days for core treatment and associated assessments."
36535566,Standard Chemotherapy - Docetaxel,control,2,4,7,11,15,19,0,2,5,9,13,17,1,0,0,0,0,0,1,2,2,2,2,2,0,0,0,0,0,0,21,until progression,"Screening (Day -28, Day -1), then Day 1 of each 21-day cycle, plus Day 7 and Day 14 for C1 EBV DNA collection.","Screening is comprised of two distinct in-person visits: Day -28 for initial comprehensive screening procedures and Day -1 for pre-treatment labs and assessments to meet 'within 10 days' or 'within 72/24 hours' requirements.; Treatment duration is assumed to be 12 months (365 days) or until progression, whichever is earlier. For counting purposes, visits are included up to Day +365.; Cycle length for all treatments is 21 days.; Plasma EBV DNA collection occurs weekly during Cycle 1 (Day 0, Day 7, Day 14) and then pre-dose on Day 1 of all subsequent cycles.; Tumor imaging is performed every 6 weeks (every 2 cycles) for the first year (C1, C3, C5, C7, C9, C11, C13, C15, C17).; Urinalysis and Thyroid labs (T3/FT3/FT4/TSH) are performed every other cycle after Cycle 1 (C2, C4, C6, C8, C10, C12, C14, C16).; Patient-Reported Outcomes (EQ 5D) are collected on Day 1 of C1, C2, C3, C5, C7, C9, C11, C13, C15, C17 (every 2 cycles after C3 up to 1 year).; Newly obtained tissue biopsies for EBV and PD-L1 biomarker analysis at screening are categorized as imaging_diagnostics.; Docetaxel is administered via IV infusion on Day 1 of each 21-day cycle, making this day an in-person contact day for core treatment and associated assessments."
36541957,Ibrutinib + CIT (RICE or RVICI),intervention,1,10,18,21,22,23,0,8,15,15,15,15,1,1,2,5,6,7,0,1,1,1,1,1,0,0,0,0,0,0,28,"3 cycles of combination therapy, followed by 3 cycles of ibrutinib monotherapy (if PR or better), then follow-up until PD, clinical cutoff, or up to 3 years after C1D1.","Screening (1 day); Treatment Phase (3 cycles of 28 days): C1D1-C1D5 (core_treatment), C1D7 (labs), C1D14 (imaging_diagnostics); C2D1-C2D5 (core_treatment); C3D1-C3D5 (core_treatment); End-of-Treatment (imaging_diagnostics). Posttreatment Phase: Ibrutinib Monotherapy C5D1 (imaging_diagnostics), C6D1 (imaging_diagnostics), End-of-Monotherapy (imaging_diagnostics), then follow-up visits at 9 and 12 months (imaging_diagnostics).","Screening is considered a single contact day, categorized by the highest priority procedure (imaging_diagnostics).; Cycle 1 Day 1 (C1D1) is considered Day 0.; Treatment cycles are 28 days in length.; RICE/RVICI chemotherapy administration (including IV hydration and triple intrathecal therapy) is assumed to occur on 5 consecutive days (Day 1-5) for each cycle, categorized as core_treatment.; For 'Day 7 or 8' visits, Day 7 was used for calculation.; Visits or procedures marked 'if clinically indicated' or 'if applicable' (e.g., bone marrow biopsy on C2D1/C3D1, lumbar puncture/bone marrow in posttreatment follow-up for Arm A) are not counted as mandatory contact days.; The End-of-Treatment (EoT) visit is assumed to occur on Day +84 (after 3 cycles of 28 days).; For Arm A, the start of Ibrutinib monotherapy (C4D1) is assumed to coincide with the EoT visit on Day +84, and is counted as a single day, categorized by the highest priority procedure (imaging_diagnostics).; The End-of-Monotherapy (EoM) visit for Arm A is assumed to occur on Day +168 (after 3 monotherapy cycles).; Ibrutinib self-administration is not counted as a contact day.; For RVICI subjects, ECG/MUGA is required at the end of each cycle (within 3 days prior to the next cycle). This is assumed to occur on C2D1 and C3D1, but since these days also have core_treatment, the day is categorized as core_treatment.; Follow-up visits are counted until Day +365 as per the schedules in Table 3 and Table 4."
36541957,CIT (RICE or RVICI) alone,control,1,9,17,18,19,20,0,8,15,15,15,15,1,1,2,3,4,5,0,0,0,0,0,0,0,0,0,0,0,0,28,"3 cycles of combination therapy, then follow-up until PD, clinical cutoff, or up to 3 years after C1D1.","Screening (1 day); Treatment Phase (3 cycles of 28 days): C1D1-C1D5 (core_treatment), C1D7 (clinic_visits), C1D14 (imaging_diagnostics); C2D1-C2D5 (core_treatment); C3D1-C3D5 (core_treatment); End-of-Treatment (imaging_diagnostics). Posttreatment Phase: follow-up visits at 6, 9, and 12 months (imaging_diagnostics).","Screening is considered a single contact day, categorized by the highest priority procedure (imaging_diagnostics).; Cycle 1 Day 1 (C1D1) is considered Day 0.; Treatment cycles are 28 days in length.; RICE/RVICI chemotherapy administration (including IV hydration and triple intrathecal therapy) is assumed to occur on 5 consecutive days (Day 1-5) for each cycle, categorized as core_treatment.; For 'Day 7 or 8' visits, Day 7 was used for calculation.; Visits or procedures marked 'if clinically indicated' or 'if applicable' (e.g., bone marrow biopsy on C2D1/C3D1, lumbar puncture/bone marrow in posttreatment follow-up) are not counted as mandatory contact days.; The End-of-Treatment (EoT) visit is assumed to occur on Day +84 (after 3 cycles of 28 days).; For RVICI subjects, ECG/MUGA is required at the end of each cycle (within 3 days prior to the next cycle). This is assumed to occur on C2D1 and C3D1, but since these days also have core_treatment, the day is categorized as core_treatment.; Follow-up visits are counted until Day +365 as per the schedules in Table 3 and Table 4."
36623230,Arm A: 45 Gy twice daily for 3 weeks,intervention,1,19,29,41,43,45,0,18,24,34,34,34,1,0,1,3,4,5,0,1,3,3,3,3,0,0,1,1,2,3,21,"Chemotherapy for 4 cycles (12 weeks), Radiotherapy for 3 weeks, PCI for 2 weeks. Follow-up for 10 years until progression.","Chemotherapy (Cisplatin/Carboplatin on D1, Etoposide on D1-3) every 21 days for 4 cycles. Radiotherapy (45 Gy BID Mon-Fri) for 3 weeks. Labs on D1 and D8 of each cycle. Restaging (CT scan) at end of Cycle 2 and 4. PCI (10 fractions Mon-Fri) for 2 weeks after chemo/RT. Follow-up visits with imaging and labs at 6, 9, 12 months. QOL assessments at specified weeks.","Radiotherapy (RT) is assumed to start on Cycle 1 Day 1 (Day 0).; Prophylactic Cranial Irradiation (PCI) is assumed to be offered and started 3 weeks after the completion of Cycle 4 chemotherapy (Day 84 + 21 = Day 105).; MRI/CT Brain prior to PCI is assumed to occur one day before PCI starts (Day 104).; All 'Prior to Registration' procedures are assumed to occur on a single day (Day -28) within the screening window.; Optional Quality of Life (QOL) assessments and Plasma Collection visits are included in the counts.; Follow-up visits (including PE, vitals, weight, PS, tumor measurements, CT Chest/Abdomen, PFT, Plasma) are assumed to occur at 6, 9, and 12 months from C1D1 (Day 180, Day 270, Day 365) to align with fixed time windows.; Weekly weight measurements during RT are assumed to overlap with RT days and are categorized as core_treatment due to precedence.; QOL assessments on Day 21 (C2D1), Day 49 (C3D8), Day 84 (Restaging), Day 180 (Follow-up), Day 270 (Follow-up), Day 365 (Follow-up) are categorized by the highest priority procedure on that day."
36623230,Arm B: 70 Gy once daily for 7 weeks,intervention,1,22,42,54,56,58,0,21,38,48,48,48,1,1,2,4,5,6,0,0,2,2,2,2,0,0,0,0,1,2,21,"Chemotherapy for 4 cycles (12 weeks), Radiotherapy for 7 weeks, PCI for 2 weeks. Follow-up for 10 years until progression.","Chemotherapy (Cisplatin/Carboplatin on D1, Etoposide on D1-3) every 21 days for 4 cycles. Radiotherapy (70 Gy QD Mon-Fri) for 7 weeks. Labs on D1 and D8 of each cycle. Second CT scan for RT planning around Day 27. Restaging (CT scan) at end of Cycle 2 and 4. PCI (10 fractions Mon-Fri) for 2 weeks after chemo/RT. Follow-up visits with imaging and labs at 6, 9, 12 months. QOL assessments at specified weeks.","Radiotherapy (RT) is assumed to start on Cycle 1 Day 1 (Day 0).; Prophylactic Cranial Irradiation (PCI) is assumed to be offered and started 3 weeks after the completion of Cycle 4 chemotherapy (Day 84 + 21 = Day 105).; MRI/CT Brain prior to PCI is assumed to occur one day before PCI starts (Day 104).; All 'Prior to Registration' procedures are assumed to occur on a single day (Day -28) within the screening window.; Optional Quality of Life (QOL) assessments and Plasma Collection visits are included in the counts.; Follow-up visits (including PE, vitals, weight, PS, tumor measurements, CT Chest/Abdomen, PFT, Plasma) are assumed to occur at 6, 9, and 12 months from C1D1 (Day 180, Day 270, Day 365) to align with fixed time windows.; Weekly weight measurements during RT are assumed to overlap with RT days and are categorized as core_treatment due to precedence.; A second volumetric treatment planning CT study for Arm B (for PTV-2) is assumed to occur on Day 27, one week prior to the start of PTV-2 RT (Week 5, starting Day 28).; QOL assessments on Day 21 (C2D1), Day 35 (RT), Day 49 (C3D8), Day 84 (Restaging), Day 180 (Follow-up), Day 270 (Follow-up), Day 365 (Follow-up) are categorized by the highest priority procedure on that day."
36669140,Regimen A (VDC/IE),intervention,2,11,29,55,68,68,0,9,23,43,53,53,1,0,0,0,2,2,1,2,6,12,13,13,0,0,0,0,0,0,14,"Treatment continues through Metastatic Site Radiation, followed by a defined follow-up schedule.","Induction (6 cycles, 2-week each), followed by End Induction Evaluation. Local Control (surgery/XRT) occurs after Induction. Consolidation (8 cycles, 2-week each), followed by End Consolidation Evaluation. Metastatic Site Radiation (5 days) after Consolidation. Then scheduled follow-up visits.","Screening evaluations are consolidated into 2 distinct days: one for labs and one for imaging/diagnostics.; Growth factor support is assumed to be administered outside of in-person clinic visits (e.g., self-administered or by home nurse) and therefore not counted as a contact day.; Local Control (surgery and/or radiation) is integrated into the treatment schedule. If surgery occurs, it is assumed to be a single day. If radiation is used for local control, it can be concurrent with Consolidation Cycle 1. Given that Consolidation Cycle 1 Day 1 (Day 84) is already a core_treatment day, no additional unique contact days are added for Local Control.; Metastatic Site Radiation is assumed to be SBRT (5 fractions over 5 days), starting 3 weeks after the start of Consolidation Week 15 (Day 182 + 21 days = Day 203).; Follow-up visits are timed from the end of Consolidation therapy (Day 195).; For days with multiple procedures, the category precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied."
36669140,Regimen B (VDC/IE plus ganitumab),intervention,2,11,29,55,68,68,0,9,23,43,53,53,1,0,0,0,2,2,1,2,6,12,13,13,0,0,0,0,0,0,14,"Treatment continues through Metastatic Site Radiation, followed by a defined follow-up schedule.","Induction (6 cycles, 2-week each), followed by End Induction Evaluation. Local Control (surgery/XRT) occurs after Induction. Consolidation (8 cycles, 2-week each), followed by End Consolidation Evaluation. Metastatic Site Radiation (5 days) after Consolidation. Then scheduled follow-up visits.","As of March 20, 2019, ganitumab administration was discontinued for all patients on Regimen B due to lack of significant benefit and potential increased toxicity (Page 1, 3, 15, 38). Therefore, Regimen B is currently identical to Regimen A in terms of treatment and visit schedule.; Screening evaluations are consolidated into 2 distinct days: one for labs and one for imaging/diagnostics.; Growth factor support is assumed to be administered outside of in-person clinic visits (e.g., self-administered or by home nurse) and therefore not counted as a contact day.; Local Control (surgery and/or radiation) is integrated into the treatment schedule. If surgery occurs, it is assumed to be a single day. If radiation is used for local control, it can be concurrent with Consolidation Cycle 1. Given that Consolidation Cycle 1 Day 1 (Day 84) is already a core_treatment day, no additional unique contact days are added for Local Control.; Metastatic Site Radiation is assumed to be SBRT (5 fractions over 5 days), starting 3 weeks after the start of Consolidation Week 15 (Day 182 + 21 days = Day 203).; Follow-up visits are timed from the end of Consolidation therapy (Day 195).; For days with multiple procedures, the category precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied."
36764316,AMG 510,intervention,1,4,9,17,25,35,0,3,3,3,3,3,1,0,2,4,6,8,0,1,4,10,16,24,0,0,0,0,0,0,21,until progression (calculated up to Day +365),"Screening (1 day). Treatment cycles (21 days each): C1D1, C1D8, C2D1, C2D8, then D1 and D8 of each subsequent 21-day cycle. Imaging: Weeks 7, 13, 19, 25, 31, 37, 43, 49.","Cycle length is 21 days.; Screening is considered 1 contact day, occurring on Day -7 for calculation purposes.; All procedures marked 'X' in the Schedule of Activities tables are considered in-person contact days, unless specified as 'at home' or 'phone call'.; Procedures marked '(X)' are considered in-person contact days if the associated note implies they are generally performed or if they are a key assessment for the study (e.g., PK on Day 8 of cycles for AMG 510, Cholesterol/Triglycerides on odd cycles). ECGs marked (X) for AMG 510 after C2D1 are not counted as mandated visits based on the specific note.; When multiple activities occur on the same calendar day, the day is assigned to the highest-priority category present (core_treatment > imaging_diagnostics > labs > clinic_visits).; Tumor assessments (CT/MRI) are scheduled every 6 weeks from C1D1 (Week 7, 13, 19, 25, 31, 37, 43, 49) and then every 9 weeks. If these dates coincide with a cycle visit day, they are consolidated into a single contact day, with imaging_diagnostics taking precedence over core_treatment/labs/clinic_visits.; AMG 510 oral dosing is in-clinic for C1D1, C1D8, C2D1. For subsequent cycles, Day 1 and Day 8 dosing is at home, but PK collection on these days constitutes an in-person lab visit.; Docetaxel IV infusion is always an in-clinic core_treatment day.; Safety Follow-up (SFU) visit is 30 days after the last dose. Assuming treatment continues until Day 365, the SFU would fall outside the 12-month window (Day 365) and thus is not counted in the provided intervals."
36764316,Docetaxel,control,1,2,5,9,13,18,0,2,3,5,7,10,1,0,2,4,6,8,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression (calculated up to Day +365),"Screening (1 day). Treatment cycles (21 days each): D1 of each 21-day cycle. Imaging: Weeks 7, 13, 19, 25, 31, 37, 43, 49.","Cycle length is 21 days.; Screening is considered 1 contact day, occurring on Day -7 for calculation purposes.; All procedures marked 'X' in the Schedule of Activities tables are considered in-person contact days, unless specified as 'at home' or 'phone call'.; Procedures marked '(X)' are considered in-person contact days if the associated note implies they are generally performed or if they are a key assessment for the study (e.g., PK on Day 8 of cycles for AMG 510, Cholesterol/Triglycerides on odd cycles). ECGs marked (X) for AMG 510 after C2D1 are not counted as mandated visits based on the specific note.; When multiple activities occur on the same calendar day, the day is assigned to the highest-priority category present (core_treatment > imaging_diagnostics > labs > clinic_visits).; Tumor assessments (CT/MRI) are scheduled every 6 weeks from C1D1 (Week 7, 13, 19, 25, 31, 37, 43, 49) and then every 9 weeks. If these dates coincide with a cycle visit day, they are consolidated into a single contact day, with imaging_diagnostics taking precedence over core_treatment/labs/clinic_visits.; AMG 510 oral dosing is in-clinic for C1D1, C1D8, C2D1. For subsequent cycles, Day 1 and Day 8 dosing is at home, but PK collection on these days constitutes an in-person lab visit.; Docetaxel IV infusion is always an in-clinic core_treatment day.; Safety Follow-up (SFU) visit is 30 days after the last dose. Assuming treatment continues until Day 365, the SFU would fall outside the 12-month window (Day 365) and thus is not counted in the provided intervals."
36795891,Rucaparib,intervention,2,3,7,13,20,27,0,0,0,0,0,0,2,0,1,3,4,5,0,3,6,10,16,22,0,0,0,0,0,0,28,until progression,"Screening: Day -28 (Imaging), Day -14 (Imaging). Treatment: Day 0, Day 15, Day 29, Day 43, Day 57 (Imaging), Day 71, Day 85, Day 99, Day 113 (Imaging), Day 127, Day 141, Day 155, Day 169 (Imaging), Day 183, Day 197, Day 211, Day 225, Day 239, Day 253 (Imaging), Day 267, Day 281, Day 295, Day 309, Day 323, Day 337 (Imaging), Day 351, Day 365. All non-imaging/non-core-treatment days are primarily labs due to multiple lab procedures.","Screening procedures within a window are consolidated into the minimum number of distinct days, prioritizing higher category procedures.; A separate optional tumor biopsy day is counted during screening (imaging_diagnostics).; Day 0 is the first on-treatment visit, following randomization.; The schedule for Rucaparib and Abiraterone Acetate or Enzalutamide is identical as per Table 5 (Amendment 4, pages 111-113).; For Rucaparib and Abiraterone/Enzalutamide, treatment continues 'until radiographic disease progression', so visits are counted up to Day +365.; Study Drug Dispensation, Adverse Events checks, Patient-reported outcome (PRO) done in clinic, Physical Examination, Vital Signs, Medical/Oncology History, Prior/Concomitant Medications/Procedures, ECOG Performance Status, and Informed Consent are categorized as clinic_visits.; Blood samples for plasma ctDNA analysis, Serum Testosterone, PSA Measurement, Clinical Laboratory Assessments, Pharmacogenomic blood sample, and Archival Primary/Metastatic Tumor Tissue Sample (if collected in-person) are categorized as labs.; Tumor Assessment/CT/MRI/Bone Scan, 12-lead ECG, and Tumor Biopsy (optional) are categorized as imaging_diagnostics.; Docetaxel Administration is categorized as core_treatment.; For days with multiple procedures, the highest priority category is assigned (core_treatment > imaging_diagnostics > labs > clinic_visits)."
36795891,Abiraterone Acetate or Enzalutamide,control,2,3,7,13,20,27,0,0,0,0,0,0,2,0,1,3,4,5,0,3,6,10,16,22,0,0,0,0,0,0,28,until progression,"Screening: Day -28 (Imaging), Day -14 (Imaging). Treatment: Day 0, Day 15, Day 29, Day 43, Day 57 (Imaging), Day 71, Day 85, Day 99, Day 113 (Imaging), Day 127, Day 141, Day 155, Day 169 (Imaging), Day 183, Day 197, Day 211, Day 225, Day 239, Day 253 (Imaging), Day 267, Day 281, Day 295, Day 309, Day 323, Day 337 (Imaging), Day 351, Day 365. All non-imaging/non-core-treatment days are primarily labs due to multiple lab procedures.","Screening procedures within a window are consolidated into the minimum number of distinct days, prioritizing higher category procedures.; A separate optional tumor biopsy day is counted during screening (imaging_diagnostics).; Day 0 is the first on-treatment visit, following randomization.; The schedule for Rucaparib and Abiraterone Acetate or Enzalutamide is identical as per Table 5 (Amendment 4, pages 111-113).; For Rucaparib and Abiraterone/Enzalutamide, treatment continues 'until radiographic disease progression', so visits are counted up to Day +365.; Study Drug Dispensation, Adverse Events checks, Patient-reported outcome (PRO) done in clinic, Physical Examination, Vital Signs, Medical/Oncology History, Prior/Concomitant Medications/Procedures, ECOG Performance Status, and Informed Consent are categorized as clinic_visits.; Blood samples for plasma ctDNA analysis, Serum Testosterone, PSA Measurement, Clinical Laboratory Assessments, Pharmacogenomic blood sample, and Archival Primary/Metastatic Tumor Tissue Sample (if collected in-person) are categorized as labs.; Tumor Assessment/CT/MRI/Bone Scan, 12-lead ECG, and Tumor Biopsy (optional) are categorized as imaging_diagnostics.; Docetaxel Administration is categorized as core_treatment.; For days with multiple procedures, the highest priority category is assigned (core_treatment > imaging_diagnostics > labs > clinic_visits)."
36795891,Docetaxel,control,2,3,8,17,21,26,0,2,4,8,8,8,2,0,1,3,4,5,0,1,3,6,9,13,0,0,0,0,0,0,21,"max 10 cycles for docetaxel administration, assessments continue until progression","Screening: Day -28 (Imaging), Day -14 (Imaging). Treatment: Day 0 (Core Treatment), Day 21 (Core Treatment), Day 28 (Labs), Day 42 (Core Treatment), Day 56 (Labs), Day 57 (Imaging), Day 63 (Core Treatment), Day 84 (Labs), Day 105 (Core Treatment), Day 112 (Labs), Day 113 (Imaging), Day 126 (Core Treatment), Day 140 (Labs), Day 147 (Core Treatment), Day 168 (Labs), Day 169 (Imaging), Day 189 (Core Treatment). Post-treatment assessments (PRO, PSA, AE, Tumor Assessment) continue on Day 196 (Labs), Day 224 (Labs), Day 252 (Labs), Day 253 (Imaging), Day 280 (Labs), Day 308 (Labs), Day 336 (Labs), Day 337 (Imaging), Day 364 (Labs).","Screening procedures within a window are consolidated into the minimum number of distinct days, prioritizing higher category procedures.; A separate optional tumor biopsy day is counted during screening (imaging_diagnostics).; Day 0 is the first on-treatment visit, following randomization.; Docetaxel administration is for a maximum of 10 cycles (21-day cycle), but assessments continue thereafter as per the schedule.; Study Drug Dispensation, Adverse Events checks, Patient-reported outcome (PRO) done in clinic, Physical Examination, Vital Signs, Medical/Oncology History, Prior/Concomitant Medications/Procedures, ECOG Performance Status, and Informed Consent are categorized as clinic_visits.; Blood samples for plasma ctDNA analysis, Serum Testosterone, PSA Measurement, Clinical Laboratory Assessments, Pharmacogenomic blood sample, and Archival Primary/Metastatic Tumor Tissue Sample (if collected in-person) are categorized as labs.; Tumor Assessment/CT/MRI/Bone Scan, 12-lead ECG, and Tumor Biopsy (optional) are categorized as imaging_diagnostics.; Docetaxel Administration is categorized as core_treatment.; For days with multiple procedures, the highest priority category is assigned (core_treatment > imaging_diagnostics > labs > clinic_visits)."
36969338,BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1),intervention,4,4,10,21,30,40,2,4,10,21,30,40,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression (calculated up to Day +365),"Screening (2 days for Arm 2, 4 days for Arm 1 including BBI-608 run-in). Treatment cycles are 28 days. Nab-paclitaxel/gemcitabine IV infusions on Day 1, 8, 15 of each cycle. BBI-608 oral daily continuous for Arm 1. Radiology/Imaging every 56 days. QoL at Day 28, 56, 84, 112, 168. Arm 1 also has correlative blood samples on Day 8, 15 of C1 and Day 28 (C2D1).","Randomization (C1D1) is Day 0.; Baseline/Screening procedures are assumed to occur on two distinct days within the screening window: one for comprehensive assessments (imaging_diagnostics due to CT/MRI/biopsy) and one for repeat labs (<72h prior to randomization).; BBI-608 run-in period (Day -2, Day -1) is counted as core_treatment days.; All scheduled visits on Day 1, Day 8, and Day 15 of each 28-day cycle involve IV infusions (nab-paclitaxel and gemcitabine), thus categorized as core_treatment. Any other procedures on these days (e.g., labs, ECG, patient history, AE assessment, QoL, correlative blood samples for Arm 1) are overridden by core_treatment due to precedence.; Radiology & Imaging (every 8 weeks) and Quality of Life (QoL) assessments (at 4, 8, 12, 16, 24 weeks) fall on days that also have IV infusions (C*D1 days). Therefore, these days are categorized as core_treatment.; Correlative blood samples for Arm 1 on Day 8, 15 of Cycle 1 and Day 1 of Cycle 2 (Day 28) fall on days with IV infusions, thus categorized as core_treatment.; The 'After Permanent Protocol Treatment Discontinuation' schedule is not included in the 'per treatment arm' count, as it applies after treatment cessation."
36969338,nab-paclitaxel with gemcitabine (Arm 2),control,2,4,10,21,30,40,0,4,10,21,30,40,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression (calculated up to Day +365),"Screening (2 days). Treatment cycles are 28 days. Nab-paclitaxel/gemcitabine IV infusions on Day 1, 8, 15 of each cycle. Radiology/Imaging every 56 days. QoL at Day 28, 56, 84, 112, 168.","Randomization (C1D1) is Day 0.; Baseline/Screening procedures are assumed to occur on two distinct days within the screening window: one for comprehensive assessments (imaging_diagnostics due to CT/MRI/biopsy) and one for repeat labs (<72h prior to randomization).; No BBI-608 run-in period for Arm 2.; All scheduled visits on Day 1, Day 8, and Day 15 of each 28-day cycle involve IV infusions (nab-paclitaxel and gemcitabine), thus categorized as core_treatment. Any other procedures on these days (e.g., labs, ECG, patient history, AE assessment, QoL) are overridden by core_treatment due to precedence.; Radiology & Imaging (every 8 weeks) and Quality of Life (QoL) assessments (at 4, 8, 12, 16, 24 weeks) fall on days that also have IV infusions (C*D1 days). Therefore, these days are categorized as core_treatment.; Arm 2 does not have sparse PK collection.; The 'After Permanent Protocol Treatment Discontinuation' schedule is not included in the 'per treatment arm' count, as it applies after treatment cessation."
36996380,Arm A: Enzalutamide alone,intervention,2,1,4,7,10,14,0,0,0,0,0,0,1,0,1,3,4,5,0,1,3,4,6,9,1,0,0,0,0,0,28,until progression,"Screening: Day -28 (imaging), Day -14 (clinic/labs). On-treatment: Day 1 of each 28-day cycle for clinic and labs. Imaging at Day 56 (C3D1), Day 112 (C5D1), Day 168 (C7D1), Day 252 (C10D1), Day 336 (C13D1). Total Testosterone labs at C1D1, C3D1, C10D1. PK samples at C1D1-C6D1.","Screening procedures are assumed to occur on two distinct days: one for imaging (Day -28) and one for H&P, ECG, and all blood labs (Day -14), as the protocol allows for different time windows for these activities.; All 'X' marks in the 'Prior to Registration' and 'Day 1 of each cycle' columns of the 'Tests & Observations' table (page 19) represent in-person visits.; Participation in 'Correlative studies' and 'Pharmacokinetics samples' is assumed for all patients, adding to lab contact days.; Routine Adverse Event Reporting (Section 6.1.3) at 'baseline and for each cycle of treatment' implies a clinic visit for AE checks on C1D1 and subsequent CxD1, which is categorized under 'clinic_visits' but is overridden by 'labs' or 'imaging_diagnostics' due to precedence.; Treatment duration is assumed to be at least 12 months for calculation purposes, as therapy continues 'until confirmed disease progression or unacceptable toxicity'.; For on-treatment visits, if imaging is scheduled on a cycle Day 1, that day is categorized as 'imaging_diagnostics'. Otherwise, it is categorized as 'labs' due to the presence of blood draws and higher precedence over 'clinic_visits'."
36996380,"Arm B: Enzalutamide, Abiraterone, and Prednisone",intervention,2,3,7,10,13,17,0,0,0,0,0,0,1,0,1,3,4,5,0,3,6,7,9,12,1,0,0,0,0,0,28,until progression,"Screening: Day -28 (imaging), Day -14 (clinic/labs). On-treatment: Day 1 of each 28-day cycle for clinic and labs. Additional lab days at Day 14 (C1D15), Day 42 (C2D15), Day 70 (C3D15) for AST/ALT, Alk. Phos., Bili. Imaging at Day 56 (C3D1), Day 112 (C5D1), Day 168 (C7D1), Day 252 (C10D1), Day 336 (C13D1). Total Testosterone labs at C1D1, C3D1, C10D1. PK samples at C1D1-C6D1.","Screening procedures are assumed to occur on two distinct days: one for imaging (Day -28) and one for H&P, ECG, and all blood labs (Day -14), as the protocol allows for different time windows for these activities.; All 'X' marks in the 'Prior to Registration' and 'Day 1 of each cycle' columns of the 'Tests & Observations' table (page 19) represent in-person visits.; Participation in 'Correlative studies' and 'Pharmacokinetics samples' is assumed for all patients, adding to lab contact days.; Routine Adverse Event Reporting (Section 6.1.3) at 'baseline and for each cycle of treatment' implies a clinic visit for AE checks on C1D1 and subsequent CxD1, which is categorized under 'clinic_visits' but is overridden by 'labs' or 'imaging_diagnostics' due to precedence.; Treatment duration is assumed to be at least 12 months for calculation purposes, as therapy continues 'until confirmed disease progression or unacceptable toxicity'.; For on-treatment visits, if imaging is scheduled on a cycle Day 1, that day is categorized as 'imaging_diagnostics'. Otherwise, it is categorized as 'labs' due to the presence of blood draws and higher precedence over 'clinic_visits'.; For Arm B, AST/ALT, Alk. Phos., Bili are collected every two weeks for the first 3 months (C1D1, C1D15, C2D1, C2D15, C3D1, C3D15), then on Day 1 of each subsequent cycle (Footnote 1 on page 19)."
37069359,BL-8040 + G-CSF,intervention,1,18,42,43,44,45,0,10,10,10,10,10,1,1,1,2,2,2,0,7,31,31,32,33,0,0,0,0,0,0,,Fixed schedule up to 12 months post-transplantation.,"Screening, Baseline (Day 0), Daily G-CSF (Day 1-8), BL-8040/Placebo (Day 4, optional Day 6), Apheresis (Day 5, optional Day 6, 7, 8), Conditioning (Visit 9), Transplantation (Visit 10), Daily Post-Transplant (Day 1-29 post-transplant), Fixed follow-up visits (Day 30, 60, 100, 180, 270, 360 post-transplant).","One distinct screening day is counted, separate from Day 0.; Conditional visits for Days 6, 7, 8 (second BL-8040/placebo dose and subsequent apheresis sessions) are assumed to occur to capture maximum potential mandated contact days.; Bone marrow biopsies on Screening and Day 100 (Visit 13) are assumed to occur.; Daily post-transplant assessments are assumed to occur for the full 29 days (Day 1-29 post-transplant).; Transplantation (Visit 10) is assumed to occur on Day 23 (relative to C1D1=Day 0), with Conditioning (Visit 9) on Day 22. This timing is chosen as the earliest possible within the specified window of 3-5 weeks after the last apheresis session (Day 8), to maximize inclusion in earlier time windows."
37069359,Placebo + G-CSF,control,1,18,42,43,44,45,0,10,10,10,10,10,1,1,1,2,2,2,0,7,31,31,32,33,0,0,0,0,0,0,,Fixed schedule up to 12 months post-transplantation.,"Screening, Baseline (Day 0), Daily G-CSF (Day 1-8), BL-8040/Placebo (Day 4, optional Day 6), Apheresis (Day 5, optional Day 6, 7, 8), Conditioning (Visit 9), Transplantation (Visit 10), Daily Post-Transplant (Day 1-29 post-transplant), Fixed follow-up visits (Day 30, 60, 100, 180, 270, 360 post-transplant).","One distinct screening day is counted, separate from Day 0.; Conditional visits for Days 6, 7, 8 (second BL-8040/placebo dose and subsequent apheresis sessions) are assumed to occur to capture maximum potential mandated contact days.; Bone marrow biopsies on Screening and Day 100 (Visit 13) are assumed to occur.; Daily post-transplant assessments are assumed to occur for the full 29 days (Day 1-29 post-transplant).; Transplantation (Visit 10) is assumed to occur on Day 23 (relative to C1D1=Day 0), with Conditioning (Visit 9) on Day 22. This timing is chosen as the earliest possible within the specified window of 3-5 weeks after the last apheresis session (Day 8), to maximize inclusion in earlier time windows."
37071094,mFOLFOX6 + Panitumumab,intervention,2,9,21,39,57,78,0,9,21,39,57,78,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,14,"guided duration of 12 months, continuing until discontinuation criteria are met (calculated until Day 365)","Screening: 2 days. Treatment cycles (14-day cycle): Day 1, Day 2, Day 3 for infusions and associated assessments/labs. Imaging/Tumor markers: Every 8 weeks on Day 1 of cycles (coinciding with treatment days).","Two distinct screening visits are assumed: one earlier for imaging/tumor markers/HBsAg/RAS status (Day -28), and one closer to C1D1 for clinical labs/H&P/ECOG PS/ICF/Patient background (Day -1), based on varying allowance ranges for 'At enrollment' procedures.; For 'During protocol treatment', imaging and tumor markers are considered mandatory every 8 weeks (56 days) as per text on page 40 and Table 9.b (page 31), overriding the 'O: Perform as necessary' in Table 9.a. These visits are assumed to coincide with Day 1 of relevant cycles (Day 0, 56, 112, etc.) and thus do not add new contact days, with the category remaining 'core_treatment' due to precedence.; Infusional 5-FU (civ 46 hr) is assumed to require in-person contact for pump management/disconnection on Day 2 and Day 3 of each cycle.; Treatment is calculated for a full 12 months (365 days), resulting in 26 full cycles (Day 0 to Day 352), as per 'guided duration of 12 months' and the instruction to enumerate through Day +365 assuming regimen continues.; The 'Discontinuation of protocol treatment' visit is assumed to occur on Day 366, falling outside the 12-month window."
37071094,mFOLFOX6 + Bevacizumab,intervention,2,9,21,39,57,78,0,9,21,39,57,78,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,14,"guided duration of 12 months, continuing until discontinuation criteria are met (calculated until Day 365)","Screening: 2 days. Treatment cycles (14-day cycle): Day 1, Day 2, Day 3 for infusions and associated assessments/labs. Imaging/Tumor markers: Every 8 weeks on Day 1 of cycles (coinciding with treatment days).","Two distinct screening visits are assumed: one earlier for imaging/tumor markers/HBsAg/RAS status (Day -28), and one closer to C1D1 for clinical labs/H&P/ECOG PS/ICF/Patient background (Day -1), based on varying allowance ranges for 'At enrollment' procedures.; For 'During protocol treatment', imaging and tumor markers are considered mandatory every 8 weeks (56 days) as per text on page 40 and Table 9.b (page 31), overriding the 'O: Perform as necessary' in Table 9.a. These visits are assumed to coincide with Day 1 of relevant cycles (Day 0, 56, 112, etc.) and thus do not add new contact days, with the category remaining 'core_treatment' due to precedence.; Infusional 5-FU (civ 46 hr) is assumed to require in-person contact for pump management/disconnection on Day 2 and Day 3 of each cycle.; Treatment is calculated for a full 12 months (365 days), resulting in 26 full cycles (Day 0 to Day 352), as per 'guided duration of 12 months' and the instruction to enumerate through Day +365 assuming regimen continues.; The 'Discontinuation of protocol treatment' visit is assumed to occur on Day 366, falling outside the 12-month window."
37075781,Pembrolizumab plus Gemcitabine and Cisplatin,experimental,3,4,9,18,26,36,0,4,9,18,26,36,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,21,Pembrolizumab up to 35 cycles; Gemcitabine until disease progression or unacceptable toxicity (assumed to continue for 35 cycles); Cisplatin up to 8 cycles.,"Initial Intervention Phase: 3 distinct screening days. Day 1 and Day 8 of each 21-day cycle for infusions and associated assessments. Tumor imaging every 6 weeks through Week 54, coinciding with Day 1 of various cycles.","Screening procedures are consolidated into 3 distinct in-person contact days based on varying time windows for different assessments (imaging/tissue collection, labs, and clinical assessments/consent).; Gemcitabine is assumed to continue for the full 35 cycles (735 days) in the Initial Intervention Phase, as it continues 'until disease progression or unacceptable toxicity' and the protocol states to assume the drug continues if conditional.; Cisplatin is administered for a maximum of 8 cycles (168 days).; Pembrolizumab is administered for a maximum of 35 cycles (735 days).; The Second Course Phase (Retreatment) for Arm A is assumed to occur after the 12-month window from C1D1 and therefore does not contribute to the contact day counts within the specified intervals.; All Day 1 and Day 8 visits within the intervention phase involve IV infusions (Pembrolizumab/Placebo, Gemcitabine, Cisplatin), which are categorized as 'core_treatment'. Due to tie-breaker precedence, any other procedures on these days (e.g., imaging, labs, clinic visits) do not change the primary category of the day.; Scheduled tumor imaging assessments (every 6 weeks through Week 54) fall on the same calendar days as Day 1 of various cycles (e.g., Day 42 is C3D1, Day 84 is C5D1, etc.). These days are already counted as 'core_treatment' due to infusions and do not add new unique contact days.; Survival Follow-up visits are not explicitly mandated as in-person contact days and are therefore not counted."
37075781,Placebo plus Gemcitabine and Cisplatin,control,3,4,9,18,26,36,0,4,9,18,26,36,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,21,Placebo up to 35 cycles; Gemcitabine until disease progression or unacceptable toxicity (assumed to continue for 35 cycles); Cisplatin up to 8 cycles.,"Initial Intervention Phase: 3 distinct screening days. Day 1 and Day 8 of each 21-day cycle for infusions and associated assessments. Tumor imaging every 6 weeks through Week 54, coinciding with Day 1 of various cycles.","Screening procedures are consolidated into 3 distinct in-person contact days based on varying time windows for different assessments (imaging/tissue collection, labs, and clinical assessments/consent).; Gemcitabine is assumed to continue for the full 35 cycles (735 days) in the Initial Intervention Phase, as it continues 'until disease progression or unacceptable toxicity' and the protocol states to assume the drug continues if conditional.; Cisplatin is administered for a maximum of 8 cycles (168 days).; Placebo is administered for a maximum of 35 cycles (735 days).; All Day 1 and Day 8 visits within the intervention phase involve IV infusions (Placebo, Gemcitabine, Cisplatin), which are categorized as 'core_treatment'. Due to tie-breaker precedence, any other procedures on these days (e.g., imaging, labs, clinic visits) do not change the primary category of the day.; Scheduled tumor imaging assessments (every 6 weeks through Week 54) fall on the same calendar days as Day 1 of various cycles (e.g., Day 42 is C3D1, Day 84 is C5D1, etc.). These days are already counted as 'core_treatment' due to infusions and do not add new unique contact days.; Survival Follow-up visits are not explicitly mandated as in-person contact days and are therefore not counted."
37080222,Arm A (Tislelizumab + Chemotherapy),intervention,1,13,31,51,71,91,0,10,25,45,65,85,1,0,0,0,0,0,0,3,6,6,6,6,0,0,0,0,0,0,21,until progression,"Screening (1 day); Cycles 1-3: Day 1-5 (core_treatment), Day 8 (labs), Day 15 (labs); Cycles 4+: Day 1-5 (core_treatment). Periodic assessments (imaging, labs, clinic) are integrated into these days.","Assumed the chemotherapy doublet with the highest number of in-person contact days (Platinum + 5-FU, with 5 days of IV infusion per cycle: Day 1 for Platinum and 5-FU, Days 2-5 for 5-FU) for calculating core_treatment days. This is based on the 'Platinum (cisplatin or oxaliplatin) + 5-FU' regimen as detailed in Table 2 (Page 19) and Section 5.2.3 (Page 20-21).; A fresh tumor biopsy at screening is conditional ('If no archival samples are available') and thus not counted as a mandatory contact day for all patients.; End of Treatment (EOT) and Survival Follow-up visits are assumed to occur after Day +365 if treatment continues until Day +365, thus not included in the 12-month window.; Visits marked 'as clinically indicated' or 'optional' are excluded from the fixed schedule counts.; Telephone calls for follow-up (e.g., AEs, Conmeds on C1D8/C1D15, Survival Follow-up) are not counted as in-person contact days.; Oral capecitabine administration is not counted as an in-person contact day.; The Screening visit is counted as one day, with the highest priority procedure (imaging_diagnostics) determining its category.; For cycles 4 and subsequent cycles, Day 8 and Day 15 lab visits are not explicitly marked in Appendix 1 and are excluded based on Note 13 ('performed weekly for the first 3 cycles and then at the beginning of subsequent cycles').; All periodic assessments (ECG, OCT/Visual acuity, Tumor assessment, Thyroid function, HBV/HCV tests, PK/ADA, PROs) that fall on Day 1 of a cycle are subsumed under the 'core_treatment' category due to IV infusions occurring on those days, following the tie-breaker precedence rule."
37080222,Arm B (Placebo + Chemotherapy),control,1,13,31,51,71,91,0,10,25,45,65,85,1,0,0,0,0,0,0,3,6,6,6,6,0,0,0,0,0,0,21,until progression,"Screening (1 day); Cycles 1-3: Day 1-5 (core_treatment), Day 8 (labs), Day 15 (labs); Cycles 4+: Day 1-5 (core_treatment). Periodic assessments (imaging, labs, clinic) are integrated into these days.","Assumed the chemotherapy doublet with the highest number of in-person contact days (Platinum + 5-FU, with 5 days of IV infusion per cycle: Day 1 for Platinum and 5-FU, Days 2-5 for 5-FU) for calculating core_treatment days. This is based on the 'Platinum (cisplatin or oxaliplatin) + 5-FU' regimen as detailed in Table 2 (Page 19) and Section 5.2.3 (Page 20-21).; A fresh tumor biopsy at screening is conditional ('If no archival samples are available') and thus not counted as a mandatory contact day for all patients.; End of Treatment (EOT) and Survival Follow-up visits are assumed to occur after Day +365 if treatment continues until Day +365, thus not included in the 12-month window.; Visits marked 'as clinically indicated' or 'optional' are excluded from the fixed schedule counts.; Telephone calls for follow-up (e.g., AEs, Conmeds on C1D8/C1D15, Survival Follow-up) are not counted as in-person contact days.; Oral capecitabine administration is not counted as an in-person contact day.; The Screening visit is counted as one day, with the highest priority procedure (imaging_diagnostics) determining its category.; For cycles 4 and subsequent cycles, Day 8 and Day 15 lab visits are not explicitly marked in Appendix 1 and are excluded based on Note 13 ('performed weekly for the first 3 cycles and then at the beginning of subsequent cycles').; All periodic assessments (ECG, OCT/Visual acuity, Tumor assessment, Thyroid function, HBV/HCV tests, PK/ADA, PROs) that fall on Day 1 of a cycle are subsumed under the 'core_treatment' category due to IV infusions occurring on those days, following the tie-breaker precedence rule."
37080223,Arm A - Control Arm,control,1,22,35,36,37,38,0,22,33,33,33,33,1,0,0,1,1,1,0,0,0,0,0,0,0,0,2,2,3,4,28,"Fixed duration for active treatment (chemoradiation up to 8 weeks), then until progression for follow-up.","Baseline (1 day), Concurrent Chemoradiation (33 days over 8 weeks), End of Treatment visit (1 day), Follow-up visits (every 3 months for 2 years, then every 6 months).","Screening visit (including CT/PET/MRI, labs, H&P, QoL) occurs once at Day -7 (within Day -28 to Day -1).; Concurrent chemoradiation (EBRT + Cisplatin + Brachytherapy) starts on Day 0.; EBRT is 5 days/week for 6 weeks, totaling 30 contact days. Cisplatin (5 doses) is given on 5 of these EBRT days.; Brachytherapy consists of 3 insertions, each on a separate day, after EBRT completion, within the 8-week total treatment time. Placed at Day 42, 49, 56.; Weekly assessments during chemoradiation are assumed to coincide with the 30 EBRT days or 3 brachytherapy days.; End of Treatment (EoT) visit for Arm A is 4 weeks post completion of chemoradiation (Day 56 + 28 = Day 84). This visit includes clinical review, toxicity, bloods, and QoL.; Follow-up visits are scheduled at 3, 6, 9, 12 months from randomization (Day 0).; The 6-month follow-up visit includes CT/PET/MRI and is categorized as imaging_diagnostics.; Other follow-up visits are categorized as clinic_visits (including H&P, labs, QoL)."
37080223,Arm B - Intervention Arm,intervention,1,22,34,37,39,40,0,22,34,37,37,37,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,2,21,"Fixed duration for active treatment (chemoradiation up to 8 weeks, adjuvant chemo 4 cycles), then until progression for follow-up.","Baseline (1 day), Concurrent Chemoradiation (33 days over 8 weeks), Adjuvant Chemotherapy (4 cycles, 3-weekly), End of Treatment visit (consolidated with 6-month FU), Follow-up visits (every 3 months for 2 years, then every 6 months).","Screening visit (including CT/PET/MRI, labs, H&P, QoL) occurs once at Day -7 (within Day -28 to Day -1).; Concurrent chemoradiation (EBRT + Cisplatin + Brachytherapy) starts on Day 0.; EBRT is 5 days/week for 6 weeks, totaling 30 contact days. Cisplatin (5 doses) is given on 5 of these EBRT days.; Brachytherapy consists of 3 insertions, each on a separate day, after EBRT completion, within the 8-week total treatment time. Placed at Day 42, 49, 56.; Weekly assessments during chemoradiation are assumed to coincide with the 30 EBRT days or 3 brachytherapy days.; Adjuvant chemotherapy (4 cycles, 3-weekly) starts 4 weeks after completion of chemoradiation (Day 56 + 28 = Day 84). Each cycle is one contact day for infusion and pre-cycle assessments.; The first adjuvant chemotherapy visit (Day 84) is assumed to consolidate the 'End of Treatment' assessments for the chemoradiation phase (QoL, H&P, labs).; The 3-month follow-up visit (Day 90) is omitted as a separate contact day for Arm B, as it falls within the adjuvant treatment period, per protocol footnote A.; End of Treatment (EoT) visit for Arm B is 4 weeks post completion of adjuvant chemotherapy (Day 147 + 28 = Day 182). This visit includes clinical review, toxicity, bloods, QoL, CT/PET/MRI, and tumour assessment.; The 6-month follow-up visit (Day 180) is consolidated with the EoT visit at Day 182, per protocol footnote I. Since Day 182 falls outside the '6 months' window (Day 0-180), this consolidated visit is counted in the '9 months' window.; Other follow-up visits are categorized as clinic_visits (including H&P, labs, QoL)."
37104748,Arm 1: Dose-escalated RT alone,intervention,5,23,44,45,46,47,0,23,44,44,44,44,1,0,0,0,0,0,3,0,0,0,0,0,1,0,0,1,2,3,,RT until 44 fractions are delivered; follow-up until progression or death.,"Screening visits, followed by 44 daily RT fractions (5 days/week) for 9 weeks. Follow-up visits at 3, 6, 9, and 12 months post RT.","Radiotherapy (RT) is delivered 5 days per week (Monday-Friday).; The 44 RT fractions are spread over approximately 9 calendar weeks (Day 0 to Day 59 for Arm 1).; Weekly performance status and AE evaluations during RT are integrated into the RT treatment days.; Last week of RT labs (AST, ALT, alk phosphatase) are integrated into the last RT treatment day.; Follow-up visits (Performance status, physical, DRE, PSA) are counted as clinic_visits days, as clinic_visits has higher precedence than labs.; Optional visits (e.g., QOL assessments, tissue/blood banking, brachytherapy-specific imaging/AUA) are excluded from the contact day count.; CT or MRI abd/pelvis & bone scan, PSA, AST/ALT/alk phosphatase, and Serum testosterone are assumed to be performed for all patients during screening, as they are listed as 'Required Evaluations/Management' or 'X' in the pre-treatment table for both arms, unless explicitly stated otherwise for an arm."
37104748,Arm 2: Dose-escalated RT combined with short-term (6 months) androgen blockade (LHRH agonist + anti-androgen),intervention,5,1,28,49,50,51,0,1,28,49,50,50,1,0,0,0,0,0,3,0,0,0,0,0,1,0,0,0,0,1,30,"ADT for 6 months, RT until 44 fractions are delivered; follow-up until progression or death.","Screening visits, followed by monthly LHRH agonist injections for 6 months. RT starts 8 weeks after the first LHRH injection, consisting of 44 daily fractions (5 days/week) for 9 weeks. Follow-up visits at 6, 9, and 12 months post RT.","The anchor (Day 0) is the first LHRH agonist injection.; LHRH agonist injections occur monthly for 6 months (Day 0, 30, 60, 90, 120, 150).; Monthly AST/ALT and Serum testosterone for Arm 2 are integrated into the LHRH injection days if they coincide, or are separate lab days if they do not.; Radiotherapy (RT) starts 8 weeks (56 days) after Day 0, so on Day +56.; RT is delivered 5 days per week (Monday-Friday). The 44 RT fractions are spread over approximately 9 calendar weeks (Day +56 to Day +115).; Weekly performance status and AE evaluations during RT are integrated into the RT treatment days.; Last week of RT labs (AST, ALT, alk phosphatase) are integrated into the last RT treatment day.; Follow-up visits (Performance status, physical, DRE, PSA, Serum testosterone) are counted as clinic_visits days, as clinic_visits has higher precedence than labs.; Optional visits (e.g., QOL assessments, tissue/blood banking, brachytherapy-specific imaging/AUA) are excluded from the contact day count.; CT or MRI abd/pelvis & bone scan, PSA, AST/ALT/alk phosphatase, and Serum testosterone are assumed to be performed for all patients during screening, as they are listed as 'Required Evaluations/Management' or 'X' in the pre-treatment table for both arms, unless explicitly stated otherwise for an arm."
37141294,Pembrolizumab (MK-3475) 2 mg/kg Q3W,intervention,2,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,21,until progression or unacceptable adverse event (up to 35 administrations for Pembrolizumab),"Screening visits (2 days), then treatment every 21 days (Q3W) on Day 1 of each cycle. Imaging occurs on Day 0, Day 63 (C4), Day 126 (C7), Day 189 (C10), Day 252 (C13), Day 315 (C16). Labs and clinic visits occur on most treatment days. Optional biopsies for Pembrolizumab on Day 63 (C4), Day 105 (C6), Day 231 (C12).","Screening phase assumed to have 2 distinct in-person contact days due to multiple procedures with different timing requirements (e.g., imaging within 28 days, labs within 10 days, pregnancy test within 72 hours). One day for imaging/initial consent (Day -28), another for labs (Day -10).; Treatment duration assumed to continue until Day 365 for calculation purposes, as per 'until progression' rule and the 12-month window. The maximum 35 administrations for pembrolizumab (735 days) extends beyond the 12-month window.; Post-treatment follow-up visits are not included in the 12-month window (Day 0 to Day 365) as treatment is assumed to continue until Day 365.; The Second Course Phase for Pembrolizumab is not included as it is a re-treatment phase after initial progression and would fall outside the primary 12-month observation window from C1D1.; Optional biopsies for the Pembrolizumab arm are included as they are 'highly desired when feasible' (Note 17, Page 27), implying they are expected to occur. However, their category (labs) is superseded by core_treatment on those days.; Cycle 1 imaging is explicitly marked in the table, so it's counted on Day 0.; TSH and Urinalysis schedules follow the 'X' marks in the Schedule of Events table, which sometimes deviate from the general notes (e.g., TSH 'every other cycle', Urinalysis 'every 4 cycles after C13'). The table marks are considered more specific for each cycle."
37141294,Docetaxel 75 mg/m² Q3W,control,2,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,21,until disease progression or unacceptable adverse event,"Screening visits (2 days), then treatment every 21 days (Q3W) on Day 1 of each cycle. Imaging occurs on Day 0, Day 63 (C4), Day 126 (C7), Day 189 (C10), Day 252 (C13), Day 315 (C16). Labs and clinic visits occur on most treatment days.","Screening phase assumed to have 2 distinct in-person contact days due to multiple procedures with different timing requirements (e.g., imaging within 28 days, labs within 10 days, pregnancy test within 72 hours). One day for imaging/initial consent (Day -28), another for labs (Day -10).; Treatment duration assumed to continue until Day 365 for calculation purposes, as per 'until progression' rule and the 12-month window.; Post-treatment follow-up visits are not included in the 12-month window (Day 0 to Day 365) as treatment is assumed to continue until Day 365.; The Docetaxel arm does not have optional biopsies, but this does not change the highest priority category for any treatment day, which remains 'core_treatment'.; Cycle 1 imaging is explicitly marked in the table, so it's counted on Day 0.; TSH and Urinalysis schedules follow the 'X' marks in the Schedule of Events table, which sometimes deviate from the general notes (e.g., TSH 'every other cycle', Urinalysis 'every 4 cycles after C13'). The table marks are considered more specific for each cycle."
37257422,Arm A (SS) - Standard Steroids,intervention,1,23,36,43,49,56,0,23,36,43,49,56,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,planned 12 cycles of adjuvant depatuxizumab mafodotin,"Screening (1 day). Chemoradiation Phase (Day 0 to Day 48): Depatuxizumab Mafodotin IV on Day 0, 14, 28. Radiation daily (5 days/week) for 7 weeks (35 days). Week 7 Day 1 (Day 42) visit. Adjuvant Phase (Day 76 to Day 411): Depatuxizumab Mafodotin IV on Day 1 and Day 15 of each 28-day cycle for 12 cycles.","Screening is considered one in-person day, with all listed screening activities occurring on this day. The required tissue sample for EGFR amplification testing (diagnostic biopsy), ECG, and ophthalmology exam categorize this day as imaging_diagnostics.; The Chemoradiation Phase is assumed to last 7 weeks (Day 0 to Day 48), with focal radiation therapy (RT) administered 5 days per week for these 7 weeks, totaling 35 days of RT. Depatuxizumab mafodotin IV is administered on Day 0, Day 14 (Week 3 Day 1), and Day 28 (Week 5 Day 1).; The 4-week recovery period between the Chemoradiation Phase and Adjuvant Phase is assumed to have no in-person contact days.; The Adjuvant Phase is assumed to start on Day 76 (Day 48 + 28 days recovery).; Depatuxizumab mafodotin IV is administered on Day 1 and Day 15 of each 28-day cycle for 12 cycles in the Adjuvant Phase. Oral Temozolomide (TMZ) is administered on Days 1-5 of each cycle for the first 6 cycles, but as an oral medication, it does not constitute an in-person contact day unless other procedures are scheduled on the same day.; All days involving Depatuxizumab mafodotin IV infusion or Radiation Therapy are categorized as core_treatment, overriding other activities due to tie-breaker precedence.; Ophthalmology exams are considered in-person and categorized as imaging_diagnostics, but are overridden by core_treatment if an infusion or RT occurs on the same day.; Central laboratory tests and urine pregnancy tests are considered in-person and categorized as labs, but are overridden by higher priority categories if other activities occur on the same day.; All other interview, patient-reported outcome (PRO), physical exam, and assessment activities are categorized as clinic_visits, but are overridden by higher priority categories if other activities occur on the same day.; Optional or 'as needed' visits are excluded from the count."
37257422,Arm B (SS/VC) - Standard Steroid/Vasoconstrictor and Cold Compress,intervention,1,23,36,43,49,56,0,23,36,43,49,56,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,planned 12 cycles of adjuvant depatuxizumab mafodotin,"Screening (1 day). Chemoradiation Phase (Day 0 to Day 48): Depatuxizumab Mafodotin IV on Day 0, 14, 28. Radiation daily (5 days/week) for 7 weeks (35 days). Week 7 Day 1 (Day 42) visit. Adjuvant Phase (Day 76 to Day 411): Depatuxizumab Mafodotin IV on Day 1 and Day 15 of each 28-day cycle for 12 cycles.","Screening is considered one in-person day, with all listed screening activities occurring on this day. The required tissue sample for EGFR amplification testing (diagnostic biopsy), ECG, and ophthalmology exam categorize this day as imaging_diagnostics.; The Chemoradiation Phase is assumed to last 7 weeks (Day 0 to Day 48), with focal radiation therapy (RT) administered 5 days per week for these 7 weeks, totaling 35 days of RT. Depatuxizumab mafodotin IV is administered on Day 0, Day 14 (Week 3 Day 1), and Day 28 (Week 5 Day 1).; The 4-week recovery period between the Chemoradiation Phase and Adjuvant Phase is assumed to have no in-person contact days.; The Adjuvant Phase is assumed to start on Day 76 (Day 48 + 28 days recovery).; Depatuxizumab mafodotin IV is administered on Day 1 and Day 15 of each 28-day cycle for 12 cycles in the Adjuvant Phase. Oral Temozolomide (TMZ) is administered on Days 1-5 of each cycle for the first 6 cycles, but as an oral medication, it does not constitute an in-person contact day unless other procedures are scheduled on the same day.; All days involving Depatuxizumab mafodotin IV infusion or Radiation Therapy are categorized as core_treatment, overriding other activities due to tie-breaker precedence.; Ophthalmology exams are considered in-person and categorized as imaging_diagnostics, but are overridden by core_treatment if an infusion or RT occurs on the same day.; Central laboratory tests and urine pregnancy tests are considered in-person and categorized as labs, but are overridden by higher priority categories if other activities occur on the same day.; All other interview, patient-reported outcome (PRO), physical exam, and assessment activities are categorized as clinic_visits, but are overridden by higher priority categories if other activities occur on the same day.; Optional or 'as needed' visits are excluded from the count."
37257422,Arm C (ES/VC) - Enhanced Steroids/Vasoconstrictor and Cold Compress,intervention,1,23,36,43,49,56,0,23,36,43,49,56,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,planned 12 cycles of adjuvant depatuxizumab mafodotin,"Screening (1 day). Chemoradiation Phase (Day 0 to Day 48): Depatuxizumab Mafodotin IV on Day 0, 14, 28. Radiation daily (5 days/week) for 7 weeks (35 days). Week 7 Day 1 (Day 42) visit. Adjuvant Phase (Day 76 to Day 411): Depatuxizumab Mafodotin IV on Day 1 and Day 15 of each 28-day cycle for 12 cycles.","Screening is considered one in-person day, with all listed screening activities occurring on this day. The required tissue sample for EGFR amplification testing (diagnostic biopsy), ECG, and ophthalmology exam categorize this day as imaging_diagnostics.; The Chemoradiation Phase is assumed to last 7 weeks (Day 0 to Day 48), with focal radiation therapy (RT) administered 5 days per week for these 7 weeks, totaling 35 days of RT. Depatuxizumab mafodotin IV is administered on Day 0, Day 14 (Week 3 Day 1), and Day 28 (Week 5 Day 1).; The 4-week recovery period between the Chemoradiation Phase and Adjuvant Phase is assumed to have no in-person contact days.; The Adjuvant Phase is assumed to start on Day 76 (Day 48 + 28 days recovery).; Depatuxizumab mafodotin IV is administered on Day 1 and Day 15 of each 28-day cycle for 12 cycles in the Adjuvant Phase. Oral Temozolomide (TMZ) is administered on Days 1-5 of each cycle for the first 6 cycles, but as an oral medication, it does not constitute an in-person contact day unless other procedures are scheduled on the same day.; All days involving Depatuxizumab mafodotin IV infusion or Radiation Therapy are categorized as core_treatment, overriding other activities due to tie-breaker precedence.; Ophthalmology exams are considered in-person and categorized as imaging_diagnostics, but are overridden by core_treatment if an infusion or RT occurs on the same day.; Central laboratory tests and urine pregnancy tests are considered in-person and categorized as labs, but are overridden by higher priority categories if other activities occur on the same day.; All other interview, patient-reported outcome (PRO), physical exam, and assessment activities are categorized as clinic_visits, but are overridden by higher priority categories if other activities occur on the same day.; Optional or 'as needed' visits are excluded from the count."
37272516,Vorasidenib,intervention,3,3,6,9,12,16,0,0,0,0,0,0,2,3,6,9,12,16,0,0,0,0,0,0,1,0,0,0,0,0,28,until progression,"Prescreening (D-84 to D-28), Screening (D-28 to D-1), Randomization (D-28 to D-1), C1D1, C1D15, C2D1, C2D15, C3D1, then D1 of Cycles 4-14. MRI assessments occur every 12 weeks (C4D1, C7D1, C10D1, C13D1). ECGs and PK blood draws occur on all D1 and D15 visits in Cycles 1-2, and all D1 visits from Cycle 3 onwards.","All procedures scheduled for a single 'Study Day' column (e.g., C1D1) in Table 1 and Table 2 are assumed to occur on that single calendar day, and the highest priority category is assigned to that day.; Randomization is counted as a separate contact day from other screening activities within the screening window, as it is a distinct event and the protocol states it 'may occur up to 3 days before C1D1'.; Oral study drug administration is not counted as a contact day for daily dosing, only for scheduled visits where drug is dispensed/initiated.; Optional buccal swab for germline mutation analysis (Table 1, footnote 26) is excluded.; CSF sample for crossover subjects only (Table 1, footnote 28) is excluded for the main treatment arms.; Survival status and subsequent anticancer therapy check in OS Follow-up (Table 1, footnote 5) is a phone contact and thus excluded.; Treatment is assumed to continue for the full 12 months for calculation purposes, based on the 'until progression' rule."
37272516,Placebo,control,3,3,6,9,12,16,0,0,0,0,0,0,2,3,6,9,12,16,0,0,0,0,0,0,1,0,0,0,0,0,28,until progression,"Prescreening (D-84 to D-28), Screening (D-28 to D-1), Randomization (D-28 to D-1), C1D1, C1D15, C2D1, C2D15, C3D1, then D1 of Cycles 4-14. MRI assessments occur every 12 weeks (C4D1, C7D1, C10D1, C13D1). ECGs and PK blood draws occur on all D1 and D15 visits in Cycles 1-2, and all D1 visits from Cycle 3 onwards.","All procedures scheduled for a single 'Study Day' column (e.g., C1D1) in Table 1 and Table 2 are assumed to occur on that single calendar day, and the highest priority category is assigned to that day.; Randomization is counted as a separate contact day from other screening activities within the screening window, as it is a distinct event and the protocol states it 'may occur up to 3 days before C1D1'.; Oral study drug administration is not counted as a contact day for daily dosing, only for scheduled visits where drug is dispensed/initiated.; Optional buccal swab for germline mutation analysis (Table 1, footnote 26) is excluded.; CSF sample for crossover subjects only (Table 1, footnote 28) is excluded for the main treatment arms.; Survival status and subsequent anticancer therapy check in OS Follow-up (Table 1, footnote 5) is a phone contact and thus excluded.; Treatment is assumed to continue for the full 12 months for calculation purposes, based on the 'until progression' rule."
37276510,SGI-110 Arm,intervention,1,11,27,45,63,83,0,8,19,32,46,62,1,0,1,3,4,5,0,3,7,10,13,16,0,0,0,0,0,0,28,until progression,"Screening (1 day). Cycles 1-2: Dosing on Days 1-5, interim visits on Days 8, 15, 22. Cycles ≥3: Dosing on Days 1-5, interim visit on Day 15. BM aspirate/biopsy on C1D1 (screening), C3D1, C5D1, C7D1, C10D1, C13D1.","Screening is assumed to occur on 1 day (Day -7) within the screening window, with the highest priority procedure (BM aspirate/biopsy) determining the category.; Treatment is assumed to continue until progression, so calculations are made up to Day 365.; Cycle length is 28 days.; All visits marked 'X' in Table 16 are considered in-person unless explicitly stated as telephone.; BM aspirate/biopsy is performed at screening, and on Day 1 of Cycles 3, 5, 7. After Cycle 7, it is performed every 3 months for the first year (Day 252 for C10D1, Day 336 for C13D1). These days are categorized as 'imaging_diagnostics' and override 'core_treatment' if they coincide with a dosing day.; PK samples are collected only in Cycle 1 Day 1 and Day 5 for SGI-110.; ECG is collected only in Cycle 1 Day 1."
37276510,Treatment Choice (TC) Arm,control,1,15,42,78,111,146,0,13,36,67,96,127,1,0,1,3,4,5,0,2,5,8,11,14,0,0,0,0,0,0,28,until progression,"Screening (1 day). Cycles 1-2: Dosing on Days 1-10, interim visits on Days 15, 22. Cycles ≥3: Dosing on Days 1-10, interim visit on Day 15. BM aspirate/biopsy on C1D1 (screening), C3D1, C5D1, C7D1, C10D1, C13D1.","Screening is assumed to occur on 1 day (Day -7) within the screening window, with the highest priority procedure (BM aspirate/biopsy) determining the category.; For the Treatment Choice arm, the Cytarabine regimen (20 mg SC BID on Days 1-10 every 28 days) is used for calculations, as it represents the highest number of treatment days among the three TC options.; Treatment is assumed to continue until progression, so calculations are made up to Day 365.; Cycle length is 28 days.; All visits marked 'X' in Table 16 are considered in-person unless explicitly stated as telephone.; BM aspirate/biopsy is performed at screening, and on Day 1 of Cycles 3, 5, 7. After Cycle 7, it is performed every 3 months for the first year (Day 252 for C10D1, Day 336 for C13D1). These days are categorized as 'imaging_diagnostics' and override 'core_treatment' if they coincide with a dosing day.; PK samples are collected only in Cycle 1 Day 1 for Decitabine (if applicable to TC arm).; ECG is collected only in Cycle 1 Day 1."
37284847,Group 1: Olanzapine + Fosaprepitant/Aprepitant,intervention,1,4,4,4,4,4,0,4,4,4,4,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,6,maximum of 24 days (4 cycles),"1 screening visit, followed by Day 1 of 4 treatment cycles (Day 0, Day 6, Day 12, Day 18).","All 'Prior to Registration' activities (History and physical, Serum/Urine HCG, Creatinine/AST/ALT, Blood sample for pharmacogenomics) are consolidated into a single in-person screening visit within the screening window (e.g., Day -7).; All 'Prior to treatment on Day 1' activities (Height/Weight/ECOG PS, Blood sample for pharmacogenomics, Baseline Questionnaires completed in clinic) are consolidated with the Cycle 1 Day 1 (Day 0) treatment visit.; Chemotherapy administration and IV/oral study drug administration on Day 1 of each cycle (C1D1, C2D1, C3D1, C4D1) require an in-person visit.; Adverse Event Assessments for continuation phases (Cycles 2-4) are performed during the in-person chemotherapy cycle visits (Day 1 of each cycle).; Patient-completed questionnaires (Nausea and Vomiting Daily Diary/Questionnaire, EQ-5D-3L) and 'Daily Nurse Telephone Contact' are not considered in-person healthcare contact days.; The study duration is strictly limited to a maximum of 24 days, which includes 4 cycles of 6 days each. Therefore, no visits occur beyond Day 18 (C4D1)."
37284847,Group 2: Olanzapine + Placebo,control,1,4,4,4,4,4,0,4,4,4,4,4,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,6,maximum of 24 days (4 cycles),"1 screening visit, followed by Day 1 of 4 treatment cycles (Day 0, Day 6, Day 12, Day 18).","All 'Prior to Registration' activities (History and physical, Serum/Urine HCG, Creatinine/AST/ALT, Blood sample for pharmacogenomics) are consolidated into a single in-person screening visit within the screening window (e.g., Day -7).; All 'Prior to treatment on Day 1' activities (Height/Weight/ECOG PS, Blood sample for pharmacogenomics, Baseline Questionnaires completed in clinic) are consolidated with the Cycle 1 Day 1 (Day 0) treatment visit.; Chemotherapy administration and IV/oral study drug administration on Day 1 of each cycle (C1D1, C2D1, C3D1, C4D1) require an in-person visit.; Adverse Event Assessments for continuation phases (Cycles 2-4) are performed during the in-person chemotherapy cycle visits (Day 1 of each cycle).; Patient-completed questionnaires (Nausea and Vomiting Daily Diary/Questionnaire, EQ-5D-3L) and 'Daily Nurse Telephone Contact' are not considered in-person healthcare contact days.; The study duration is strictly limited to a maximum of 24 days, which includes 4 cycles of 6 days each. Therefore, no visits occur beyond Day 18 (C4D1)."
37290035,Arm 1 (pembrolizumab 200 mg IV Q3W plus olaparib 300 mg PO BID),intervention,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression (or up to 2 years),"Screening (Day -28), then Cycle Day 1 visits every 21 days (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315, 336, 357). Imaging (CT/MRI, bone scan) occurs at Screening and on Cycle Day 1 visits at Weeks 9, 18, 27, 36, 45 (which coincide with C4D1, C7D1, C10D1, C13D1, C16D1).","Screening (Visit 1) is considered a single in-person contact day, occurring at Day -28 (the earliest possible day in the window -42 to -1).; Cycle Day 1 visits are in-person contact days for drug administration/dispensing and assessments.; Olaparib dispensing/container return and Pembrolizumab IV infusion are considered in-person core_treatment days.; The 'Telephone contact or visit' on C1D8 is conditional/optional and explicitly includes 'telephone contact,' so it is excluded as an in-person contact day.; Amendment 06 changes are applied: Efficacy Follow-up, Survival Follow-up, ePRO assessments, and biomarker sample collections (CTC, genetic, RNA, plasma, serum, ctDNA) are discontinued and thus excluded from contact day counts.; Local tumor imaging continues per SOC schedule as per Amendment 06, so the imaging schedule in the SoA is used.; Tumor tissue collection (biopsy) at screening is counted as an imaging_diagnostics day.; Treatment continues 'until progression' or up to 2 years; for the 12-month window, visits are counted up to Day 365, assuming treatment continues. End of Treatment Visit and Safety Follow-up are assumed to occur after Day 365 if treatment continues that long, and thus are not counted within the 12-month window.; All procedures listed for a given visit column are assumed to occur on that single visit day.; Category tie-breaker precedence: core_treatment > imaging_diagnostics > labs > clinic_visits. The screening day includes tumor imaging and biopsy, making it an imaging_diagnostics day. All Cycle Day 1 visits include drug administration/dispensing, making them core_treatment days."
37290035,Arm 2 (abiraterone acetate 1000 mg PO QD plus prednisone/prednisolone 5 mg PO BID) or enzalutamide 160 mg PO QD),control,1,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression (or up to 2 years),"Screening (Day -28), then Cycle Day 1 visits every 21 days (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315, 336, 357). Imaging (CT/MRI, bone scan) occurs at Screening and on Cycle Day 1 visits at Weeks 9, 18, 27, 36, 45 (which coincide with C4D1, C7D1, C10D1, C13D1, C16D1).","Screening (Visit 1) is considered a single in-person contact day, occurring at Day -28 (the earliest possible day in the window -42 to -1).; Cycle Day 1 visits are in-person contact days for drug administration/dispensing and assessments.; Abiraterone/Prednisone or Enzalutamide dispensing/container return are considered in-person core_treatment days.; The 'Telephone contact or visit' on C1D8 is conditional/optional and explicitly includes 'telephone contact,' so it is excluded as an in-person contact day.; Amendment 06 changes are applied: Efficacy Follow-up, Survival Follow-up, ePRO assessments, and biomarker sample collections (CTC, genetic, RNA, plasma, serum, ctDNA) are discontinued and thus excluded from contact day counts.; Local tumor imaging continues per SOC schedule as per Amendment 06, so the imaging schedule in the SoA is used.; Tumor tissue collection (biopsy) at screening is counted as an imaging_diagnostics day.; Treatment continues 'until progression' or up to 2 years; for the 12-month window, visits are counted up to Day 365, assuming treatment continues. End of Treatment Visit and Safety Follow-up are assumed to occur after Day 365 if treatment continues that long, and thus are not counted within the 12-month window.; All procedures listed for a given visit column are assumed to occur on that single visit day.; Category tie-breaker precedence: core_treatment > imaging_diagnostics > labs > clinic_visits. The screening day includes tumor imaging and biopsy, making it an imaging_diagnostics day. All Cycle Day 1 visits include drug administration/dispensing, making them core_treatment days.; Arm 2 is treated as a single arm for visit counting, as the Schedule of Activities does not differentiate between the Abiraterone/Prednisone and Enzalutamide subgroups for visit schedules."
37290461,Atezolizumab + Cabozantinib,intervention,3,2,5,9,13,18,0,2,5,9,13,18,2,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,21,until disease progression,"Screening visits (3 days) followed by Day 1 of each 21-day cycle for treatment and assessments. Specific assessments (ECG, TSH, UPCR, Tumor Response) occur at varying frequencies.","Day 1 of Cycle 1 is considered Day 0 for time window calculations.; Treatment continues until disease progression, so calculations are made assuming treatment continues for the full 365 days.; Screening activities are consolidated into 3 distinct in-person days: one for initial consent/general screening, one for fresh biopsy, and one for imaging/closer-to-randomization labs/ECG.; Cabozantinib dispensing/reconciliation on Day 1 of each cycle is considered an in-person clinic visit for drug supply and adherence check, even if subsequent doses are taken at home.; For Arm 1, all Day 1 of cycle visits are categorized as 'core_treatment' due to the Atezolizumab IV infusion, which takes precedence over other activities like imaging, labs, or clinic visits occurring on the same day.; For Arm 2, the first Cabozantinib dose on Day 0 is categorized as 'core_treatment' as it's administered in the clinic. Subsequent Day 1 of cycle visits are categorized based on the highest precedence activity occurring: 'imaging_diagnostics' if imaging (CT/MRI/ECG) is scheduled, otherwise 'clinic_visits' (for dispensing/reconciliation, vitals, PE, PROs, etc.)."
37290461,Cabozantinib Alone,control,3,2,5,9,13,18,0,1,1,1,1,1,2,1,4,6,9,13,0,0,0,0,0,0,1,0,0,2,3,4,21,until disease progression,"Screening visits (3 days) followed by Day 1 of each 21-day cycle for treatment and assessments. Specific assessments (ECG, TSH, UPCR, Tumor Response) occur at varying frequencies.","Day 1 of Cycle 1 is considered Day 0 for time window calculations.; Treatment continues until disease progression, so calculations are made assuming treatment continues for the full 365 days.; Screening activities are consolidated into 3 distinct in-person days: one for initial consent/general screening, one for fresh biopsy, and one for imaging/closer-to-randomization labs/ECG.; Cabozantinib dispensing/reconciliation on Day 1 of each cycle is considered an in-person clinic visit for drug supply and adherence check, even if subsequent doses are taken at home.; For Arm 1, all Day 1 of cycle visits are categorized as 'core_treatment' due to the Atezolizumab IV infusion, which takes precedence over other activities like imaging, labs, or clinic visits occurring on the same day.; For Arm 2, the first Cabozantinib dose on Day 0 is categorized as 'core_treatment' as it's administered in the clinic. Subsequent Day 1 of cycle visits are categorized based on the highest precedence activity occurring: 'imaging_diagnostics' if imaging (CT/MRI/ECG) is scheduled, otherwise 'clinic_visits' (for dispensing/reconciliation, vitals, PE, PROs, etc.)."
37315297,Arm 1: External Beam Radiation Therapy and then Brachytherapy,intervention,3,23,27,29,30,31,0,23,26,26,26,26,2,0,1,1,1,1,1,0,0,2,3,4,0,0,0,0,0,0,,until progression,"Screening (3 days: 1 labs, 2 imaging_diagnostics). EBRT (25 days: core_treatment, Day 0-32). Brachytherapy implant (1 day: core_treatment, Day 53). Post-implant imaging (1 day: imaging_diagnostics, Day 81). Follow-up visits (1 day each: labs, at Day 120, 180, 270, 360).","Screening procedures (H&P/Qs/Labs, Prostate biopsy/TRUS, Lymph node assessment) are spread across 3 distinct days for practical reasons: Day -28 (Labs), Day -21 (Prostate biopsy/TRUS), Day -14 (Lymph node assessment).; External Beam Radiation Therapy (EBRT) is 5 days/week (Monday-Friday) for 5 weeks, totaling 25 distinct core_treatment days. Weekly radiation oncologist visits are assumed to coincide with one of the EBRT treatment days.; Brachytherapy implant for Arm 1 is assumed to occur 3 weeks after EBRT completion (EBRT ends on Day 32, so implant on Day 53).; Post-implant imaging (CT/X-rays) is assumed to occur 4 weeks after the brachytherapy implant (Arm 1: Day 53 + 28 = Day 81).; Follow-up visits are scheduled at 4, 6, 9, and 12 months post treatment start (Day 0), assumed to occur on Day 120, Day 180, Day 270, and Day 360 respectively.; All follow-up visits include History & Physical, Zubrod, Tumor Measurement, Toxicity Evaluation (clinic_visits) and PSA/Free PSA (labs). Per tie-breaker precedence, these days are categorized as 'labs'.; Questionnaires (AUA, EPIC, EQ5D, Utilization of Sexual Medications/Devices) are completed during the clinic visit and do not add separate contact days.; Conditional visits (e.g., 'if clinically indicated', 'if your doctor feels these tests are needed', 'if advised by the urologist', 'if disease worsens') are excluded from the contact day count."
37315297,Arm 2: Brachytherapy Alone,intervention,3,1,2,4,5,6,0,1,1,1,1,1,2,0,1,1,1,1,1,0,0,2,3,4,0,0,0,0,0,0,,until progression,"Screening (3 days: 1 labs, 2 imaging_diagnostics). Brachytherapy implant (1 day: core_treatment, Day 21). Post-implant imaging (1 day: imaging_diagnostics, Day 49). Follow-up visits (1 day each: labs, at Day 120, 180, 270, 360).","Screening procedures (H&P/Qs/Labs, Prostate biopsy/TRUS, Lymph node assessment) are spread across 3 distinct days for practical reasons: Day -28 (Labs), Day -21 (Prostate biopsy/TRUS), Day -14 (Lymph node assessment).; Brachytherapy implant for Arm 2 is assumed to occur 3 weeks after Day 0 (Day 21).; Post-implant imaging (CT/X-rays) is assumed to occur 4 weeks after the brachytherapy implant (Arm 2: Day 21 + 28 = Day 49).; Follow-up visits are scheduled at 4, 6, 9, and 12 months post treatment start (Day 0), assumed to occur on Day 120, Day 180, Day 270, and Day 360 respectively.; All follow-up visits include History & Physical, Zubrod, Tumor Measurement, Toxicity Evaluation (clinic_visits) and PSA/Free PSA (labs). Per tie-breaker precedence, these days are categorized as 'labs'.; Questionnaires (AUA, EPIC, EQ5D, Utilization of Sexual Medications/Devices) are completed during the clinic visit and do not add separate contact days.; Conditional visits (e.g., 'if clinically indicated', 'if your doctor feels these tests are needed', 'if advised by the urologist', 'if disease worsens') are excluded from the contact day count."
37331369,Fruquintinib + Best Supportive Care (BSC),intervention,1,3,7,13,19,27,0,3,6,10,14,18,1,0,1,3,5,9,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (Day -1). Treatment cycles are 28 days long, with visits on Day 1 and Day 21 of each cycle. Specific assessments (e.g., Echocardiogram, Tumor Evaluation/Imaging, Blood amylase and lipase, Thyroid Function, Urinalysis) occur on a repeating schedule across cycles. An End of Treatment (EOT) visit occurs 7 days after the last dose. A Safety Follow-Up visit occurs 30 days after EOT.","Two screening visit windows (-28 to -1 days and -7 to -1 days) are consolidated into a single in-person screening visit on Day -1, encompassing all screening procedures listed in Table 1.; Patient Randomization (Footnote 22) is assumed to occur on the single screening visit (Day -1) to consolidate contact days.; PK plasma sampling (Footnote 21) and specific ECG/Echocardiogram evaluations from Table 2 and Table 3 are for a 'subset' of patients and are therefore not included in the contact day count for the main treatment arms, which apply to all subjects.; Study Treatment (Footnote 24) and Drug Dispense&Return (Footnote 23) on C*D1 visits are considered in-person core_treatment days for drug-related activities (dispensing, return, and potential on-site administration).; Urine pregnancy test (Footnote 16) is counted from C2D1 onwards, as specified in the footnote, overriding the 'X' in C1D21 in Table 1.; Echocardiogram/MUGA schedule (Footnote 18: Screening, C2D1, and every 3 cycles thereafter, i.e., C5D1, C8D1, C11D1, C14D1, etc.) overrides the 'X' in Table 1 for other C*D1 visits.; 12-lead ECG (Footnote 17) is counted on all C*D1 visits as per Table 1, assuming 'clinically indicated' in the footnote refers to additional, unscheduled ECGs.; Survival Follow-Up (Footnote 26) is explicitly stated as 'by telephone' and is therefore not counted as an in-person contact day.; Treatment is assumed to continue until the end of the 12-month window (Day +365) or the last full cycle before that, followed by an End of Treatment (EOT) visit. The last full cycle before Day 365 is Cycle 13 (C13D1 on Day 336, C13D21 on Day 356). The EOT visit is 7 days after the last dose, so Day 356 + 7 = Day 363. This EOT visit is included in the 12-month window."
37331369,Placebo + Best Supportive Care (BSC),control,1,3,7,13,19,27,0,3,6,10,14,18,1,0,1,3,5,9,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (Day -1). Treatment cycles are 28 days long, with visits on Day 1 and Day 21 of each cycle. Specific assessments (e.g., Echocardiogram, Tumor Evaluation/Imaging, Blood amylase and lipase, Thyroid Function, Urinalysis) occur on a repeating schedule across cycles. An End of Treatment (EOT) visit occurs 7 days after the last dose. A Safety Follow-Up visit occurs 30 days after EOT.","Two screening visit windows (-28 to -1 days and -7 to -1 days) are consolidated into a single in-person screening visit on Day -1, encompassing all screening procedures listed in Table 1.; Patient Randomization (Footnote 22) is assumed to occur on the single screening visit (Day -1) to consolidate contact days.; PK plasma sampling (Footnote 21) and specific ECG/Echocardiogram evaluations from Table 2 and Table 3 are for a 'subset' of patients and are therefore not included in the contact day count for the main treatment arms, which apply to all subjects.; Study Treatment (Footnote 24) and Drug Dispense&Return (Footnote 23) on C*D1 visits are considered in-person core_treatment days for drug-related activities (dispensing, return, and potential on-site administration).; Urine pregnancy test (Footnote 16) is counted from C2D1 onwards, as specified in the footnote, overriding the 'X' in C1D21 in Table 1.; Echocardiogram/MUGA schedule (Footnote 18: Screening, C2D1, and every 3 cycles thereafter, i.e., C5D1, C8D1, C11D1, C14D1, etc.) overrides the 'X' in Table 1 for other C*D1 visits.; 12-lead ECG (Footnote 17) is counted on all C*D1 visits as per Table 1, assuming 'clinically indicated' in the footnote refers to additional, unscheduled ECGs.; Survival Follow-Up (Footnote 26) is explicitly stated as 'by telephone' and is therefore not counted as an in-person contact day.; Treatment is assumed to continue until the end of the 12-month window (Day +365) or the last full cycle before that, followed by an End of Treatment (EOT) visit. The last full cycle before Day 365 is Cycle 13 (C13D1 on Day 336, C13D21 on Day 356). The EOT visit is 7 days after the last dose, so Day 356 + 7 = Day 363. This EOT visit is included in the 12-month window."
37342922,Tacrolimus/Methotrexate (Tac/MTX),intervention,4,9,17,19,20,21,1,5,5,5,5,5,1,0,0,1,1,2,2,4,12,13,14,14,0,0,0,0,0,0,,1 year post-PBSC transplant,"Pre-transplant visits on Day -28, -14, -1. Post-transplant visits on Day 0, +1, +3, +6, +7, +11, +14, +21, +28, +35, +42, +49, +56, +63, +70, +77, +84, +98, +180, +270, +365.","All 'X' marks in Table 4.6B (page 127, v4.0) indicate an in-person contact day.; Pre-conditioning (Day -28 to -1) is counted as one contact day for general evaluations (Day -28).; Mi-Immune pre-conditioning samples (Day -14 to -7) are counted as a separate contact day (Day -14).; Pre-infusion (Day -1 to 0) is counted as one contact day (Day -1).; Weekly visits from Day 7 to Day 84 are counted as 1 day per week.; Tacrolimus administration (initiation) is categorized as core_treatment.; Methotrexate IV administration is categorized as core_treatment.; PTCy IV administration is categorized as core_treatment.; MMF oral initiation on Day +5 for PTCy/Tac/MMF arm is a clinic_visit, but Day +5 is categorized as core_treatment due to Tacrolimus initiation on the same day.; Tacrolimus serum level monitoring (weekly from Day +7) is a lab procedure.; Disease evaluation (bone marrow biopsy/imaging) is imaging_diagnostics.; CBC, blood chemistries, infectious disease titers, chimerism, Mi-Immune blood/urine/stool samples are labs. Mi-Immune blood samples are considered mandatory if marked 'X' in Table 4.6B, as per Appendix J, Section 4.3.1 (page J-10, v4.0). Mi-Immune stool samples are mandatory until Day 28, then optional. Mi-Immune urine samples are always optional. However, since blood samples are mandatory and collected on all 'Mi-Immune research samples' days, these days are counted as contact days for labs.; H&P, KPS, GVHD assessments, Toxicity assessments, Infection assessments, PRO are clinic_visits.; Tie-breaker precedence: core_treatment > imaging_diagnostics > labs > clinic_visits."
37342922,Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil (PTCy/Tac/MMF),intervention,3,8,16,18,19,20,0,4,4,4,4,4,1,0,0,1,1,2,2,4,12,13,14,14,0,0,0,0,0,0,,1 year post-PBSC transplant,"Pre-transplant visits on Day -28, -14, -1. Post-transplant visits on Day 0, +3, +4, +5, +7, +14, +21, +28, +35, +42, +49, +56, +63, +70, +77, +84, +98, +180, +270, +365.","All 'X' marks in Table 4.6B (page 127, v4.0) indicate an in-person contact day.; Pre-conditioning (Day -28 to -1) is counted as one contact day for general evaluations (Day -28).; Mi-Immune pre-conditioning samples (Day -14 to -7) are counted as a separate contact day (Day -14).; Pre-infusion (Day -1 to 0) is counted as one contact day (Day -1).; Weekly visits from Day 7 to Day 84 are counted as 1 day per week.; Tacrolimus administration (initiation) is categorized as core_treatment.; Methotrexate IV administration is categorized as core_treatment.; PTCy IV administration is categorized as core_treatment.; MMF oral initiation on Day +5 for PTCy/Tac/MMF arm is a clinic_visit, but Day +5 is categorized as core_treatment due to Tacrolimus initiation on the same day.; Tacrolimus serum level monitoring (weekly from Day +7) is a lab procedure.; Disease evaluation (bone marrow biopsy/imaging) is imaging_diagnostics.; CBC, blood chemistries, infectious disease titers, chimerism, Mi-Immune blood/urine/stool samples are labs. Mi-Immune blood samples are considered mandatory if marked 'X' in Table 4.6B, as per Appendix J, Section 4.3.1 (page J-10, v4.0). Mi-Immune stool samples are mandatory until Day 28, then optional. Mi-Immune urine samples are always optional. However, since blood samples are mandatory and collected on all 'Mi-Immune research samples' days, these days are counted as contact days for labs.; H&P, KPS, GVHD assessments, Toxicity assessments, Infection assessments, PRO are clinic_visits.; Tie-breaker precedence: core_treatment > imaging_diagnostics > labs > clinic_visits."
37379502,Lazertinib,intervention,1,4,7,9,11,13,0,4,7,9,11,13,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening (Day -28), then Cycle 1 Day 1 (Day 0), Cycle 1 Day 8 (Day 7), Cycle 1 Day 15 (Day 14). Subsequent cycles are 21 days long, with visits on Day 1 of each cycle (C2D1, C3D1, C4D1). From Cycle 5 onwards, visits occur on Day 1 of every other cycle (C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, C17D1...).","Both Lazertinib and Gefitinib arms follow the same Schedule of Activities in Table 5.; The 'Screening' visit (Day -28) is considered an in-person contact day, with the highest priority activity being imaging_diagnostics due to mandatory biopsy/tumor sample collection and RECIST imaging.; For treatment period visits, 'Dispense study treatment' and 'Dose with study treatment' are considered core_treatment activities requiring in-person contact, taking precedence over other activities on the same day.; The 'Randomization' activity listed under the 'Screening' column in Table 5 is assumed to occur on Cycle 1 Day 1 (Day 0) as per protocol text (page 54, footnote 26: 'Once randomized, the first dose should be administered on the randomization day').; PK blood samples are collected on C1D1, C2D1, C5D1, C9D1, C13D1 as per footnote 19 and section 6.10.1, and not during screening despite an 'X' in the Screening column of Table 5, as Table 7 explicitly shows 'NA' for PK analysis at screening.; Clinical laboratory tests on C1D1 are counted as per footnote 17, which states they are performed unless screening labs are very recent.; Efficacy assessments (RECIST v1.1) and Echocardiography/MUGA scans are considered in-person imaging diagnostics.; Questionnaires and Health Resource Use Module are assumed to be completed in clinic.; Treatment continues 'until progression' and for the purpose of this calculation, it is assumed to continue through the 12-month window.; Unscheduled visits, 28-day Safety F/U (via telephone contact), Progression F/U (conditional), and Survival F/U (via telephone contact) are not counted as fixed in-person contact days."
37379502,Gefitinib,intervention,1,4,7,9,11,13,0,4,7,9,11,13,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression,"Screening (Day -28), then Cycle 1 Day 1 (Day 0), Cycle 1 Day 8 (Day 7), Cycle 1 Day 15 (Day 14). Subsequent cycles are 21 days long, with visits on Day 1 of each cycle (C2D1, C3D1, C4D1). From Cycle 5 onwards, visits occur on Day 1 of every other cycle (C5D1, C7D1, C9D1, C11D1, C13D1, C15D1, C17D1...).","Both Lazertinib and Gefitinib arms follow the same Schedule of Activities in Table 5.; The 'Screening' visit (Day -28) is considered an in-person contact day, with the highest priority activity being imaging_diagnostics due to mandatory biopsy/tumor sample collection and RECIST imaging.; For treatment period visits, 'Dispense study treatment' and 'Dose with study treatment' are considered core_treatment activities requiring in-person contact, taking precedence over other activities on the same day.; The 'Randomization' activity listed under the 'Screening' column in Table 5 is assumed to occur on Cycle 1 Day 1 (Day 0) as per protocol text (page 54, footnote 26: 'Once randomized, the first dose should be administered on the randomization day').; PK blood samples are collected on C1D1, C2D1, C5D1, C9D1, C13D1 as per footnote 19 and section 6.10.1, and not during screening despite an 'X' in the Screening column of Table 5, as Table 7 explicitly shows 'NA' for PK analysis at screening.; Clinical laboratory tests on C1D1 are counted as per footnote 17, which states they are performed unless screening labs are very recent.; Efficacy assessments (RECIST v1.1) and Echocardiography/MUGA scans are considered in-person imaging diagnostics.; Questionnaires and Health Resource Use Module are assumed to be completed in clinic.; Treatment continues 'until progression' and for the purpose of this calculation, it is assumed to continue through the 12-month window.; Unscheduled visits, 28-day Safety F/U (via telephone contact), Progression F/U (conditional), and Survival F/U (via telephone contact) are not counted as fixed in-person contact days."
37423228,Atezolizumab,intervention,1,2,6,10,14,19,0,2,5,9,13,18,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,21,until disease progression,"Screening (Day -14), C1D1 (Day 0), C2D1 (Day 21), C3D1 (Day 42, with Week 6 TA), Week 7 Plasma (Day 49), C4D1 (Day 63), C5D1 (Day 84, with Week 12 TA, TSH), C6D1 (Day 105), C7D1 (Day 126, with Week 18 TA), C8D1 (Day 147), C9D1 (Day 168, with Week 24 TA, TSH), C10D1 (Day 189), C11D1 (Day 210, with Week 30 TA), C12D1 (Day 231), C13D1 (Day 252, with Week 36 TA, TSH), C14D1 (Day 273), C15D1 (Day 294, with Week 42 TA), C16D1 (Day 315), C17D1 (Day 336, with Week 48 TA, TSH), C18D1 (Day 357).","The 'Schedule of Activities' (Appendix 1, pages 64-66) is the primary source for visit frequency and procedures.; The screening period (Day -28 to Day -1) is assumed to involve one in-person contact day for all listed screening procedures, with the highest precedence category applied (imaging_diagnostics due to CT/MRI and ECG). The baseline tumor assessment is considered covered by the screening imaging.; Cycle 1 Day 1 (Day 0) is the anchor date. All procedures marked for C1D1 are performed on this day.; Atezolizumab is administered every 21 days (q3w).; Chemotherapy cycle length is assumed to be 21 days (q3w) for consistency and based on the 'Day 1 ± 5 days' marking in the SoA for 'Cycles ≥ 2'. The protocol states chemotherapy cycles 'may be 3-weekly or 4-weekly' and vinorelbine/gemcitabine can be d1/8 q21d or d1/8/15 q28d, but the SoA table only indicates a Day 1 visit for subsequent cycles. Therefore, only Day 1 of each chemotherapy cycle is counted as a treatment contact day.; Treatment continues 'until disease progression', which is assumed to be at least 12 months for calculation purposes.; Tumor response assessments are scheduled at baseline (covered by screening), then every 6 weeks (Day 42, 84, 126, 168, 210, 252, 294, 336). These days coincide with Day 1 of cycles 3, 5, 7, 9, 11, 13, 15, 17 respectively. When multiple activities occur on the same day, the highest precedence category is applied (core_treatment > imaging_diagnostics).; TSH assessments are scheduled at screening (Day -14), C1D1 (Day 0), and then C5D1 (Day 84), C9D1 (Day 168), C13D1 (Day 252), C17D1 (Day 336). These days coincide with core treatment days.; Plasma for exploratory biomarkers is collected at baseline (Day 0), Week 7 (Day 49), and at PD. Week 7 (Day 49) is a separate contact day.; 12-lead ECG is performed at screening (Day -14), C1D1 (Day 0), and Day 1 of every subsequent cycle.; The Treatment Discontinuation visit occurs after the 12-month window if treatment continues for 12 months, so it is not included in the 12-month count.; Follow-up visits are typically telephone calls or clinic visits every 2 months after treatment discontinuation, which would fall outside the 12-month treatment window and are not explicitly mandated as in-person for all instances, thus not counted."
37423228,Chemotherapy,control,1,2,6,10,14,19,0,2,5,9,13,18,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,21,until disease progression,"Screening (Day -14), C1D1 (Day 0), C2D1 (Day 21), C3D1 (Day 42, with Week 6 TA), Week 7 Plasma (Day 49), C4D1 (Day 63), C5D1 (Day 84, with Week 12 TA, TSH), C6D1 (Day 105), C7D1 (Day 126, with Week 18 TA), C8D1 (Day 147), C9D1 (Day 168, with Week 24 TA, TSH), C10D1 (Day 189), C11D1 (Day 210, with Week 30 TA), C12D1 (Day 231), C13D1 (Day 252, with Week 36 TA, TSH), C14D1 (Day 273), C15D1 (Day 294, with Week 42 TA), C16D1 (Day 315), C17D1 (Day 336, with Week 48 TA, TSH), C18D1 (Day 357).","The 'Schedule of Activities' (Appendix 1, pages 64-66) is the primary source for visit frequency and procedures.; The screening period (Day -28 to Day -1) is assumed to involve one in-person contact day for all listed screening procedures, with the highest precedence category applied (imaging_diagnostics due to CT/MRI and ECG). The baseline tumor assessment is considered covered by the screening imaging.; Cycle 1 Day 1 (Day 0) is the anchor date. All procedures marked for C1D1 are performed on this day.; Atezolizumab is administered every 21 days (q3w).; Chemotherapy cycle length is assumed to be 21 days (q3w) for consistency and based on the 'Day 1 ± 5 days' marking in the SoA for 'Cycles ≥ 2'. The protocol states chemotherapy cycles 'may be 3-weekly or 4-weekly' and vinorelbine/gemcitabine can be d1/8 q21d or d1/8/15 q28d, but the SoA table only indicates a Day 1 visit for subsequent cycles. Therefore, only Day 1 of each chemotherapy cycle is counted as a treatment contact day.; Treatment continues 'until disease progression', which is assumed to be at least 12 months for calculation purposes.; Tumor response assessments are scheduled at baseline (covered by screening), then every 6 weeks (Day 42, 84, 126, 168, 210, 252, 294, 336). These days coincide with Day 1 of cycles 3, 5, 7, 9, 11, 13, 15, 17 respectively. When multiple activities occur on the same day, the highest precedence category is applied (core_treatment > imaging_diagnostics).; TSH assessments are scheduled at screening (Day -14), C1D1 (Day 0), and then C5D1 (Day 84), C9D1 (Day 168), C13D1 (Day 252), C17D1 (Day 336). These days coincide with core treatment days.; Plasma for exploratory biomarkers is collected at baseline (Day 0), Week 7 (Day 49), and at PD. Week 7 (Day 49) is a separate contact day.; 12-lead ECG is performed at screening (Day -14), C1D1 (Day 0), and Day 1 of every subsequent cycle.; The Treatment Discontinuation visit occurs after the 12-month window if treatment continues for 12 months, so it is not included in the 12-month count.; Follow-up visits are typically telephone calls or clinic visits every 2 months after treatment discontinuation, which would fall outside the 12-month treatment window and are not explicitly mandated as in-person for all instances, thus not counted."
37478390,Arm A (Zanubrutinib),intervention,5,1,7,13,19,26,0,1,3,5,7,10,3,0,4,8,12,16,1,0,0,0,0,0,1,0,0,0,0,0,28,until progression,"Screening (5 days). Treatment cycles (28 days): D1 of every cycle for drug administration, CBC, patient diary, ECOG, weight, vital signs/physical exam. Specific D1 visits include ECG (C1D1, C2D1, C6D1, C10D1), QOL (C1D1, C3D1, C6D1, C9D1, C12D1 for Arm A), Chemistry/β2-microglobulin, Quantitative Ig, SPEP/Immunofixation (every cycle for first 48 weeks, then every 3 cycles), CT scans (C4D1, C7D1, C10D1, C13D1), Bone Marrow Biopsy (C13D1). Additional D1+4 visits for Arms A & C for PK and ECG (Cycles 2-13).","The 'Screening' column in Table 3 (Day -35 to -1) is interpreted as a period during which multiple in-person visits occur, consolidated into 5 distinct contact days for different types of procedures (general clinic, imaging, biopsy, labs).; 'Randomization via IRT' (marked 'X' under Screening) is considered part of a general screening clinic visit day, not a separate contact day.; The note 'Subjects must come every cycle for CBC, study drug, and patient diary review' (under C16, C19, C22+ column header) is interpreted as a general rule applying to D1 of *every* cycle (Day 0, Day 28, Day 56, etc.) for all arms. These D1 visits are considered in-person contact days.; The columns 'Cycle 2 D1±4', 'C3-13 D1±4' in Table 3 indicate *additional* in-person visits on those specific days (e.g., Day 32, Day 60, etc.) for the assessments marked with 'X' in those columns. The 'D1±4' is interpreted as a specific day (Day 1+4=Day 5) within the cycle, not a flexible window around Day 1.; Pharmacokinetics (PK) samples for Arms A and C are collected on C1D1, and then on D1+4 of Cycles 2-13 (i.e., Day 32, 60, 88, etc.), as indicated by Table 3, despite a slight discrepancy with text on page 45 (which mentions C2D1 for PK). The table is followed for specific visit days. PK sampling is considered a 'labs' activity.; ECG for Arms A and C is performed on C1D1, C2D1, and then every 4 cycles (C6D1, C10D1, etc.) as per page 74. Table 3 also indicates ECG on D1+4 for Cycles 2-13 for Arms A and C. These D1+4 ECGs are counted as additional imaging_diagnostics days.; Quality of Life (QOL) assessments are for Cohort 1 (Arms A and B) only, on C1D1, then every 3 cycles during the first 12 cycles (C3D1, C6D1, C9D1, C12D1), then every 6 cycles thereafter, as per page 45, footnote 17.; CT scans are performed on C4D1, C7D1, C10D1, C13D1 for all arms, as per page 62, footnote 16.; Bone marrow biopsy/aspiration is performed at Screening and C13D1 (48 weeks) for all arms, as per page 62, footnote 15.; End of Treatment (EOT) and Safety Follow-up visits are assumed to occur *after* the 12-month window, as treatment is assumed to continue 'until progression' for the full 12 months. Conditional labs/CTs at these visits are therefore not counted.; Survival follow-up is via phone contact and not counted as an in-person day.; For category assignment, drug administration (core_treatment) takes precedence over imaging_diagnostics, which takes precedence over labs, which takes precedence over clinic_visits. For visits with multiple activities, the highest priority activity determines the day's category."
37478390,Arm B (Ibrutinib),intervention,5,1,4,7,10,14,0,1,3,5,7,10,3,0,1,2,3,4,1,0,0,0,0,0,1,0,0,0,0,0,28,until progression,"Screening (5 days). Treatment cycles (28 days): D1 of every cycle for drug administration, CBC, patient diary, ECOG, weight, vital signs/physical exam. Specific D1 visits include ECG (C1D1, C2D1, C6D1, C10D1), QOL (C1D1, C3D1, C6D1, C9D1, C12D1), Chemistry/β2-microglobulin, Quantitative Ig, SPEP/Immunofixation (every cycle for first 48 weeks, then every 3 cycles), CT scans (C4D1, C7D1, C10D1, C13D1), Bone Marrow Biopsy (C13D1). No D1+4 or D1+7 visits for Arm B.","The 'Screening' column in Table 3 (Day -35 to -1) is interpreted as a period during which multiple in-person visits occur, consolidated into 5 distinct contact days for different types of procedures (general clinic, imaging, biopsy, labs).; 'Randomization via IRT' (marked 'X' under Screening) is considered part of a general screening clinic visit day, not a separate contact day.; The note 'Subjects must come every cycle for CBC, study drug, and patient diary review' (under C16, C19, C22+ column header) is interpreted as a general rule applying to D1 of *every* cycle (Day 0, Day 28, Day 56, etc.) for all arms. These D1 visits are considered in-person contact days.; Arm B does not have D1+4 or D1+7 visits as indicated by the absence of 'X' in Table 3 for these columns.; ECG for Arm B is performed on C1D1, C2D1, and then every 4 cycles (C6D1, C10D1, etc.) as per page 75.; Quality of Life (QOL) assessments are for Cohort 1 (Arms A and B) only, on C1D1, then every 3 cycles during the first 12 cycles (C3D1, C6D1, C9D1, C12D1), then every 6 cycles thereafter, as per page 45, footnote 17.; CT scans are performed on C4D1, C7D1, C10D1, C13D1 for all arms, as per page 62, footnote 16.; Bone marrow biopsy/aspiration is performed at Screening and C13D1 (48 weeks) for all arms, as per page 62, footnote 15.; End of Treatment (EOT) and Safety Follow-up visits are assumed to occur *after* the 12-month window, as treatment is assumed to continue 'until progression' for the full 12 months. Conditional labs/CTs at these visits are therefore not counted.; Survival follow-up is via phone contact and not counted as an in-person day.; For category assignment, drug administration (core_treatment) takes precedence over imaging_diagnostics, which takes precedence over labs, which takes precedence over clinic_visits. For visits with multiple activities, the highest priority activity determines the day's category."
37478390,Arm C (Zanubrutinib),intervention,5,1,7,13,19,26,0,1,3,5,7,10,3,0,4,8,12,16,1,0,0,0,0,0,1,0,0,0,0,0,28,until progression,"Screening (5 days). Treatment cycles (28 days): D1 of every cycle for drug administration, CBC, patient diary, ECOG, weight, vital signs/physical exam. Specific D1 visits include ECG (C1D1, C2D1, C6D1, C10D1), Chemistry/β2-microglobulin, Quantitative Ig, SPEP/Immunofixation (every cycle for first 48 weeks, then every 3 cycles), CT scans (C4D1, C7D1, C10D1, C13D1), Bone Marrow Biopsy (C13D1). Additional D1+4 visits for Arms A & C for PK and ECG (Cycles 2-13). No QOL assessments for Arm C.","The 'Screening' column in Table 3 (Day -35 to -1) is interpreted as a period during which multiple in-person visits occur, consolidated into 5 distinct contact days for different types of procedures (general clinic, imaging, biopsy, labs).; 'Randomization via IRT' (marked 'X' under Screening) is considered part of a general screening clinic visit day, not a separate contact day.; The note 'Subjects must come every cycle for CBC, study drug, and patient diary review' (under C16, C19, C22+ column header) is interpreted as a general rule applying to D1 of *every* cycle (Day 0, Day 28, Day 56, etc.) for all arms. These D1 visits are considered in-person contact days.; The columns 'Cycle 2 D1±4', 'C3-13 D1±4' in Table 3 indicate *additional* in-person visits on those specific days (e.g., Day 32, Day 60, etc.) for the assessments marked with 'X' in those columns. The 'D1±4' is interpreted as a specific day (Day 1+4=Day 5) within the cycle, not a flexible window around Day 1.; Pharmacokinetics (PK) samples for Arms A and C are collected on C1D1, and then on D1+4 of Cycles 2-13 (i.e., Day 32, 60, 88, etc.), as indicated by Table 3, despite a slight discrepancy with text on page 45 (which mentions C2D1 for PK). The table is followed for specific visit days. PK sampling is considered a 'labs' activity.; ECG for Arms A and C is performed on C1D1, C2D1, and then every 4 cycles (C6D1, C10D1, etc.) as per page 74. Table 3 also indicates ECG on D1+4 for Cycles 2-13 for Arms A and C. These D1+4 ECGs are counted as additional imaging_diagnostics days.; Quality of Life (QOL) assessments are *not* performed for Arm C at C1D1 or subsequent cycles, as per page 45, footnote 17, which states QOL is for Cohort 1 (Arms A and B) only.; CT scans are performed on C4D1, C7D1, C10D1, C13D1 for all arms, as per page 62, footnote 16.; Bone marrow biopsy/aspiration is performed at Screening and C13D1 (48 weeks) for all arms, as per page 62, footnote 15.; End of Treatment (EOT) and Safety Follow-up visits are assumed to occur *after* the 12-month window, as treatment is assumed to continue 'until progression' for the full 12 months. Conditional labs/CTs at these visits are therefore not counted.; Survival follow-up is via phone contact and not counted as an in-person day.; For category assignment, drug administration (core_treatment) takes precedence over imaging_diagnostics, which takes precedence over labs, which takes precedence over clinic_visits. For visits with multiple activities, the highest priority activity determines the day's category."
37499670,Experimental Arm: Camrelizumab + Rivoceranib,intervention,3,3,7,14,20,27,0,3,7,14,20,27,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (Day -28, Day -14, Day -7). Treatment: D1 and D15 of each 28-day cycle. Tumor imaging on Day 0, 56, 112, 168, 224, 280, 336.","Treatment continues 'until progression' is interpreted as continuing treatment and associated visits up to Day 365 for calculation purposes.; End-of-Treatment and Safety Follow-up visits are assumed to occur after Day 365, thus not included in the 12-month window.; Telephone visits are not counted as in-person contact days.; When the Schedule of Activities table and text descriptions for specific procedures on specific days conflict, the text is used for the frequency of repeating procedures (e.g., tumor imaging every 8 weeks), while the table is used for the presence of a visit type on a specific day (e.g., C1D1 procedures).; For C1D1, ECOG-PS, Physical examination, Vital signs, Hematology, Urinalysis, Blood biochemistry, Blood electrolytes, Child-Pugh, AFP, Thyroid function, Virology, Fecal occult blood, 12-lead ECG, Blood HCG are not performed based on the table, despite some text suggesting they might be done within 24h/72h prior to C1D1.; Randomization is considered a clinic_visit.; All D1 and D15 visits involve administration of study drug (intravenous infusion or oral administration), therefore all these days are categorized as core_treatment, overriding other procedures on those days.; Tumor imaging days (Day 0, 56, 112, 168, 224, 280, 336) coincide with D1 visits, which involve core treatment, thus these days are categorized as core_treatment."
37499670,Control Arm: Sorafenib,control,3,3,7,10,13,17,0,3,7,10,13,17,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (Day -28, Day -14, Day -7). Treatment: D1 and D15 for Cycles 1-3, then D1 only for Cycles 4 onwards. Tumor imaging on Day 0, 56, 112, 168, 224, 280, 336.","Treatment continues 'until progression' is interpreted as continuing treatment and associated visits up to Day 365 for calculation purposes.; End-of-Treatment and Safety Follow-up visits are assumed to occur after Day 365, thus not included in the 12-month window.; Telephone visits are not counted as in-person contact days.; When the Schedule of Activities table and text descriptions for specific procedures on specific days conflict, the text is used for the frequency of repeating procedures (e.g., tumor imaging every 8 weeks), while the table is used for the presence of a visit type on a specific day (e.g., C1D1 procedures).; For C1D1, ECOG-PS, Physical examination, Vital signs, Hematology, Urinalysis, Blood biochemistry, Blood electrolytes, Child-Pugh, AFP, Thyroid function, Virology, Fecal occult blood, 12-lead ECG, Blood HCG are not performed based on the table, despite some text suggesting they might be done within 24h/72h prior to C1D1.; Randomization is considered a clinic_visit.; All D1 and D15 visits involve administration of study drug (oral administration), therefore all these days are categorized as core_treatment, overriding other procedures on those days.; Tumor imaging days (Day 0, 56, 112, 168, 224, 280, 336) coincide with D1 visits, which involve core treatment, thus these days are categorized as core_treatment."
37524096,Everolimus,intervention,1,2,4,6,8,10,0,1,1,1,1,1,1,0,0,1,2,2,0,0,0,0,0,0,0,1,3,4,5,7,42,9 cycles (54 weeks or 378 days),"Screening (Day -28 to -1); Cycle 1: Day 0, Day 21; Cycle 2: Day 42; Cycle 3: Day 84; Cycles 4-9: Day 126, Day 168, Day 210, Day 252, Day 294, Day 336. CT scans on Day 126 and Day 252.","The study calendar on page 27-28 is applicable to both arms due to the double-blind nature of the study.; A single screening visit is assumed where all 'PRE STUDY' procedures (H&P, Weight/PS, Labs, CT Scan) are performed. The highest priority procedure (CT Scan) determines the category for this day.; History and Physical Exam and Weight and Performance Status on Cycle 1 Day 1 (WK 1) are not counted as separate contact days because footnote Я states they are not repeated if obtained during screening (which they are).; Toxicity Notation for Cycle 1 Weeks 2, 3, 5, and 6 are not counted as in-person contact days, as footnote Ω states these assessments 'may be performed via a phone call during weeks when a physical exam is not required'. Since no physical exam is scheduled for these weeks, they are assumed to be non-contact.; The 'Archived Tumor Specimen' in the PRE STUDY column is considered a submission of an existing specimen (from nephrectomy) and not a new patient contact day.; Conditional visits such as 'HBV DNA or HCV RNA-PCR' (footnote Δ) and 'Bone Scan' (footnote Ħ) are excluded from the contact day count.; The CT scan schedule is based on the text 'CT scan to assess your disease every eighteen weeks' (page 42) and footnote Ж ('every 4 months (18 weeks) during Year 1'), leading to CT scans on Day 126 and Day 252 within the 12-month window. This overrides the ambiguous 'X' in the table for 'Cycle 2 WK 7->12' and 'Cycle 3 WK 13->18' for CT scans.; Cycle start visits from Cycle 4 onwards follow the pattern of Cycle 3 Day 1 (WK 13) as per footnote §."
37524096,Placebo,control,1,2,4,6,8,10,0,1,1,1,1,1,1,0,0,1,2,2,0,0,0,0,0,0,0,1,3,4,5,7,42,9 cycles (54 weeks or 378 days),"Screening (Day -28 to -1); Cycle 1: Day 0, Day 21; Cycle 2: Day 42; Cycle 3: Day 84; Cycles 4-9: Day 126, Day 168, Day 210, Day 252, Day 294, Day 336. CT scans on Day 126 and Day 252.","The study calendar on page 27-28 is applicable to both arms due to the double-blind nature of the study.; A single screening visit is assumed where all 'PRE STUDY' procedures (H&P, Weight/PS, Labs, CT Scan) are performed. The highest priority procedure (CT Scan) determines the category for this day.; History and Physical Exam and Weight and Performance Status on Cycle 1 Day 1 (WK 1) are not counted as separate contact days because footnote Я states they are not repeated if obtained during screening (which they are).; Toxicity Notation for Cycle 1 Weeks 2, 3, 5, and 6 are not counted as in-person contact days, as footnote Ω states these assessments 'may be performed via a phone call during weeks when a physical exam is not required'. Since no physical exam is scheduled for these weeks, they are assumed to be non-contact.; The 'Archived Tumor Specimen' in the PRE STUDY column is considered a submission of an existing specimen (from nephrectomy) and not a new patient contact day.; Conditional visits such as 'HBV DNA or HCV RNA-PCR' (footnote Δ) and 'Bone Scan' (footnote Ħ) are excluded from the contact day count.; The CT scan schedule is based on the text 'CT scan to assess your disease every eighteen weeks' (page 42) and footnote Ж ('every 4 months (18 weeks) during Year 1'), leading to CT scans on Day 126 and Day 252 within the 12-month window. This overrides the ambiguous 'X' in the table for 'Cycle 2 WK 7->12' and 'Cycle 3 WK 13->18' for CT scans.; Cycle start visits from Cycle 4 onwards follow the pattern of Cycle 3 Day 1 (WK 13) as per footnote §."
37604981,Intensive Chemotherapy + Glasdegib,intervention,1,15,34,47,50,54,0,10,20,26,26,26,1,3,7,9,12,16,0,2,7,12,12,12,0,0,0,0,0,0,28,up to 2 years post-randomization or until progression/toxicity/MRD-negative status,"Screening (1 day); Induction 1 (7 core_treatment, 3 imaging_diagnostics, 2 labs); Induction 2 (7 core_treatment, 1 imaging_diagnostics, 4 labs); Remission BM (1 imaging_diagnostics); Consolidation Cycles 1-2 (3 core_treatment, 1 imaging_diagnostics, 1 labs each); Consolidation Cycles 3-4 (3 core_treatment, 2 labs each); Post Consolidation BM (1 imaging_diagnostics); Maintenance (7 monthly imaging_diagnostics visits); End of Treatment (1 imaging_diagnostics).","Screening is counted as 1 day, with the highest priority procedure (ECHO/MUGA, BM Aspirate/Biopsy) determining the category.; Day 0 is Cycle 1 Day 1 (C1D1).; Intensive chemotherapy consists of 1 Induction 1 cycle (28 days), followed by 1 Induction 2 cycle (28 days), followed by 4 Consolidation cycles (each 28 days).; Induction 2 is assumed to be the '7+3' option (Cytarabine Days 1-7, Daunorubicin Days 1-3).; Consolidation cycles involve Cytarabine on Days 1, 3, 5 (BID).; Glasdegib/Placebo is administered daily throughout the treatment period for up to 2 years, but oral administration is not counted as a contact day unless other in-person procedures occur.; HSCT is considered an optional alternative path and is assumed not to occur within the 12-month window for the purpose of calculating scheduled visits, to provide a consistent estimate for chemotherapy-based treatment.; PK/ECG schedule (Table 2) is integrated, and its visits take precedence for categorization if they include imaging (ECG) or labs (PK samples).; Post first Induction BM is assumed on Day 14 (C1D15) and Day 42 (Ind2D15).; Remission BM is assumed on Day 65.; Post Consolidation BM is assumed on Day 168.; After 4 consolidation cycles (Day 168), a maintenance phase with monthly visits (Day 1 of each 28-day cycle) and quarterly BM assessments (Day 253, Day 337) continues until Day 365.; The End of Treatment Visit is assumed to occur on Day 365.; All procedures listed in the Schedule of Activities (Table 1) and Pharmacokinetics & ECG Schedule (Table 2) are considered in-person contact days unless explicitly stated as tele-visits or optional.; For Intensive Arm, PK/ECG is collected in Induction 1 (C1D1, C1D10, C1D15, C1D21) and Consolidation Cycles 1-2 (C1D1, C1D10, C2D1, C2D10), and monthly during maintenance (Day 1 of each 28-day cycle) and at EOT. Induction 2 does not have PK/ECG collections per footnote 1 of Table 2."
37604981,Intensive Chemotherapy + Placebo,control,1,15,34,47,50,54,0,10,20,26,26,26,1,3,7,9,12,16,0,2,7,12,12,12,0,0,0,0,0,0,28,up to 2 years post-randomization or until progression/toxicity/MRD-negative status,"Screening (1 day); Induction 1 (7 core_treatment, 3 imaging_diagnostics, 2 labs); Induction 2 (7 core_treatment, 1 imaging_diagnostics, 4 labs); Remission BM (1 imaging_diagnostics); Consolidation Cycles 1-2 (3 core_treatment, 1 imaging_diagnostics, 1 labs each); Consolidation Cycles 3-4 (3 core_treatment, 2 labs each); Post Consolidation BM (1 imaging_diagnostics); Maintenance (7 monthly imaging_diagnostics visits); End of Treatment (1 imaging_diagnostics).","Screening is counted as 1 day, with the highest priority procedure (ECHO/MUGA, BM Aspirate/Biopsy) determining the category.; Day 0 is Cycle 1 Day 1 (C1D1).; Intensive chemotherapy consists of 1 Induction 1 cycle (28 days), followed by 1 Induction 2 cycle (28 days), followed by 4 Consolidation cycles (each 28 days).; Induction 2 is assumed to be the '7+3' option (Cytarabine Days 1-7, Daunorubicin Days 1-3).; Consolidation cycles involve Cytarabine on Days 1, 3, 5 (BID).; Glasdegib/Placebo is administered daily throughout the treatment period for up to 2 years, but oral administration is not counted as a contact day unless other in-person procedures occur.; HSCT is considered an optional alternative path and is assumed not to occur within the 12-month window for the purpose of calculating scheduled visits, to provide a consistent estimate for chemotherapy-based treatment.; PK/ECG schedule (Table 2) is integrated, and its visits take precedence for categorization if they include imaging (ECG) or labs (PK samples).; Post first Induction BM is assumed on Day 14 (C1D15) and Day 42 (Ind2D15).; Remission BM is assumed on Day 65.; Post Consolidation BM is assumed on Day 168.; After 4 consolidation cycles (Day 168), a maintenance phase with monthly visits (Day 1 of each 28-day cycle) and quarterly BM assessments (Day 253, Day 337) continues until Day 365.; The End of Treatment Visit is assumed to occur on Day 365.; All procedures listed in the Schedule of Activities (Table 1) and Pharmacokinetics & ECG Schedule (Table 2) are considered in-person contact days unless explicitly stated as tele-visits or optional.; For Intensive Arm, PK/ECG is collected in Induction 1 (C1D1, C1D10, C1D15, C1D21) and Consolidation Cycles 1-2 (C1D1, C1D10, C2D1, C2D10), and monthly during maintenance (Day 1 of each 28-day cycle) and at EOT. Induction 2 does not have PK/ECG collections per footnote 1 of Table 2."
37604981,Non-Intensive Chemotherapy + Glasdegib,intervention,1,12,30,46,49,53,0,10,28,42,42,42,1,1,1,3,6,10,0,1,1,1,1,1,0,0,0,0,0,0,28,up to 2 years post-randomization or until progression/toxicity/MRD-negative status,"Screening (1 day); Azacitidine Cycles 1-6 (7 core_treatment days per cycle, with C1 having 1 imaging_diagnostics and 1 labs day); Post Cycle 6 BM (1 imaging_diagnostics); Maintenance (7 monthly imaging_diagnostics visits); End of Treatment (1 imaging_diagnostics).","Screening is counted as 1 day, with the highest priority procedure (Bone Marrow Biopsy/Aspirate) determining the category.; Day 0 is Cycle 1 Day 1 (C1D1).; Non-intensive chemotherapy consists of Azacitidine administered for 7 days in 28-day cycles, for at least 6 cycles.; Glasdegib/Placebo is administered daily throughout the treatment period for up to 2 years, but oral administration is not counted as a contact day unless other in-person procedures occur.; HSCT is considered an optional alternative path and is assumed not to occur within the 12-month window for the purpose of calculating scheduled visits, to provide a consistent estimate for chemotherapy-based treatment.; PK/ECG schedule (Table 4) is integrated, and its visits take precedence for categorization if they include imaging (ECG) or labs (PK samples).; Post Cycle 6 BM is assumed on Day 168.; After 6 Azacitidine cycles (Day 168), a maintenance phase with monthly visits (Day 1 of each 28-day cycle) and quarterly BM assessments (Day 253, Day 337) continues until Day 365.; The End of Treatment Visit is assumed to occur on Day 365.; All procedures listed in the Schedule of Activities (Table 3) and Pharmacokinetics & ECG Schedule (Table 4) are considered in-person contact days unless explicitly stated as tele-visits or optional.; For Non-Intensive Arm, PK/ECG is collected in Cycle 1 (C1D1, C1D15) and Cycle 2 (C2D1), and monthly during maintenance (Day 1 of each 28-day cycle) and at EOT."
37604981,Non-Intensive Chemotherapy + Placebo,control,1,12,30,46,49,53,0,10,28,42,42,42,1,1,1,3,6,10,0,1,1,1,1,1,0,0,0,0,0,0,28,up to 2 years post-randomization or until progression/toxicity/MRD-negative status,"Screening (1 day); Azacitidine Cycles 1-6 (7 core_treatment days per cycle, with C1 having 1 imaging_diagnostics and 1 labs day); Post Cycle 6 BM (1 imaging_diagnostics); Maintenance (7 monthly imaging_diagnostics visits); End of Treatment (1 imaging_diagnostics).","Screening is counted as 1 day, with the highest priority procedure (Bone Marrow Biopsy/Aspirate) determining the category.; Day 0 is Cycle 1 Day 1 (C1D1).; Non-intensive chemotherapy consists of Azacitidine administered for 7 days in 28-day cycles, for at least 6 cycles.; Glasdegib/Placebo is administered daily throughout the treatment period for up to 2 years, but oral administration is not counted as a contact day unless other in-person procedures occur.; HSCT is considered an optional alternative path and is assumed not to occur within the 12-month window for the purpose of calculating scheduled visits, to provide a consistent estimate for chemotherapy-based treatment.; PK/ECG schedule (Table 4) is integrated, and its visits take precedence for categorization if they include imaging (ECG) or labs (PK samples).; Post Cycle 6 BM is assumed on Day 168.; After 6 Azacitidine cycles (Day 168), a maintenance phase with monthly visits (Day 1 of each 28-day cycle) and quarterly BM assessments (Day 253, Day 337) continues until Day 365.; The End of Treatment Visit is assumed to occur on Day 365.; All procedures listed in the Schedule of Activities (Table 3) and Pharmacokinetics & ECG Schedule (Table 4) are considered in-person contact days unless explicitly stated as tele-visits or optional.; For Non-Intensive Arm, PK/ECG is collected in Cycle 1 (C1D1, C1D15) and Cycle 2 (C2D1), and monthly during maintenance (Day 1 of each 28-day cycle) and at EOT."
37646660,Arm A: Melflufen + Daratumumab + Dexamethasone,intervention,1,5,11,17,20,24,0,5,11,17,20,24,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,"until documented disease progression, unacceptable toxicity, or withdrawal of consent","Screening (Day -28 to -1). Treatment cycles are 28 days. Cycle 1-2: Day 1, 8, 15, 22. Cycle 3-6: Day 1, 15. Cycle 7+: Day 1.","Screening is counted as 1 contact day, categorized as 'imaging_diagnostics' due to procedures like bone marrow aspiration, X-rays, ECG, and PFTs.; Dexamethasone pre-medication for Daratumumab administration in Arm B is considered an in-person healthcare contact for treatment delivery, making all Daratumumab administration days 'core_treatment'.; Treatment is assumed to continue until Day +365 for calculation purposes, as per the 'until progression' rule.; The Schedule of Activities (Table 1-2) and drug administration schedules (Tables 6-2, 6-3) were used to determine visit frequency. Footnotes specifying exact cycle/day for certain assessments (e.g., PK, Immunogenicity) were followed.; The crossover arm for Arm B patients is not included in the primary arm calculations."
37646660,Arm B: Daratumumab monotherapy,control,1,5,11,17,20,24,0,5,11,17,20,24,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,"until documented disease progression, unacceptable toxicity, or withdrawal of consent","Screening (Day -28 to -1). Treatment cycles are 28 days. Cycle 1-2: Day 1, 8, 15, 22. Cycle 3-6: Day 1, 15. Cycle 7+: Day 1.","Screening is counted as 1 contact day, categorized as 'imaging_diagnostics' due to procedures like bone marrow aspiration, X-rays, ECG, and PFTs.; Dexamethasone pre-medication for Daratumumab administration in Arm B is considered an in-person healthcare contact for treatment delivery, making all Daratumumab administration days 'core_treatment'.; Treatment is assumed to continue until Day +365 for calculation purposes, as per the 'until progression' rule.; The Schedule of Activities (Table 1-2) and drug administration schedules (Tables 6-2, 6-3) were used to determine visit frequency. Footnotes specifying exact cycle/day for certain assessments (e.g., PK, Immunogenicity) were followed.; The crossover arm for Arm B patients is not included in the primary arm calculations."
37647576,Nimotuzumab + Gemcitabine,intervention,3,5,13,26,39,52,0,5,13,26,39,52,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening I (Day -28), Screening II (Day -14), Baseline (Day -1). Treatment cycles are 28 days. Nimotuzumab/placebo is administered weekly. Gemcitabine is administered on Day 1, 8, 15 of each cycle. Major assessments (including imaging) occur every 8 weeks.","The assessment schedule is identical for both the Nimotuzumab + Gemcitabine arm and the Placebo + Gemcitabine arm.; Screening period (I) (Day -28), Screening period (II) (Day -14), and Baseline period (Day -1) are considered three distinct in-person contact days.; For the Baseline period (Day -1), even if some tests (like imaging/ECG) might not need to be repeated if recent screening results are available (as per page 20), the presence of 'X' or symbols in the table column implies a contact day where these procedures are either performed or reviewed, and other procedures (like labs within 7 days) would need to be repeated. Therefore, it is counted as a contact day.; Treatment continues 'until progression' for the entire 12-month period for calculation purposes.; Nimotuzumab/placebo is administered weekly (Day 0, 7, 14, 21, 28, etc.). Gemcitabine is administered on Day 1, 8, 15 of each 28-day cycle (Day 0, 7, 14, 28, 35, 42, etc.). All these administration days are in-person contact days.; The 'Every 8 weeks' visits (Day 56, 112, 168, etc.) are distinct in-person contact days that include drug administration and additional assessments (ECG, Urine routine, Imaging).; Due to drug administration (core_treatment) occurring on all treatment days (Day 0 onwards), these days are categorized as 'core_treatment' based on the tie-breaker precedence rule."
37647576,Placebo + Gemcitabine,control,3,5,13,26,39,52,0,5,13,26,39,52,2,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening I (Day -28), Screening II (Day -14), Baseline (Day -1). Treatment cycles are 28 days. Nimotuzumab/placebo is administered weekly. Gemcitabine is administered on Day 1, 8, 15 of each cycle. Major assessments (including imaging) occur every 8 weeks.","The assessment schedule is identical for both the Nimotuzumab + Gemcitabine arm and the Placebo + Gemcitabine arm.; Screening period (I) (Day -28), Screening period (II) (Day -14), and Baseline period (Day -1) are considered three distinct in-person contact days.; For the Baseline period (Day -1), even if some tests (like imaging/ECG) might not need to be repeated if recent screening results are available (as per page 20), the presence of 'X' or symbols in the table column implies a contact day where these procedures are either performed or reviewed, and other procedures (like labs within 7 days) would need to be repeated. Therefore, it is counted as a contact day.; Treatment continues 'until progression' for the entire 12-month period for calculation purposes.; Nimotuzumab/placebo is administered weekly (Day 0, 7, 14, 21, 28, etc.). Gemcitabine is administered on Day 1, 8, 15 of each 28-day cycle (Day 0, 7, 14, 28, 35, 42, etc.). All these administration days are in-person contact days.; The 'Every 8 weeks' visits (Day 56, 112, 168, etc.) are distinct in-person contact days that include drug administration and additional assessments (ECG, Urine routine, Imaging).; Due to drug administration (core_treatment) occurring on all treatment days (Day 0 onwards), these days are categorized as 'core_treatment' based on the tie-breaker precedence rule."
37704166,Experimental Arm A: OSE2101,intervention,1,3,6,10,13,17,0,2,5,7,8,10,1,0,0,2,4,6,0,1,1,1,1,1,0,0,0,0,0,0,21 days for cycles 1-6; 56 days for cycles 7-9; 84 days for cycles >=10,"until unequivocal RECIST 1.1-defined disease progression, unacceptable toxicity, or consent withdrawal","Screening/Randomization (Day -1). Treatment: Cycles 1-6 every 21 days (Day 0, 14, 21, 42, 63, 84, 105). Cycles 7-9 every 56 days (Day 161, 217, 273). Cycles >=10 every 84 days (Day 357). Imaging every 6 weeks from Day 0 (Day 0, 42, 84, 126, 168, 210, 252, 294, 336).","Pre-screening activities (HLA-A2 determination and associated consent) are assumed to occur on a single day (e.g., Day -30) outside the defined screening window (Day -28 to Day -1) and are therefore not counted in the screening window totals.; The 'Screening and randomization' column in Table 1 is interpreted as a single contact day for all listed mandatory procedures, occurring on Day -1.; Optional visits for biomarker blood samples and tumor samples, and optional consent for translational study/biobanking, are not counted.; Treatment is assumed to continue until Day +365 for calculation purposes, as per the instruction 'until progression'. The End of Treatment visit (4 weeks after last administration) is therefore assumed to occur outside the 12-month window if treatment continues to Day 365.; Tumor assessments are scheduled 'every 6 (± 1) weeks after Day 1 Cycle 1'. For Arm A, this results in separate imaging visits on days that do not coincide with treatment administration days (Day 126, 168, 210, 252, 294, 336)."
37704166,Control Arm B: Docetaxel or Pemetrexed,control,1,3,6,10,14,19,0,2,5,9,13,18,1,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,21,"until unequivocal RECIST 1.1-defined disease progression, unacceptable toxicity, or consent withdrawal","Screening/Randomization (Day -1). Treatment: Every 21 days (Day 0, 14, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315, 336, 357). Imaging every 6 weeks from Day 0 (Day 0, 42, 84, 126, 168, 210, 252, 294, 336) always coinciding with treatment days.","Pre-screening activities (HLA-A2 determination and associated consent) are assumed to occur on a single day (e.g., Day -30) outside the defined screening window (Day -28 to Day -1) and are therefore not counted in the screening window totals.; The 'Screening and randomization' column in Table 2 is interpreted as a single contact day for all listed mandatory procedures, occurring on Day -1.; Optional visits for biomarker blood samples and tumor samples, and optional consent for translational study/biobanking, are not counted.; Treatment is assumed to continue until Day +365 for calculation purposes, as per the instruction 'until progression'. The End of Treatment visit (4 weeks after last administration) is therefore assumed to occur outside the 12-month window if treatment continues to Day 365.; Tumor assessments are scheduled 'every 6 (± 1) weeks after Day 1 Cycle 1'. For Arm B, all imaging days coincide with treatment administration days."
37708904,Arm 1: irinotecan liposome injection+oxaliplatin+5-FU/LV,intervention,1,5,11,20,30,39,0,5,11,20,30,39,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression (calculated for 13 cycles within 365 days),"Screening (1 day); Treatment cycles (D1, D3, D15 of each 28-day cycle); Q8W imaging (coincides with treatment days).","Screening procedures (including randomisation, CT/MRI, ECG, archival tissue collection, and various labs/clinic visits) are consolidated into 1 in-person day in the screening window, categorized as 'imaging_diagnostics' due to precedence.; Optional PK sampling (C1D4-14) and optional biobanking visits are excluded.; Q8W imaging visits (Day 56, 112, 168, 224, 280, 336) coincide with D1 of odd cycles (C3, C5, C7, C9, C11, C13) and are subsumed under 'core_treatment' due to precedence.; ECG for Arm 1 (C1D1, C1D15) are subsumed under 'core_treatment' days.; CA19-9 (D1 of every other cycle) and Urinalysis/Pregnancy test (D1 of every cycle) are subsumed under 'core_treatment' days.; 5-FU pump removal on D3 of each cycle is an in-person visit and categorized as 'core_treatment'.; The End of Treatment (EoT) visit (Day 30 after last dose) falls outside the 12-month window (Day 365) if treatment continues for 13 cycles, and thus is not counted in the 12-month interval or earlier intervals."
37708904,Arm 2: nab-paclitaxel + gemcitabine,intervention,1,4,11,20,30,39,0,4,11,20,30,39,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression (calculated for 13 cycles within 365 days),"Screening (1 day); Treatment cycles (D1, D8, D15 of each 28-day cycle); Q8W imaging (coincides with treatment days).","Screening procedures (including randomisation, CT/MRI, ECG, archival tissue collection, and various labs/clinic visits) are consolidated into 1 in-person day in the screening window, categorized as 'imaging_diagnostics' due to precedence.; Optional biobanking visits are excluded.; Q8W imaging visits (Day 56, 112, 168, 224, 280, 336) coincide with D1 of odd cycles (C3, C5, C7, C9, C11, C13) and are subsumed under 'core_treatment' due to precedence.; ECG for Arm 2 (C1D1, C2D1, C3D1, C4D1) are subsumed under 'core_treatment' days.; CA19-9 (D1 of every other cycle) and Urinalysis/Pregnancy test (D1 of every cycle) are subsumed under 'core_treatment' days.; The End of Treatment (EoT) visit (Day 30 after last dose) falls outside the 12-month window (Day 365) if treatment continues for 13 cycles, and thus is not counted in the 12-month interval or earlier intervals."
37722354,Treatment Arm A (background chemotherapy + placebo),control,3,4,8,13,14,16,0,4,8,12,12,12,3,0,0,1,1,2,0,0,0,0,1,2,0,0,0,0,0,0,28,"until disease progression, unacceptable toxicity, or study end","Screening: 3 distinct days. Chemotherapy Period (Cycles 1-6): Day 1 and Day 2 of each 28-day cycle for BR regimen. Post-Chemotherapy Period: General clinic visits every 8 weeks starting at nominal C7D1. Imaging (CT/MRI/PET) and MRD blood samples at Wk12, Wk24, Wk40. PROs at C1, C6, Wk40. PK at C1D1, C2D1, C3D1. Biomarker at C1D1, C2D1.","Screening procedures (ECG, Echocardiogram/MUGA, CT/MRI, PET, Bone Marrow Aspirate/Biopsy, Hepatitis Serologies) that can be performed within 30 or 60 days of randomization are assumed to occur on 3 distinct days within the screening window to maximize contact days.; Prednisone administration (Days 1-5 for R-CHOP) is considered self-administered and not an in-person contact day, except for Day 1 which is already an in-person visit for IV chemotherapy.; The 'Every 8 weeks Starting at Cycle 7' for Post-Chemotherapy general clinic visits (dispensing, vitals, PE, CBC, serum chem) is interpreted as starting at the nominal Day 1 of Cycle 7 (Day 168 for BR, Day 126 for R-CHOP) and then every 56 days thereafter.; Imaging (CT/MRI/PET) and MRD blood samples have their own schedules (Wk12, Wk24, Wk40, Wk56). If these fall on a general clinic visit day, it's one contact day. If they fall on a non-general clinic visit day, it's an additional contact day.; For arms with different chemotherapy regimens (BR vs R-CHOP), the regimen with the higher number of total contact days (BR regimen) was used for the final count per arm, as the protocol describes 'background chemotherapy' generally.; Study drug (Ibrutinib/Placebo) is administered orally once daily, but only the dispensing visits (C1D1 and then every 8 weeks in Post-Chemo) are counted as in-person contact days.; PK samples on C1D1 and C2D1 (multiple draws) and C3D1 (predose) are counted as contact days. Biomarker samples on C1D1 and C2D1 are counted as contact days.; The treatment duration is assumed to continue until Day 365 for the purpose of counting within the 12-month window, as per 'until disease progression, unacceptable toxicity, or study end'."
37722354,Treatment Arm B (background chemotherapy + 560 mg of ibrutinib),intervention,3,4,8,13,14,16,0,4,8,12,12,12,3,0,0,1,1,2,0,0,0,0,1,2,0,0,0,0,0,0,28,"until disease progression, unacceptable toxicity, or study end","Screening: 3 distinct days. Chemotherapy Period (Cycles 1-6): Day 1 and Day 2 of each 28-day cycle for BR regimen. Post-Chemotherapy Period: General clinic visits every 8 weeks starting at nominal C7D1. Imaging (CT/MRI/PET) and MRD blood samples at Wk12, Wk24, Wk40. PROs at C1, C6, Wk40. PK at C1D1, C2D1, C3D1. Biomarker at C1D1, C2D1.","Screening procedures (ECG, Echocardiogram/MUGA, CT/MRI, PET, Bone Marrow Aspirate/Biopsy, Hepatitis Serologies) that can be performed within 30 or 60 days of randomization are assumed to occur on 3 distinct days within the screening window to maximize contact days.; Prednisone administration (Days 1-5 for R-CHOP) is considered self-administered and not an in-person contact day, except for Day 1 which is already an in-person visit for IV chemotherapy.; The 'Every 8 weeks Starting at Cycle 7' for Post-Chemotherapy general clinic visits (dispensing, vitals, PE, CBC, serum chem) is interpreted as starting at the nominal Day 1 of Cycle 7 (Day 168 for BR, Day 126 for R-CHOP) and then every 56 days thereafter.; Imaging (CT/MRI/PET) and MRD blood samples have their own schedules (Wk12, Wk24, Wk40, Wk56). If these fall on a general clinic visit day, it's one contact day. If they fall on a non-general clinic visit day, it's an additional contact day.; For arms with different chemotherapy regimens (BR vs R-CHOP), the regimen with the higher number of total contact days (BR regimen) was used for the final count per arm, as the protocol describes 'background chemotherapy' generally.; Study drug (Ibrutinib/Placebo) is administered orally once daily, but only the dispensing visits (C1D1 and then every 8 weeks in Post-Chemo) are counted as in-person contact days.; PK samples on C1D1 and C2D1 (multiple draws) and C3D1 (predose) are counted as contact days. Biomarker samples on C1D1 and C2D1 are counted as contact days.; The treatment duration is assumed to continue until Day 365 for the purpose of counting within the 12-month window, as per 'until disease progression, unacceptable toxicity, or study end'."
37748693,Arm A: Avelumab 10 mg/kg IV once every 2 weeks,intervention,1,3,7,13,20,27,0,3,7,13,20,27,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,14,until progression,"Screening (Day -28), then Avelumab infusion every 14 days from Day 0 until progression.","The 'Screening/Baseline' column in Table 1 refers to procedures performed during the screening window (Day -28 to Day -1).; The 'W 1 Day 1' column in Table 1 refers to Day 0 (Randomization/First Treatment).; All procedures marked with 'X' in the Schedule of Assessments tables require an in-person visit unless explicitly stated otherwise (e.g., phone call).; Premedication and IV infusion are considered core_treatment.; Tumor evaluation/staging (CT/MRI) and ECG are imaging_diagnostics.; Hematology, serum chemistry, urinalysis, pregnancy tests, ACTH, T4/TSH, HBV/HCV testing are labs.; Written informed consent, inclusion/exclusion criteria, medical history, demographic data, patient-reported outcomes, physical examination, vital signs, weight, ECOG PS, survival follow-up are clinic_visits.; Treatment for Arm A continues until Day 364 (within the 12-month window) as per 'until progression' rule, with visits every 14 days.; No End-of-Treatment, Safety Follow-up, or Long-term Follow-up visits fall within the 12-month window if treatment continues until Day 364."
37748693,Arm B: Investigator's choice platinum-containing chemotherapy,control,1,4,10,14,14,15,0,4,10,12,12,12,1,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,21,maximum of 6 cycles,"Screening (Day -28), then Chemotherapy infusion on Day 1 and Day 8 of each 21-day cycle for 6 cycles, followed by EoT, SFU, and LTFU visits.","The 'Screening/Baseline' column in Table 3 refers to procedures performed during the screening window (Day -28 to Day -1).; The 'W1 Day 1' column in Table 3 refers to Day 0 (Randomization/First Treatment).; For Arm B, the Gemcitabine regimen (Table 3) was used for visit scheduling as it includes Day 1 and Day 8 visits per cycle, representing the most frequent contact schedule among the chemotherapy options.; All procedures marked with 'X' in the Schedule of Assessments tables require an in-person visit unless explicitly stated otherwise (e.g., phone call).; Premedication and IV infusion are considered core_treatment.; Tumor evaluation/staging (CT/MRI) and ECG are imaging_diagnostics.; Hematology, serum chemistry, urinalysis, pregnancy tests, ACTH, T4/TSH, HBV/HCV testing are labs.; Written informed consent, inclusion/exclusion criteria, medical history, demographic data, patient-reported outcomes, physical examination, vital signs, weight, ECOG PS, survival follow-up are clinic_visits.; Treatment for Arm B is for a maximum of 6 cycles (126 days).; End-of-Treatment (EoT) visit is assumed to occur at Day 126 (end of 6 cycles).; Safety Follow-up (SFU) visit is 30 days after the last treatment dose (Day 112), placing it at Day 142.; Long-term Follow-up (LTFU) visits are every 12 weeks after the 90-day phone call (which is 90 days after the last treatment dose), placing the first LTFU visit at Day 286."
37748693,"Arm C: Avelumab 10 mg/kg IV once weekly for 12 weeks, followed by 10 mg/kg once every 2 weeks",intervention,1,5,13,19,26,33,0,5,13,19,26,33,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"7 days for first 12 weeks, then 14 days",until progression,"Screening (Day -28), then Avelumab infusion weekly for 12 weeks (Day 0-77), followed by Avelumab infusion every 14 days from Day 84 until progression.","The 'Screening/Baseline' column in Table 4 refers to procedures performed during the screening window (Day -28 to Day -1).; The 'W1 Day 1' column in Table 4 refers to Day 0 (Randomization/First Treatment).; All procedures marked with 'X' in the Schedule of Assessments tables require an in-person visit unless explicitly stated otherwise (e.g., phone call).; Premedication and IV infusion are considered core_treatment.; Tumor evaluation/staging (CT/MRI) and ECG are imaging_diagnostics.; Hematology, serum chemistry, urinalysis, pregnancy tests, ACTH, T4/TSH, HBV/HCV testing are labs.; Written informed consent, inclusion/exclusion criteria, medical history, demographic data, patient-reported outcomes, physical examination, vital signs, weight, ECOG PS, survival follow-up are clinic_visits.; Treatment for Arm C continues until Day 364 (within the 12-month window) as per 'until progression' rule, with weekly visits for 12 weeks (Day 0-77) followed by bi-weekly visits (Day 84-364).; No End-of-Treatment, Safety Follow-up, or Long-term Follow-up visits fall within the 12-month window if treatment continues until Day 364."
37788412,Canakinumab 200 mg sc,intervention,1,5,13,26,39,53,0,2,5,9,13,18,1,0,0,0,0,0,0,3,8,17,26,35,0,0,0,0,0,0,21,"18 cycles or until disease recurrence, unacceptable toxicity, treatment discontinuation, death, or lost to follow-up. For calculation purposes, assume 18 cycles (378 days).","Screening (1 day); Cycle 1 (Day 1, Day 8, Day 15); Cycles 2-18 (Day 1, Day 8, Day 15). Imaging on C1D1, C5D1, C9D1, C13D1, C17D1. PK on C1D1, C1D8, C1D15, C2D1, C4D1, C6D1, C9D1, C12D1, C18D1. IG on C1D1, C2D1, C4D1, C6D1, C9D1, C12D1, C18D1. IL-1β (PD) on C1D1, C4D1, C12D1.","All 'X' and 'S' entries within a single visit column in Table 7-1 represent procedures occurring on a single contact day.; The 'IRT Randomization' and 'IRT study drug dispensation (S)' in the 'Screening' column are part of the single screening contact day. Actual drug administration begins on C1D1.; For the screening day, multiple procedures occur. The highest priority procedure is imaging (CT/MRI chest/abdomen/pelvis, MRI of brain, Single ECG), thus categorizing the day as 'imaging_diagnostics'.; Imaging assessments ('Every 12 weeks for the first year') are assumed to occur on C1D1, C5D1, C9D1, C13D1, and C17D1. Since drug administration also occurs on these days, these days are categorized as 'core_treatment'.; PK, IG, and IL-1β (PD) sample collections occur on specific cycle days as indicated in Table 7-1. These days already have drug administration or other lab collections, so they do not change the primary category of the contact day.; Visits marked 'As clinically indicated (X)' are not counted as mandatory contact days unless other mandatory procedures are scheduled for that day.; Post-treatment surveillance and survival follow-up visits fall outside the 12-month (Day +365) window, except for C18D8 (Day 364) which is the last day within the 12-month window."
37788412,Placebo,intervention,1,5,13,26,39,53,0,2,5,9,13,18,1,0,0,0,0,0,0,3,8,17,26,35,0,0,0,0,0,0,21,"18 cycles or until disease recurrence, unacceptable toxicity, treatment discontinuation, death, or lost to follow-up. For calculation purposes, assume 18 cycles (378 days).","Screening (1 day); Cycle 1 (Day 1, Day 8, Day 15); Cycles 2-18 (Day 1, Day 8, Day 15). Imaging on C1D1, C5D1, C9D1, C13D1, C17D1. PK on C1D1, C1D8, C1D15, C2D1, C4D1, C6D1, C9D1, C12D1, C18D1. IG on C1D1, C2D1, C4D1, C6D1, C9D1, C12D1, C18D1. IL-1β (PD) on C1D1, C4D1, C12D1.","All 'X' and 'S' entries within a single visit column in Table 7-1 represent procedures occurring on a single contact day.; The 'IRT Randomization' and 'IRT study drug dispensation (S)' in the 'Screening' column are part of the single screening contact day. Actual drug administration begins on C1D1.; For the screening day, multiple procedures occur. The highest priority procedure is imaging (CT/MRI chest/abdomen/pelvis, MRI of brain, Single ECG), thus categorizing the day as 'imaging_diagnostics'.; Imaging assessments ('Every 12 weeks for the first year') are assumed to occur on C1D1, C5D1, C9D1, C13D1, and C17D1. Since drug administration also occurs on these days, these days are categorized as 'core_treatment'.; PK, IG, and IL-1β (PD) sample collections occur on specific cycle days as indicated in Table 7-1. These days already have drug administration or other lab collections, so they do not change the primary category of the contact day.; Visits marked 'As clinically indicated (X)' are not counted as mandatory contact days unless other mandatory procedures are scheduled for that day.; Post-treatment surveillance and survival follow-up visits fall outside the 12-month (Day +365) window, except for C18D8 (Day 364) which is the last day within the 12-month window."
37792130,MYL-1402O + Carboplatin + Paclitaxel followed by MYL-1402O monotherapy,intervention,2,5,13,21,25,31,0,2,5,8,12,17,1,0,0,1,1,2,0,3,8,12,12,12,1,0,0,0,0,0,21,"until disease progression, discontinuation, or study termination","Screening (1 imaging day, 1 randomization day). Period 1 (6 cycles of 21 days): Day 1 of each cycle (Bevacizumab+CP infusion, labs, clinic); Day 7 and Day 14 of each cycle (PK/Immuno labs). Week 6 and Week 12 tumor assessments coincide with treatment days. Week 18 tumor assessment is a separate imaging day. Period 2 (Bevacizumab monotherapy, 21-day cycles): Day 1 of each cycle (Bevacizumab infusion, labs, clinic). Week 30 and Week 42 tumor assessments coincide with treatment days. Safety Follow-Up visit 28 days after last dose.","Both treatment arms (MYL-1402O and Avastin) follow the identical Schedule of Events.; Screening procedures (including initial imaging, labs, and clinic visits) occur on one day, and randomization occurs on a separate day within the screening window.; Additional PK/Immunogenicity blood draws scheduled 'between Days 3 and 8' and 'between Days 10 and 18' of each cycle are assumed to occur on Day 7 and Day 14 (or equivalent days in subsequent cycles) respectively, and are counted as separate in-person lab visits.; Tumor assessments (CT/MRI/X-ray) are considered in-person contact days. When tumor assessments coincide with treatment days, the day is categorized as 'core_treatment'.; The Safety Follow-Up visit at Day 322 (28 days after the last dose at Week 42/Day 294) is assumed to include tumor assessment/imaging, labs, and clinic visits, with imaging taking precedence.; Treatment is assumed to continue every 21 days until at least Day 365 for the 12-month window, following the 'until progression' rule."
37792130,Avastin + Carboplatin + Paclitaxel followed by Avastin monotherapy,control,2,5,13,21,25,31,0,2,5,8,12,17,1,0,0,1,1,2,0,3,8,12,12,12,1,0,0,0,0,0,21,"until disease progression, discontinuation, or study termination","Screening (1 imaging day, 1 randomization day). Period 1 (6 cycles of 21 days): Day 1 of each cycle (Bevacizumab+CP infusion, labs, clinic); Day 7 and Day 14 of each cycle (PK/Immuno labs). Week 6 and Week 12 tumor assessments coincide with treatment days. Week 18 tumor assessment is a separate imaging day. Period 2 (Bevacizumab monotherapy, 21-day cycles): Day 1 of each cycle (Bevacizumab infusion, labs, clinic). Week 30 and Week 42 tumor assessments coincide with treatment days. Safety Follow-Up visit 28 days after last dose.","Both treatment arms (MYL-1402O and Avastin) follow the identical Schedule of Events.; Screening procedures (including initial imaging, labs, and clinic visits) occur on one day, and randomization occurs on a separate day within the screening window.; Additional PK/Immunogenicity blood draws scheduled 'between Days 3 and 8' and 'between Days 10 and 18' of each cycle are assumed to occur on Day 7 and Day 14 (or equivalent days in subsequent cycles) respectively, and are counted as separate in-person lab visits.; Tumor assessments (CT/MRI/X-ray) are considered in-person contact days. When tumor assessments coincide with treatment days, the day is categorized as 'core_treatment'.; The Safety Follow-Up visit at Day 322 (28 days after the last dose at Week 42/Day 294) is assumed to include tumor assessment/imaging, labs, and clinic visits, with imaging taking precedence.; Treatment is assumed to continue every 21 days until at least Day 365 for the 12-month window, following the 'until progression' rule."
37845511,Nivolumab 480 mg Q4W,intervention,1,2,4,8,11,15,0,2,4,7,10,13,1,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,28,maximum of 12 months from the first dose of study treatment,"Screening visit (1 day) before Day 0. Treatment cycles every 28 days for 13 cycles (Day 0, 28, ..., 336). Body imaging at Week 26 (Day 182) and Week 52 (Day 364).","Treatment duration is assumed to be the maximum of 12 months (365 days from Day 0) as specified, for the purpose of calculating contact days within the fixed time intervals.; The 'Screening Visit' is counted as one in-person contact day, occurring within the Day -28 to Day -1 window. It is categorized as 'imaging_diagnostics' due to the presence of Body Imaging (CT/MRI) and ECG.; All 'Day 1 of Each Cycle' visits include study drug infusion (core_treatment) along with safety assessments (physical exam, vitals, weight, AE, concomitant meds, labs, pregnancy test). Due to category precedence, these days are classified as 'core_treatment'.; Brain imaging is 'as clinically indicated' and therefore not included in the fixed schedule contact day count.; PK/Immunogenicity samples are collected on infusion days and are covered by the 'core_treatment' category due to precedence.; Long-term follow-up visits (FU1, FU2, and subsequent 12-weekly visits) occur after the 12-month treatment period and thus fall outside the Day 0 to Day 365 window."
37845511,Placebo Q4W,control,1,2,4,8,11,15,0,2,4,7,10,13,1,0,0,1,1,2,0,0,0,0,0,0,0,0,0,0,0,0,28,maximum of 12 months from the first dose of study treatment,"Screening visit (1 day) before Day 0. Treatment cycles every 28 days for 13 cycles (Day 0, 28, ..., 336). Body imaging at Week 26 (Day 182) and Week 52 (Day 364).","Treatment duration is assumed to be the maximum of 12 months (365 days from Day 0) as specified, for the purpose of calculating contact days within the fixed time intervals.; The 'Screening Visit' is counted as one in-person contact day, occurring within the Day -28 to Day -1 window. It is categorized as 'imaging_diagnostics' due to the presence of Body Imaging (CT/MRI) and ECG.; All 'Day 1 of Each Cycle' visits include study drug infusion (core_treatment) along with safety assessments (physical exam, vitals, weight, AE, concomitant meds, labs, pregnancy test). Due to category precedence, these days are classified as 'core_treatment'.; Brain imaging is 'as clinically indicated' and therefore not included in the fixed schedule contact day count.; PK/Immunogenicity samples are collected on infusion days and are covered by the 'core_treatment' category due to precedence.; Long-term follow-up visits (FU1, FU2, and subsequent 12-weekly visits) occur after the 12-month treatment period and thus fall outside the Day 0 to Day 365 window."
37870976,Arm A: Amivantamab + Carboplatin-Pemetrexed followed by Amivantamab + Pemetrexed Maintenance,intervention,3,5,8,12,16,21,0,5,8,12,16,21,1,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,21,until disease progression or discontinuation criteria are met,"Screening (Day -X), Pre-meds (Day -1), Randomization (Day -X'), then Cycle 1 Days 1, 2, 8, 15, followed by Cycle 2 Day 1, and then Cycle 3 Day 1 and subsequent cycles (every 21 days) on Day 1.","Treatment is assumed to continue until the end of the 12-month window (Day +365) for calculation purposes, as per 'until disease progression' rule.; The 'Screening' column and 'Randomization' row in Table 1 are treated as two distinct in-person days in the screening window, as per protocol instruction for separate columns and schema depiction.; Pre-infusion medications on Day -1 for Arm A/B are considered a distinct in-person clinic visit day.; All procedures (e.g., labs, vital signs, physical exams, PROs, PK/Immunogenicity samples, imaging) occurring on a day with core treatment administration are subsumed under the 'core_treatment' category due to precedence.; On-study imaging visits (CT/MRI) scheduled at 6-week intervals are assumed to coincide with Cycle Day 1 visits (Day 42, 84, 126, etc.) and are therefore subsumed under 'core_treatment' due to precedence."
37870976,Arm B: Carboplatin-Pemetrexed followed by Pemetrexed Maintenance,control,3,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,21,until disease progression or discontinuation criteria are met,"Screening (Day -X), Pre-meds (Day -1), Randomization (Day -X'), then Cycle 1 Day 1 and subsequent cycles (every 21 days) on Day 1.","Treatment is assumed to continue until the end of the 12-month window (Day +365) for calculation purposes, as per 'until disease progression' rule.; The 'Screening' column and 'Randomization' row in Table 1 are treated as two distinct in-person days in the screening window, as per protocol instruction for separate columns and schema depiction.; Pre-infusion medications on Day -1 for Arm A/B are considered a distinct in-person clinic visit day.; All procedures (e.g., labs, vital signs, physical exams, PROs, imaging) occurring on a day with core treatment administration are subsumed under the 'core_treatment' category due to precedence.; On-study imaging visits (CT/MRI) scheduled at 6-week intervals are assumed to coincide with Cycle Day 1 visits (Day 42, 84, 126, etc.) and are therefore subsumed under 'core_treatment' due to precedence."
37870976,Arm B Crossover: Amivantamab Monotherapy,intervention,1,5,8,12,16,21,0,5,8,12,16,21,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until disease progression or discontinuation criteria are met,"Crossover Screening (Day -X), then Cycle 1 Days 1, 2, 8, 15, followed by Cycle 2 Day 1, and then Cycle 3 Day 1 and subsequent cycles (every 21 days) on Day 1.","This 'Optional Crossover' arm is treated as a distinct treatment pathway with its own schedule, assuming a participant opts for it upon disease progression from Arm B.; Treatment is assumed to continue until the end of the 12-month window (Day +365) for calculation purposes, as per 'until disease progression' rule.; The crossover screening is considered 1 in-person day, with imaging procedures having the highest precedence.; All procedures (e.g., labs, vital signs, physical exams, PROs, PK/Immunogenicity samples, imaging) occurring on a day with core treatment administration are subsumed under the 'core_treatment' category due to precedence.; On-study imaging visits (CT/MRI) scheduled at 6-week intervals are assumed to coincide with Cycle Day 1 visits (Day 42, 84, 126, etc.) and are therefore subsumed under 'core_treatment' due to precedence.; PRO assessments for crossover arm (every 12 weeks) are assumed to coincide with Cycle Day 1 visits (Day 84, 168, 252, 336) and are subsumed under 'core_treatment'."
37875143,Pembrolizumab plus chemotherapy,intervention,1,1,5,9,13,18,0,1,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression (calculated up to Day 365),Screening (1 day); Intervention Phase: Day 1 of each 3-week cycle for treatment administration and assessments.,"The chemotherapy component is assumed to be CAPOX (Capecitabine and Oxaliplatin) for calculating contact days, as it represents the conservative lower estimate for in-person visits (Oxaliplatin IV on Day 1 only) compared to FP (Cisplatin IV on Day 1 and 5-FU continuous IV infusion on Days 1-5). The protocol allows for either FP or CAPOX, but the Schedule of Activities table only marks Day 1 for 'FP or CAPOX Administration'.; All procedures listed in the 'Screening Phase' column are assumed to occur on a single in-person day within the screening window.; Procedures occurring on Day 1 of each cycle (e.g., imaging, labs, clinic visits) are subsumed under the 'core_treatment' category due to the administration of Pembrolizumab/Placebo and Oxaliplatin IV infusions on the same day, following the tie-breaker precedence rule."
37875143,Placebo plus chemotherapy,control,1,1,5,9,13,18,0,1,5,9,13,18,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,21,until progression (calculated up to Day 365),Screening (1 day); Intervention Phase: Day 1 of each 3-week cycle for treatment administration and assessments.,"The chemotherapy component is assumed to be CAPOX (Capecitabine and Oxaliplatin) for calculating contact days, as it represents the conservative lower estimate for in-person visits (Oxaliplatin IV on Day 1 only) compared to FP (Cisplatin IV on Day 1 and 5-FU continuous IV infusion on Days 1-5). The protocol allows for either FP or CAPOX, but the Schedule of Activities table only marks Day 1 for 'FP or CAPOX Administration'.; All procedures listed in the 'Screening Phase' column are assumed to occur on a single in-person day within the screening window.; Procedures occurring on Day 1 of each cycle (e.g., imaging, labs, clinic visits) are subsumed under the 'core_treatment' category due to the administration of Pembrolizumab/Placebo and Oxaliplatin IV infusions on the same day, following the tie-breaker precedence rule."
37935977,Arm 1 (7+3),intervention,2,11,26,36,37,38,0,8,16,19,19,19,2,2,3,4,5,6,0,1,7,13,13,13,0,0,0,0,0,0,28,"1 Induction cycle, followed by 4 Consolidation cycles, then follow-up until 1 year after initial registration.","Screening (2 days); Induction (Day 0-6/7 for treatment, Day 14 for BM, Day 21 for labs, Day 28 for BM); Consolidation (4 cycles, each 28 days, with treatment on Day 0-X and labs/H&P on Day 0, 7, 14, 21); Follow-up (Day 90, 180, 270, 365 for BM, labs, H&P).","Screening visits are consolidated into 2 days: one for general assessments (H&P, labs, EKG, ECHO/MUGA, buccal swabs, peripheral blood) and one for invasive procedures (BM Asp/Bx, Cytogenetics/FISH). The day with EKG/ECHO is categorized as imaging_diagnostics, and the day with BM Asp/Bx is categorized as imaging_diagnostics.; One Induction cycle is assumed, followed by 4 Consolidation cycles, then follow-up for the remainder of the 12-month period. Re-induction is considered conditional and not included in the standard path.; The 'X' marks in the treatment tables for oral Vorinostat administration on specific days are interpreted as requiring in-person contact for administration/monitoring of an investigational drug, thus counted as core_treatment days.; For overlapping procedures on the same day, the tie-breaker precedence was applied: core_treatment > imaging_diagnostics > labs > clinic_visits."
37935977,Arm 2 (IA),intervention,2,12,26,36,37,38,0,6,13,16,16,16,2,1,2,3,4,5,0,5,11,17,17,17,0,0,0,0,0,0,28,"1 Induction cycle, followed by 4 Consolidation cycles, then follow-up until 1 year after initial registration.","Screening (2 days); Induction (Day 0-3 for treatment, Day 4-6 for labs, Day 14 for labs, Day 21 for labs, Day 28 for BM); Consolidation (4 cycles, each 28 days, with treatment on Day 0-X and labs/H&P on Day 0, 7, 14, 21); Follow-up (Day 90, 180, 270, 365 for BM, labs, H&P).","Screening visits are consolidated into 2 days: one for general assessments (H&P, labs, EKG, ECHO/MUGA, buccal swabs, peripheral blood) and one for invasive procedures (BM Asp/Bx, Cytogenetics/FISH). The day with EKG/ECHO is categorized as imaging_diagnostics, and the day with BM Asp/Bx is categorized as imaging_diagnostics.; One Induction cycle is assumed, followed by 4 Consolidation cycles, then follow-up for the remainder of the 12-month period. Re-induction is considered conditional and not included in the standard path.; For overlapping procedures on the same day, the tie-breaker precedence was applied: core_treatment > imaging_diagnostics > labs > clinic_visits."
37935977,Arm 3 (IA+V),intervention,2,11,35,48,49,50,0,8,25,31,31,31,2,2,3,4,5,6,0,1,7,13,13,13,0,0,0,0,0,0,28,"1 Induction cycle, followed by 4 Consolidation cycles, then follow-up until 1 year after initial registration.","Screening (2 days); Induction (Day 0-6 for treatment, Day 14 for labs, Day 21 for labs, Day 28 for BM); Consolidation (4 cycles, each 28 days, with treatment on Day 0-X and labs/H&P on Day 0, 7, 14, 21); Follow-up (Day 90, 180, 270, 365 for BM, labs, H&P).","Screening visits are consolidated into 2 days: one for general assessments (H&P, labs, EKG, ECHO/MUGA, buccal swabs, peripheral blood) and one for invasive procedures (BM Asp/Bx, Cytogenetics/FISH). The day with EKG/ECHO is categorized as imaging_diagnostics, and the day with BM Asp/Bx is categorized as imaging_diagnostics.; One Induction cycle is assumed, followed by 4 Consolidation cycles, then follow-up for the remainder of the 12-month period. Re-induction is considered conditional and not included in the standard path.; The 'X' marks in the treatment tables for oral Vorinostat administration on specific days are interpreted as requiring in-person contact for administration/monitoring of an investigational drug, thus counted as core_treatment days.; For overlapping procedures on the same day, the tie-breaker precedence was applied: core_treatment > imaging_diagnostics > labs > clinic_visits."
37935977,Arm 3 (IA only),intervention,2,12,26,36,37,38,0,6,13,16,16,16,2,1,2,3,4,5,0,5,11,17,17,17,0,0,0,0,0,0,28,"1 Induction cycle, followed by 4 Consolidation cycles, then follow-up until 1 year after initial registration.","Screening (2 days); Induction (Day 0-3 for treatment, Day 4-6 for labs, Day 14 for labs, Day 21 for labs, Day 28 for BM); Consolidation (4 cycles, each 28 days, with treatment on Day 0-X and labs/H&P on Day 0, 7, 14, 21); Follow-up (Day 90, 180, 270, 365 for BM, labs, H&P).","Screening visits are consolidated into 2 days: one for general assessments (H&P, labs, EKG, ECHO/MUGA, buccal swabs, peripheral blood) and one for invasive procedures (BM Asp/Bx, Cytogenetics/FISH). The day with EKG/ECHO is categorized as imaging_diagnostics, and the day with BM Asp/Bx is categorized as imaging_diagnostics.; One Induction cycle is assumed, followed by 4 Consolidation cycles, then follow-up for the remainder of the 12-month period. Re-induction is considered conditional and not included in the standard path.; For overlapping procedures on the same day, the tie-breaker precedence was applied: core_treatment > imaging_diagnostics > labs > clinic_visits."
37980924,Prophylactic Apixaban,intervention,1,29,30,30,30,30,0,29,29,29,29,29,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,,"Fixed duration of approximately 28 days for induction chemotherapy, followed by a single follow-up visit.","Single induction chemotherapy period with daily and scheduled treatments, followed by a single follow-up visit. Visits occur on Day -7 (Screening), Day 0 (C1D1/Randomization), Day 1-27 (daily chemotherapy), Day 29 (end of treatment with chemotherapy and imaging), and Day 35 (follow-up).","One screening visit is counted on Day -7, encompassing all screening procedures (consent, history, physical, labs, pregnancy test, etc.).; Randomization occurs on Day 0 (C1D1).; Daily administration of Dexamethasone (Days 1-14) and Prednisone (Days 1-28) counts as an in-person healthcare contact day for each day it occurs, as it involves active treatment delivery.; Intrathecal Methotrexate (IT MTX) on Days 15 & 22 (if CNS3) is assumed to occur as scheduled treatment.; The Day 35 follow-up visit is considered an in-person contact day, based on the 'telephone or in person' wording in the protocol text.; PK/anti-FXa sample collections for the Apixaban arm (on Day 8 and Day 15) are categorized as 'labs', but these days are already categorized as 'core_treatment' due to induction chemotherapy, which takes precedence. Therefore, these additional procedures do not change the primary category for those days or add unique contact days.; The 'Day 7±5' and 'Day 8±5' visit windows are interpreted such that Day 8 is the primary visit day, and any visit on Day 7 would be an alternative or additional activity on a day already covered by daily chemotherapy."
37980924,No systemic anticoagulant prophylaxis,control,1,29,30,30,30,30,0,29,29,29,29,29,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,,"Fixed duration of approximately 28 days for induction chemotherapy, followed by a single follow-up visit.","Single induction chemotherapy period with daily and scheduled treatments, followed by a single follow-up visit. Visits occur on Day -7 (Screening), Day 0 (C1D1/Randomization), Day 1-27 (daily chemotherapy), Day 29 (end of treatment with chemotherapy and imaging), and Day 35 (follow-up).","One screening visit is counted on Day -7, encompassing all screening procedures (consent, history, physical, labs, pregnancy test, etc.).; Randomization occurs on Day 0 (C1D1).; Daily administration of Dexamethasone (Days 1-14) and Prednisone (Days 1-28) counts as an in-person healthcare contact day for each day it occurs, as it involves active treatment delivery.; Intrathecal Methotrexate (IT MTX) on Days 15 & 22 (if CNS3) is assumed to occur as scheduled treatment.; The Day 35 follow-up visit is considered an in-person contact day, based on the 'telephone or in person' wording in the protocol text.; The 'Day 7±5' and 'Day 8±5' visit windows are interpreted such that Day 8 is the primary visit day, and any visit on Day 7 would be an alternative or additional activity on a day already covered by daily chemotherapy."
38039991,durvalumab + SoC CCRT,intervention,2,22,27,32,36,41,0,22,27,30,33,37,2,0,0,1,2,3,0,0,0,1,1,1,0,0,0,0,0,0,28,until progression,"Screening (2 days). Treatment: Durvalumab/Placebo infusion q28d (14 doses within 12 months). Concurrent SoC CCRT (EBRT 25 days, Cisplatin 5 days, Brachytherapy 3 days) within the first ~5 weeks. Efficacy assessments (imaging + pelvic exam + PROs) at Day 140, Day 224, Day 308. Additional ctDNA at Day 180.","Assumed 2 distinct screening days to accommodate all procedures (ECG, imaging, biopsy, labs, consent, PE, etc.).; Assumed 5 weeks of EBRT (5 days/week, Mon-Fri) for a total of 25 days, starting C1D1.; Assumed 5 weekly cisplatin doses, occurring on EBRT days (C1D1, C1D8, C1D15, C1D22, C1D29).; Assumed 3 brachytherapy sessions, each on a separate day, distinct from cisplatin days and other EBRT days, to maximize unique contact days (e.g., D17, D24, D31). This results in 25 EBRT days (including 5 cisplatin days) + 3 brachytherapy days = 28 unique CCRT days, all categorized as core_treatment.; Assumed treatment continues for the full 12-month period (i.e., no early progression or discontinuation).; Assumed q12w efficacy assessments (imaging + pelvic exam + PROs) occur on nominal dates (Day 140, Day 224, Day 308) and are distinct from infusion days unless they perfectly align (none did in this schedule).; Assumed 'Patient follow-up contact/Patient review for safety' (Days 14 of C1, C2, C3) are tele-visits and not in-person contact days.; Assumed follow-up visits from Table 2 are only for discontinued patients and thus not counted for the 'on-treatment' scenario.; PROs are done in clinic on infusion days and imaging days.; ctDNA at 6 months (Day 180) is a separate visit."
38039991,placebo + SoC CCRT,control,2,22,27,32,36,41,0,22,27,30,33,37,2,0,0,1,2,3,0,0,0,1,1,1,0,0,0,0,0,0,28,until progression,"Screening (2 days). Treatment: Placebo infusion q28d (14 doses within 12 months). Concurrent SoC CCRT (EBRT 25 days, Cisplatin 5 days, Brachytherapy 3 days) within the first ~5 weeks. Efficacy assessments (imaging + pelvic exam + PROs) at Day 140, Day 224, Day 308. Additional ctDNA at Day 180.","Assumed 2 distinct screening days to accommodate all procedures (ECG, imaging, biopsy, labs, consent, PE, etc.).; Assumed 5 weeks of EBRT (5 days/week, Mon-Fri) for a total of 25 days, starting C1D1.; Assumed 5 weekly cisplatin doses, occurring on EBRT days (C1D1, C1D8, C1D15, C1D22, C1D29).; Assumed 3 brachytherapy sessions, each on a separate day, distinct from cisplatin days and other EBRT days, to maximize unique contact days (e.g., D17, D24, D31). This results in 25 EBRT days (including 5 cisplatin days) + 3 brachytherapy days = 28 unique CCRT days, all categorized as core_treatment.; Assumed treatment continues for the full 12-month period (i.e., no early progression or discontinuation).; Assumed q12w efficacy assessments (imaging + pelvic exam + PROs) occur on nominal dates (Day 140, Day 224, Day 308) and are distinct from infusion days unless they perfectly align (none did in this schedule).; Assumed 'Patient follow-up contact/Patient review for safety' (Days 14 of C1, C2, C3) are tele-visits and not in-person contact days.; Assumed follow-up visits from Table 2 are only for discontinued patients and thus not counted for the 'on-treatment' scenario.; PROs are done in clinic on infusion days and imaging days.; ctDNA at 6 months (Day 180) is a separate visit."
38039993,Arm A: Lenvatinib Plus Pembrolizumab,intervention,1,4,10,18,26,35,0,3,8,15,21,29,1,0,1,2,4,5,0,1,1,1,1,1,0,0,0,0,0,0,21,Pembrolizumab/placebo up to 35 cycles (~2 years); Lenvatinib until progression or intolerable toxicity.,"Screening (Day -28). Treatment cycles are 21 days. Cycle 1: Day 0, Day 7, Day 14. Cycles 2-6: Day 1, Day 15. Cycles 7 onwards: Day 1 and Day 15. Tumor assessments (CT/MRI) are on Screening, C4D1, C7D1, C10D1, C13D1, C16D1. ECG on C1D1, C2D1. TSH on C2D1, C4D1, C6D1, then every two cycles (C8D1, C10D1, C12D1, C14D1, C16D1, C18D1). AFP on Screening, C4D1, C7D1, C10D1, C13D1, C16D1. Plasma/ctDNA biomarkers on C1D1, C2D1, C3D1, C5D1, then every 3 cycles (C8D1, C11D1, C14D1, C17D1). ePROs on C1-C10 D1, then every two cycles (C12D1, C14D1, C16D1, C18D1).","Screening is assumed to occur on a single day (Day -28).; Lenvatinib dispensing is considered an in-person contact day as marked in the Schedule of Activities (SoA) table, despite a note on Page 84 stating it 'may be administered at home except on Day 1 of Cycles 1 and 2'. The SoA table explicitly marks dispensing on C1D1, C1D15, C2D1, C2D15, and then D1 and D15 for all subsequent cycles (7 to last).; The 'Randomization and study intervention assignment via IRT' marked in the Screening column is not counted as a separate contact day, as randomization occurs on C1D1 (Day 0) which is already a contact day.; Optional visits like 'Stool analysis (optional)' are excluded. Conditional visits like 'Gastroenterological endoscopy' and 'Tumor assessment (CT/MRI)' at EOT are assumed to occur if needed and thus counted.; Survival Follow-up visits are not counted as in-person contact days, as notes indicate they can be conducted via telephone or email.; End of Treatment (EOT) and Post-Treatment Safety/Imaging Follow-up visits are not counted within the 365-day window, as treatment is assumed to continue until progression (beyond 365 days).; For procedures with specific notes overriding the general 'X' in the '7 to last' column (e.g., TSH, AFP, plasma/ctDNA biomarkers, ePROs), the specific schedule in the notes is followed for categorization.; The highest priority category is assigned to each day if multiple activities occur."
38039993,Arm B: Lenvatinib Plus Placebo,control,1,4,10,18,26,35,0,3,8,15,21,29,1,0,1,2,4,5,0,1,1,1,1,1,0,0,0,0,0,0,21,Pembrolizumab/placebo up to 35 cycles (~2 years); Lenvatinib until progression or intolerable toxicity.,"Screening (Day -28). Treatment cycles are 21 days. Cycle 1: Day 0, Day 7, Day 14. Cycles 2-6: Day 1, Day 15. Cycles 7 onwards: Day 1 and Day 15. Tumor assessments (CT/MRI) are on Screening, C4D1, C7D1, C10D1, C13D1, C16D1. ECG on C1D1, C2D1. TSH on C2D1, C4D1, C6D1, then every two cycles (C8D1, C10D1, C12D1, C14D1, C16D1, C18D1). AFP on Screening, C4D1, C7D1, C10D1, C13D1, C16D1. Plasma/ctDNA biomarkers on C1D1, C2D1, C3D1, C5D1, then every 3 cycles (C8D1, C11D1, C14D1, C17D1). ePROs on C1-C10 D1, then every two cycles (C12D1, C14D1, C16D1, C18D1).","Screening is assumed to occur on a single day (Day -28).; Lenvatinib dispensing is considered an in-person contact day as marked in the Schedule of Activities (SoA) table, despite a note on Page 84 stating it 'may be administered at home except on Day 1 of Cycles 1 and 2'. The SoA table explicitly marks dispensing on C1D1, C1D15, C2D1, C2D15, and then D1 and D15 for all subsequent cycles (7 to last).; The 'Randomization and study intervention assignment via IRT' marked in the Screening column is not counted as a separate contact day, as randomization occurs on C1D1 (Day 0) which is already a contact day.; Optional visits like 'Stool analysis (optional)' are excluded. Conditional visits like 'Gastroenterological endoscopy' and 'Tumor assessment (CT/MRI)' at EOT are assumed to occur if needed and thus counted.; Survival Follow-up visits are not counted as in-person contact days, as notes indicate they can be conducted via telephone or email.; End of Treatment (EOT) and Post-Treatment Safety/Imaging Follow-up visits are not counted within the 365-day window, as treatment is assumed to continue until progression (beyond 365 days).; For procedures with specific notes overriding the general 'X' in the '7 to last' column (e.g., TSH, AFP, plasma/ctDNA biomarkers, ePROs), the specific schedule in the notes is followed for categorization.; The highest priority category is assigned to each day if multiple activities occur."
38060199,ipatasertib + atezolizumab + paclitaxel,intervention,1,4,10,21,32,43,0,4,10,20,30,40,1,0,0,1,2,3,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (1 day), then repeating 28-day cycles with visits on Day 1, Day 8, and Day 15. Tumor assessments occur on C3D1, C5D1, C7D1, C9D1, C11D1, C13D1 (every 8 weeks). Bone scans occur on one day within Days 16-28 of every fourth cycle (C4, C8, C12).","The 'Schedule of Activities: Applicable before unblinding' (Appendix 1, Table 1) was used as the primary schedule for all arms, representing the full intended protocol.; All listed procedures in the 'Screening' column are assumed to occur on a single contact day within the screening window.; Ipatasertib/placebo dispensing and accountability, atezolizumab/placebo administration (IV infusion), and paclitaxel administration (IV infusion) are considered in-person core_treatment activities.; For 'Bone scan' (Days 16-28 of every fourth cycle), one contact day (e.g., Day 27 of the cycle) was assumed within the specified window.; PK and ADA sample collection is excluded as per protocol Version 5 update (Page 30, 97).; Patient-Reported Outcome (PRO) assessments (EORTC QLQ-C30, PRO-CTCAE, EQ-5D-5L) are listed in the schedule as occurring in-person during clinic visits. However, due to precedence rules, these days are categorized as core_treatment or imaging_diagnostics if those activities also occur.; 'Urinalysis (s)' is marked 'As clinically indicated' in the table and is therefore excluded from scheduled contact days.; 'Tumor tissue sample obtained at time of progression (optional)' is optional and post-progression, so excluded from scheduled contact days.; All D1, D8, D15 visits within a cycle involve core_treatment (drug administration/infusion) and therefore are categorized as 'core_treatment' days.; The single screening day includes multiple imaging diagnostics (tumor tissue biopsy, cardiac function, ECG, tumor assessments, bone scan, head scan) and is therefore categorized as 'imaging_diagnostics' due to precedence.; Standalone bone scan days (C4D27, C8D27, C12D27) are categorized as 'imaging_diagnostics'."
38060199,ipatasertib + paclitaxel,intervention,1,4,10,21,32,43,0,4,10,20,30,40,1,0,0,1,2,3,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (1 day), then repeating 28-day cycles with visits on Day 1, Day 8, and Day 15. Tumor assessments occur on C3D1, C5D1, C7D1, C9D1, C11D1, C13D1 (every 8 weeks). Bone scans occur on one day within Days 16-28 of every fourth cycle (C4, C8, C12).","The 'Schedule of Activities: Applicable before unblinding' (Appendix 1, Table 1) was used as the primary schedule for all arms, representing the full intended protocol.; All listed procedures in the 'Screening' column are assumed to occur on a single contact day within the screening window.; Ipatasertib/placebo dispensing and accountability, atezolizumab/placebo administration (IV infusion), and paclitaxel administration (IV infusion) are considered in-person core_treatment activities.; For 'Bone scan' (Days 16-28 of every fourth cycle), one contact day (e.g., Day 27 of the cycle) was assumed within the specified window.; PK and ADA sample collection is excluded as per protocol Version 5 update (Page 30, 97).; Patient-Reported Outcome (PRO) assessments (EORTC QLQ-C30, PRO-CTCAE, EQ-5D-5L) are listed in the schedule as occurring in-person during clinic visits. However, due to precedence rules, these days are categorized as core_treatment or imaging_diagnostics if those activities also occur.; 'Urinalysis (s)' is marked 'As clinically indicated' in the table and is therefore excluded from scheduled contact days.; 'Tumor tissue sample obtained at time of progression (optional)' is optional and post-progression, so excluded from scheduled contact days.; All D1, D8, D15 visits within a cycle involve core_treatment (drug administration/infusion) and therefore are categorized as 'core_treatment' days.; The single screening day includes multiple imaging diagnostics (tumor tissue biopsy, cardiac function, ECG, tumor assessments, bone scan, head scan) and is therefore categorized as 'imaging_diagnostics' due to precedence.; Standalone bone scan days (C4D27, C8D27, C12D27) are categorized as 'imaging_diagnostics'."
38060199,atezolizumab + paclitaxel,intervention,1,4,10,21,32,43,0,4,10,20,30,40,1,0,0,1,2,3,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (1 day), then repeating 28-day cycles with visits on Day 1, Day 8, and Day 15. Tumor assessments occur on C3D1, C5D1, C7D1, C9D1, C11D1, C13D1 (every 8 weeks). Bone scans occur on one day within Days 16-28 of every fourth cycle (C4, C8, C12).","The 'Schedule of Activities: Applicable before unblinding' (Appendix 1, Table 1) was used as the primary schedule for all arms, representing the full intended protocol.; All listed procedures in the 'Screening' column are assumed to occur on a single contact day within the screening window.; Ipatasertib/placebo dispensing and accountability, atezolizumab/placebo administration (IV infusion), and paclitaxel administration (IV infusion) are considered in-person core_treatment activities.; For 'Bone scan' (Days 16-28 of every fourth cycle), one contact day (e.g., Day 27 of the cycle) was assumed within the specified window.; PK and ADA sample collection is excluded as per protocol Version 5 update (Page 30, 97).; Patient-Reported Outcome (PRO) assessments (EORTC QLQ-C30, PRO-CTCAE, EQ-5D-5L) are listed in the schedule as occurring in-person during clinic visits. However, due to precedence rules, these days are categorized as core_treatment or imaging_diagnostics if those activities also occur.; 'Urinalysis (s)' is marked 'As clinically indicated' in the table and is therefore excluded from scheduled contact days.; 'Tumor tissue sample obtained at time of progression (optional)' is optional and post-progression, so excluded from scheduled contact days.; All D1, D8, D15 visits within a cycle involve core_treatment (drug administration/infusion) and therefore are categorized as 'core_treatment' days.; The single screening day includes multiple imaging diagnostics (tumor tissue biopsy, cardiac function, ECG, tumor assessments, bone scan, head scan) and is therefore categorized as 'imaging_diagnostics' due to precedence.; Standalone bone scan days (C4D27, C8D27, C12D27) are categorized as 'imaging_diagnostics'."
38060199,paclitaxel alone,control,1,4,10,21,32,43,0,4,10,20,30,40,1,0,0,1,2,3,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (1 day), then repeating 28-day cycles with visits on Day 1, Day 8, and Day 15. Tumor assessments occur on C3D1, C5D1, C7D1, C9D1, C11D1, C13D1 (every 8 weeks). Bone scans occur on one day within Days 16-28 of every fourth cycle (C4, C8, C12).","The 'Schedule of Activities: Applicable before unblinding' (Appendix 1, Table 1) was used as the primary schedule for all arms, representing the full intended protocol.; All listed procedures in the 'Screening' column are assumed to occur on a single contact day within the screening window.; Ipatasertib/placebo dispensing and accountability, atezolizumab/placebo administration (IV infusion), and paclitaxel administration (IV infusion) are considered in-person core_treatment activities.; For 'Bone scan' (Days 16-28 of every fourth cycle), one contact day (e.g., Day 27 of the cycle) was assumed within the specified window.; PK and ADA sample collection is excluded as per protocol Version 5 update (Page 30, 97).; Patient-Reported Outcome (PRO) assessments (EORTC QLQ-C30, PRO-CTCAE, EQ-5D-5L) are listed in the schedule as occurring in-person during clinic visits. However, due to precedence rules, these days are categorized as core_treatment or imaging_diagnostics if those activities also occur.; 'Urinalysis (s)' is marked 'As clinically indicated' in the table and is therefore excluded from scheduled contact days.; 'Tumor tissue sample obtained at time of progression (optional)' is optional and post-progression, so excluded from scheduled contact days.; All D1, D8, D15 visits within a cycle involve core_treatment (drug administration/infusion) and therefore are categorized as 'core_treatment' days.; The single screening day includes multiple imaging diagnostics (tumor tissue biopsy, cardiac function, ECG, tumor assessments, bone scan, head scan) and is therefore categorized as 'imaging_diagnostics' due to precedence.; Standalone bone scan days (C4D27, C8D27, C12D27) are categorized as 'imaging_diagnostics'."
38103088,Arm 1: F-627,intervention,1,26,57,57,57,57,0,4,8,8,8,8,1,0,1,1,1,1,0,22,48,48,48,48,0,0,0,0,0,0,21,4 cycles (84 days) with a final visit on Day 84,"Screening (Day -7); Chemotherapy (Day 0, 21, 42, 63); Study Drug Administration (Day 1, 22, 43, 64); ANC Monitoring (Daily C1: Day 2-20; EOD C2-4: Day 23,25..41, Day 44,46..62, Day 65,67..83); End of Study (Day 84).","Assumed 1 in-person contact day for the 'Screening Days -15 to -1' period, categorized as imaging_diagnostics due to the presence of ECG and Chest X-Ray.; Assumed a fixed 21-day cycle length for chemotherapy, for a total of 4 cycles (84 days of treatment).; Assumed ANC monitoring visits (Body temperature, CBC with Differentials, AE-reporting) occur as scheduled in the 'Cycles 1-4 (Cycle Days 3-21, Study Days 3-84)' column of the SoE table: daily for Cycle 1 (Day 3-20) and every other day for Cycles 2-4 (Day 3-21 of each cycle).; Conditional daily ANC blood draws 'if ANC level of a subject is < 0.5 ×10^9/L' were excluded as per the rule for optional/conditional visits.; Day 2 of each cycle (study drug administration) is categorized as core_treatment, overriding labs for ANC monitoring on that day due to precedence.; The final study visit is on Day 84, as indicated in the SoE table and protocol text."
38103088,"Arm 2: Placebo (C1), F-627 (C2-4)",control,1,26,57,57,57,57,0,4,8,8,8,8,1,0,1,1,1,1,0,22,48,48,48,48,0,0,0,0,0,0,21,4 cycles (84 days) with a final visit on Day 84,"Screening (Day -7); Chemotherapy (Day 0, 21, 42, 63); Study Drug Administration (Day 1, 22, 43, 64); ANC Monitoring (Daily C1: Day 2-20; EOD C2-4: Day 23,25..41, Day 44,46..62, Day 65,67..83); End of Study (Day 84).","Assumed 1 in-person contact day for the 'Screening Days -15 to -1' period, categorized as imaging_diagnostics due to the presence of ECG and Chest X-Ray.; Assumed a fixed 21-day cycle length for chemotherapy, for a total of 4 cycles (84 days of treatment).; Assumed ANC monitoring visits (Body temperature, CBC with Differentials, AE-reporting) occur as scheduled in the 'Cycles 1-4 (Cycle Days 3-21, Study Days 3-84)' column of the SoE table: daily for Cycle 1 (Day 3-20) and every other day for Cycles 2-4 (Day 3-21 of each cycle).; Conditional daily ANC blood draws 'if ANC level of a subject is < 0.5 ×10^9/L' were excluded as per the rule for optional/conditional visits.; Day 2 of each cycle (study drug administration) is categorized as core_treatment, overriding labs for ANC monitoring on that day due to precedence.; The final study visit is on Day 84, as indicated in the SoE table and protocol text."
38159809,Pembrolizumab Monotherapy,intervention,1,4,10,19,27,36,0,2,5,9,13,18,1,0,0,0,0,0,0,2,5,10,14,18,0,0,0,0,0,0,21,until discontinuation criteria are met or up to Cycle 35,"Screening (1 day); Cycle 1 (Day 1, Day 8, Day 15); Cycles 2-35 (Day 1, Day 15).","Only the 'Pembrolizumab Monotherapy' arm is considered, as lenvatinib and matching placebo were removed from the study per Amendment 007-06.; Day 0 is Cycle 1 Day 1 (C1D1).; Treatment is assumed to continue for the full 35 cycles (735 days) or until the end of the 12-month window, whichever is earlier, for the purpose of calculating contact days within fixed intervals.; The 'X' for 'Treatment randomization' in the Screening column is considered an administrative setup and not a separate in-person contact day; randomization is assumed to occur on C1D1 (Day 0).; The 'X' for 'Pembrolizumab administration' in the Screening column is ignored, as per protocol text stating treatment begins after screening on C1D1.; Urinalysis/urine dipstick testing is excluded from routine contact days after screening, as the protocol note explicitly links it to participants who received lenvatinib/matching placebo, which are no longer part of the study.; ECHO/MUGA and Brain MRI are only counted at screening unless explicitly stated as routine follow-up or 'if clinically indicated' for specific conditions, which are not assumed to be routine contact days.; Safety and Survival Follow-up visits (Every 12 weeks) are considered phone contacts and not in-person healthcare contact days, as indicated by protocol text.; Category tie-breaker precedence: core_treatment > imaging_diagnostics > labs > clinic_visits."
38252907,Arm A: Nivolumab plus Platinum-doublet Chemotherapy,intervention,1,2,7,14,20,26,1,2,6,11,15,19,0,0,1,3,5,7,0,0,0,0,0,0,0,0,0,0,0,0,21,"4 cycles of Nivo+Pem/Plat, then Nivo+Pem maintenance until progression or max 24 months.","Screening (Day -7), Dosing (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315, 336, 357), Tumor Assessments (Day 49, 91, 133, 175, 217, 259, 301, 343). IM B12 on Day -7, 84, 147, 210, 273, 336. Brain MRI/CT on Day 0, 84, 168, 252, 336. Audiometric testing on Day -7, 21, 42, 63.","A single screening visit is assumed on Day -7 to accommodate all screening procedures (within 28 days prior to randomization) and the pre-C1D1 IM B12 injection (1 week prior to C1D1).; Randomization is considered part of the C1D1 visit for physical attendance, but the screening visit on Day -7 covers the initial randomization procedures.; All dosing days are considered in-person contact days for administration of IV drugs and associated safety/clinical assessments.; Pemetrexed premedications (oral corticosteroid, oral folic acid) are not counted as in-person contact days.; IM B12 injections are counted as in-person core_treatment days.; Audiometric testing (for cisplatin) is counted as an in-person imaging_diagnostics day, but if it falls on a dosing day, the day is categorized as core_treatment.; Tumor assessments (CT/MRI) are counted as in-person imaging_diagnostics days, but if they fall on a dosing day, the day is categorized as core_treatment.; Re-biopsy at Week 7 is counted as an in-person core_treatment day as it is 'highly recommended'.; Brain MRI/CT scans every 12 weeks are counted as in-person imaging_diagnostics days, but if they fall on a dosing day, the day is categorized as core_treatment.; On-study laboratory assessments are assumed to be performed on the dosing days and are subsumed by the higher priority core_treatment category.; EQ-5D-3L and LCSS assessments are performed on dosing days and are subsumed by the higher priority core_treatment category.; Treatment is assumed to continue for the full 12-month duration (365 days) as 'until progression' is specified, and the maximum duration for nivolumab-containing regimens (24 months) is beyond the 12-month window.; Follow-up visits (FU1, FU2, Survival FU) fall outside the 12-month window and are not counted."
38252907,Arm B: Nivolumab plus Ipilimumab,intervention,1,3,9,18,26,35,1,3,8,15,21,28,0,0,1,3,5,7,0,0,0,0,0,0,0,0,0,0,0,0,14,"Nivo every 2 weeks, Ipi every 6 weeks until progression or max 24 months.","Screening (Day -7), Nivo Dosing (Day 0, 14, 28, 42, 56, 70, 84, 98, 112, 126, 140, 154, 168, 182, 196, 210, 224, 238, 252, 266, 280, 294, 308, 322, 336, 350, 364), Ipi Dosing (Day 0, 42, 84, 126, 168, 210, 252, 294, 336), Tumor Assessments (Day 49, 91, 133, 175, 217, 259, 301, 343). Brain MRI/CT on Day 0, 84, 168, 252, 336.","A single screening visit is assumed on Day -7 to accommodate all screening procedures (within 28 days prior to randomization).; Enrollment to Arm B is closed, but existing subjects continue treatment, so calculations are performed.; All dosing days are considered in-person contact days for administration of IV drugs and associated safety/clinical assessments.; No premedications are recommended for Nivolumab/Ipilimumab.; Audiometric testing is not applicable for this arm.; Tumor assessments (CT/MRI) are counted as in-person imaging_diagnostics days, but if they fall on a dosing day, the day is categorized as core_treatment.; Re-biopsy at Week 7 is counted as an in-person core_treatment day as it is 'highly recommended'.; Brain MRI/CT scans every 12 weeks are counted as in-person imaging_diagnostics days, but if they fall on a dosing day, the day is categorized as core_treatment.; On-study laboratory assessments (including TSH every 6 weeks) are assumed to be performed on the dosing days and are subsumed by the higher priority core_treatment category.; EQ-5D-3L and LCSS assessments are performed on dosing days and are subsumed by the higher priority core_treatment category.; Treatment is assumed to continue for the full 12-month duration (365 days) as 'until progression' is specified, and the maximum duration (24 months) is beyond the 12-month window.; Follow-up visits (FU1, FU2, Survival FU) fall outside the 12-month window and are not counted."
38252907,Arm C: Platinum Doublet Chemotherapy,control,1,2,7,14,20,26,1,2,6,11,15,19,0,0,1,3,5,7,0,0,0,0,0,0,0,0,0,0,0,0,21,"4 cycles of Pem/Plat, then Pem maintenance until progression.","Screening (Day -7), Dosing (Day 0, 21, 42, 63, 84, 105, 126, 147, 168, 189, 210, 231, 252, 273, 294, 315, 336, 357), Tumor Assessments (Day 49, 91, 133, 175, 217, 259, 301, 343). IM B12 on Day -7, 84, 147, 210, 273, 336. Brain MRI/CT on Day 0, 84, 168, 252, 336. Audiometric testing on Day -7, 21, 42, 63.","A single screening visit is assumed on Day -7 to accommodate all screening procedures (within 28 days prior to randomization) and the pre-C1D1 IM B12 injection (1 week prior to C1D1).; All dosing days are considered in-person contact days for administration of IV drugs and associated safety/clinical assessments.; Pemetrexed premedications (oral corticosteroid, oral folic acid) are not counted as in-person contact days.; IM B12 injections are counted as in-person core_treatment days.; Audiometric testing (for cisplatin) is counted as an in-person imaging_diagnostics day, but if it falls on a dosing day, the day is categorized as core_treatment.; Tumor assessments (CT/MRI) are counted as in-person imaging_diagnostics days, but if they fall on a dosing day, the day is categorized as core_treatment.; Re-biopsy at Week 7 is counted as an in-person core_treatment day as it is 'highly recommended'.; Brain MRI/CT scans every 12 weeks are counted as in-person imaging_diagnostics days, but if they fall on a dosing day, the day is categorized as core_treatment.; On-study laboratory assessments are assumed to be performed on the dosing days and are subsumed by the higher priority core_treatment category.; EQ-5D-3L and LCSS assessments are performed on dosing days and are subsumed by the higher priority core_treatment category.; Treatment is assumed to continue for the full 12-month duration (365 days) as 'until progression' is specified.; Follow-up visits (FU1, FU2, Survival FU) fall outside the 12-month window and are not counted."
38319255,Ibrutinib + Venetoclax (I+VEN),intervention,1,2,4,10,12,13,0,2,4,7,8,9,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,3,3,3,28,Arm A: 15 cycles (3 Ibrutinib lead-in + 12 Ibrutinib+Venetoclax combination). Arm B: 6 cycles of G-Clb.,"Arm A: Screening (1 day). Treatment cycles 1-3: Day 1. Cycle 4: Day 1, 8, 15, 22. Cycles 5-8, 10, 13: Day 1. Disease Evaluations (DE) at Weeks 12, 24, 36, 48, 60, 72. End-of-Treatment (EOT) visit. Arm B: Screening (1 day). Cycle 1: Day 1, 2, 8, 15. Cycles 2-6: Day 1. Disease Evaluations (DE) at Weeks 12, 24, 36, 48. End-of-Treatment (EOT) visit.","Screening visit is counted as 1 day, occurring within the Day -28 to Day -1 window.; Cycle length is 28 days for all treatment cycles.; For Arm A, Ibrutinib is administered orally daily, and Venetoclax dose ramp-up starts on C4D1 with the first dose delivered in clinic. Subsequent daily doses are assumed to be home-administered unless a clinic visit is explicitly required for other procedures.; For Arm B, Chlorambucil is administered orally on D1 and D15 of each cycle. D15 Chlorambucil administration for Cycles 2-6 is assumed to be home-administered, and associated lab tests can be done outside the treating institution, thus not counting as in-person contact days.; For overlapping visits (e.g., Cycle Day 1 and Disease Evaluation visits), they are counted as a single contact day, and the category is assigned based on the highest priority procedure performed on that day.; Bone marrow aspirate and biopsy (BMA/BMB) for MRD assessment are classified as 'imaging_diagnostics' as they are diagnostic procedures for assessment, not strictly part of treatment delivery.; TLS risk assessment and prophylaxis (if not part of drug administration in clinic), Vitals, Weight, and PROs are classified as 'clinic_visits' if they are the highest priority procedure on a given day.; Labs (phlebotomy, urine collection) are classified as 'labs' if they are the highest priority procedure on a given day.; CT scans and ECGs are classified as 'imaging_diagnostics'.; IRR prophylaxis is considered part of 'core_treatment' as it is directly related to the IV infusion of Obinutuzumab.; All 'as needed' or 'optional' visits are excluded.; Post-PD Follow-Up visits (every 24 weeks) are assumed to be non-in-person contacts (e.g., phone calls or record reviews) unless specific in-person procedures are indicated.; For BMA/BMB at DE3 and DE6, it is assumed that all subjects are responders and thus these procedures are performed, maximizing contact days."
38319255,Chlorambucil + Obinutuzumab (G-Clb),control,1,5,7,10,12,13,0,5,7,9,9,9,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,2,3,28,Arm A: 15 cycles (3 Ibrutinib lead-in + 12 Ibrutinib+Venetoclax combination). Arm B: 6 cycles of G-Clb.,"Arm A: Screening (1 day). Treatment cycles 1-3: Day 1. Cycle 4: Day 1, 8, 15, 22. Cycles 5-8, 10, 13: Day 1. Disease Evaluations (DE) at Weeks 12, 24, 36, 48, 60, 72. End-of-Treatment (EOT) visit. Arm B: Screening (1 day). Cycle 1: Day 1, 2, 8, 15. Cycles 2-6: Day 1. Disease Evaluations (DE) at Weeks 12, 24, 36, 48. End-of-Treatment (EOT) visit.","Screening visit is counted as 1 day, occurring within the Day -28 to Day -1 window.; Cycle length is 28 days for all treatment cycles.; For Arm A, Ibrutinib is administered orally daily, and Venetoclax dose ramp-up starts on C4D1 with the first dose delivered in clinic. Subsequent daily doses are assumed to be home-administered unless a clinic visit is explicitly required for other procedures.; For Arm B, Chlorambucil is administered orally on D1 and D15 of each cycle. D15 Chlorambucil administration for Cycles 2-6 is assumed to be home-administered, and associated lab tests can be done outside the treating institution, thus not counting as in-person contact days.; For overlapping visits (e.g., Cycle Day 1 and Disease Evaluation visits), they are counted as a single contact day, and the category is assigned based on the highest priority procedure performed on that day.; Bone marrow aspirate and biopsy (BMA/BMB) for MRD assessment are classified as 'imaging_diagnostics' as they are diagnostic procedures for assessment, not strictly part of treatment delivery.; TLS risk assessment and prophylaxis (if not part of drug administration in clinic), Vitals, Weight, and PROs are classified as 'clinic_visits' if they are the highest priority procedure on a given day.; Labs (phlebotomy, urine collection) are classified as 'labs' if they are the highest priority procedure on a given day.; CT scans and ECGs are classified as 'imaging_diagnostics'.; IRR prophylaxis is considered part of 'core_treatment' as it is directly related to the IV infusion of Obinutuzumab.; All 'as needed' or 'optional' visits are excluded.; Post-PD Follow-Up visits (every 24 weeks) are assumed to be non-in-person contacts (e.g., phone calls or record reviews) unless specific in-person procedures are indicated.; For BMA/BMB at DE3 and DE6, it is assumed that all subjects are responders and thus these procedures are performed, maximizing contact days."
38319892,Durvalumab 1500 mg monotherapy (Arm A),intervention,1,3,7,10,13,17,0,2,4,7,10,14,1,0,0,0,0,0,0,0,0,0,0,0,0,1,3,3,3,3,28,until progression,"Screening (Day -28 to -1). Treatment cycles (28 days): Day 1 (Durvalumab infusion, labs, clinic, imaging, PROs). Day 14 (C1, C2, C3 only: clinic). Subsequent cycles Day 1 (Durvalumab infusion, labs, clinic, PROs; imaging/some PROs Q8W).","Screening is counted as 1 in-person day, categorized as imaging_diagnostics due to mandatory RECIST imaging and tumor biopsy.; Cycle length is 28 days for all arms.; Treatment is assumed to continue for the full 365 days for the 12-month window calculation, as per 'until progression' rule.; Days with drug administration (IV infusion for Durvalumab/Tremelimumab, oral Sorafenib administration requiring in-person assessment) are categorized as core_treatment.; Patient follow-up contact/Patient review for safety on Day 14 of Cycles 1, 2, and 3 are considered in-person clinic visits.; Optional ('if clinically indicated', 'optional') or 'as needed' visits are excluded.; Assessments on treatment days are performed prior to administration and are consolidated into the treatment day.; PK/ADA samples 3 months after the last dose are outside the 12-month window if treatment continues to Day 365."
38319892,Durvalumab 1500 mg plus tremelimumab 75 mg×4 doses combination therapy (Arm B),intervention,1,3,7,10,13,17,0,2,4,7,10,14,1,0,0,0,0,0,0,0,0,0,0,0,0,1,3,3,3,3,28,until progression,"Screening (Day -28 to -1). Cycles 1-4 (28 days each): Day 1 (Durvalumab + Tremelimumab infusions, labs, clinic, imaging, PROs). Day 14 (C1, C2, C3 only: clinic). Cycles 5 onwards (28 days each): Day 1 (Durvalumab infusion, labs, clinic, PROs; imaging/some PROs Q8W).","Screening is counted as 1 in-person day, categorized as imaging_diagnostics due to mandatory RECIST imaging and tumor biopsy.; Cycle length is 28 days for all arms.; Treatment is assumed to continue for the full 365 days for the 12-month window calculation, as per 'until progression' rule.; Days with drug administration (IV infusion for Durvalumab/Tremelimumab) are categorized as core_treatment.; Patient follow-up contact/Patient review for safety on Day 14 of Cycles 1, 2, and 3 are considered in-person clinic visits.; Optional ('if clinically indicated', 'optional') or 'as needed' visits are excluded.; Assessments on treatment days are performed prior to administration and are consolidated into the treatment day.; Arm B involves Durvalumab + Tremelimumab for 4 cycles, then Durvalumab monotherapy. Rechallenge is excluded as it's conditional and not part of the standard initial schedule for the first 12 months.; PK/ADA samples 3 months after the last dose are outside the 12-month window if treatment continues to Day 365."
38319892,Durvalumab 1500 mg plus tremelimumab 300 mg×1 dose combination therapy (Arm C),intervention,1,3,7,10,13,17,0,2,4,7,10,14,1,0,0,0,0,0,0,0,0,0,0,0,0,1,3,3,3,3,28,until progression,"Screening (Day -28 to -1). Cycle 1 (28 days): Day 1 (Durvalumab + Tremelimumab infusions, labs, clinic, imaging, PROs). Day 14 (C1 only: clinic). Cycles 2 onwards (28 days each): Day 1 (Durvalumab infusion, labs, clinic, PROs; imaging/some PROs Q8W).","Screening is counted as 1 in-person day, categorized as imaging_diagnostics due to mandatory RECIST imaging and tumor biopsy.; Cycle length is 28 days for all arms.; Treatment is assumed to continue for the full 365 days for the 12-month window calculation, as per 'until progression' rule.; Days with drug administration (IV infusion for Durvalumab/Tremelimumab) are categorized as core_treatment.; Patient follow-up contact/Patient review for safety on Day 14 of Cycles 1, 2, and 3 are considered in-person clinic visits.; Optional ('if clinically indicated', 'optional') or 'as needed' visits are excluded.; Assessments on treatment days are performed prior to administration and are consolidated into the treatment day.; Arm C involves Durvalumab + Tremelimumab for 1 dose (C1D1), then Durvalumab monotherapy. Rechallenge is excluded as it's conditional and not part of the standard initial schedule for the first 12 months.; PK/ADA samples 3 months after the last dose are outside the 12-month window if treatment continues to Day 365."
38319892,Sorafenib 400 mg BID therapy (Arm D),control,1,2,4,7,10,14,0,2,4,7,10,14,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (Day -28 to -1). Treatment cycles (28 days): Day 1 (Sorafenib administration, labs, clinic, imaging, PROs). Subsequent cycles Day 1 (Sorafenib administration, labs, clinic, PROs; imaging/some PROs Q8W).","Screening is counted as 1 in-person day, categorized as imaging_diagnostics due to mandatory RECIST imaging and tumor biopsy.; Cycle length is 28 days for all arms.; Treatment is assumed to continue for the full 365 days for the 12-month window calculation, as per 'until progression' rule.; Sorafenib administration days are categorized as core_treatment because they involve in-person assessments (targeted physical, vitals, Child-Pugh, ECOG, AE/SAE, labs, PROs, imaging).; Optional ('if clinically indicated', 'optional') or 'as needed' visits are excluded.; Assessments on treatment days are performed prior to administration and are consolidated into the treatment day."
38320161,Intervention Arm (Lumicell imaging directed tissue resection),intervention,1,2,2,2,2,2,0,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,N/A,until medical team determines no further surgical intervention is required and post-operative follow-up and blood sample completed or AE resolved,"Screening (Day -28 to -1), Day 0 (Surgery/Enrollment), First Post-operative visit (Day +2 to +14).","The 'Radiologic evaluation*' (Screening) is excluded as it is noted as 'not required if not part of the patient's medical history', implying it is not a mandatory trial-mandated procedure.; The 'Patient Reported Outcome Measures Survey**' (PROMs) are excluded as contact days because the protocol states they are collected via 'electronic survey' (Page 53, 8.4 and Page 48, 5.3.2.1).; The 'Routine follow up visit' column in Table 2 is interpreted as referring to the same in-person visit as '~2-14 days after surgery' due to the lack of a specified timing for a distinct 'Routine follow up visit' and the statement that 'All study safety assessments will continue until the first post-operative visit' (Page 52, 8.1), which would contradict safety assessments at a later, separate 'Routine follow up visit'. This is the most conservative interpretation given the ambiguity.; For Day 0, the 'Randomization' is an administrative event and not counted as a separate contact day.; For Day 0, 'Lumicell cavity initialization' and 'Standard of care shaves' involve imaging/device use (imaging_diagnostics), but 'LUM015 administration' and 'Main specimen resection' are core_treatment. Per tie-breaker rules, Day 0 is categorized as core_treatment.; For the 'Screening' visit and the 'First Post-operative visit (~2-14 days after surgery)', multiple activities occur. The presence of 'CBC with differentials', 'Serum chemistry', and 'Pregnancy test' (if applicable) leads to categorization as 'labs' per tie-breaker rules."
38320161,Control Arm (Standard of care alone),control,1,2,2,2,2,2,0,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,N/A,until medical team determines no further surgical intervention is required and post-operative follow-up and blood sample completed or AE resolved,"Screening (Day -28 to -1), Day 0 (Surgery/Enrollment), First Post-operative visit (Day +2 to +14).","The 'Radiologic evaluation*' (Screening) is excluded as it is noted as 'not required if not part of the patient's medical history', implying it is not a mandatory trial-mandated procedure.; The 'Patient Reported Outcome Measures Survey**' (PROMs) are excluded as contact days because the protocol states they are collected via 'electronic survey' (Page 53, 8.4 and Page 48, 5.3.2.1).; The 'Routine follow up visit' column in Table 2 is interpreted as referring to the same in-person visit as '~2-14 days after surgery' due to the lack of a specified timing for a distinct 'Routine follow up visit' and the statement that 'All study safety assessments will continue until the first post-operative visit' (Page 52, 8.1), which would contradict safety assessments at a later, separate 'Routine follow up visit'. This is the most conservative interpretation given the ambiguity.; For Day 0, the 'Randomization' is an administrative event and not counted as a separate contact day.; For Day 0, 'Lumicell cavity initialization' and 'Standard of care shaves' involve imaging/device use (imaging_diagnostics), but 'LUM015 administration' and 'Main specimen resection' are core_treatment. Per tie-breaker rules, Day 0 is categorized as core_treatment.; For the 'Screening' visit and the 'First Post-operative visit (~2-14 days after surgery)', multiple activities occur. The presence of 'CBC with differentials', 'Serum chemistry', and 'Pregnancy test' (if applicable) leads to categorization as 'labs' per tie-breaker rules."
38483412,ARM I (COPORT),intervention,2,23,37,38,38,39,0,23,37,37,37,37,0,0,0,0,0,0,1,0,0,1,1,2,1,0,0,0,0,0,N/A (radiation therapy),Radiation therapy for 37 fractions (approx. 7.4 weeks); ADT allowed for no more than 6 months (not explicitly scheduled as contact days beyond initial administration).,"Pre-treatment assessments (imaging, H&P, labs, questionnaires), daily radiation fractions (Mon-Fri) for 7.4 weeks, and scheduled follow-up visits at 6 and 12 months from start of RT.","RT Start is considered Day 0 (C1D1).; Step 1 Registration is assumed to occur on Day -28 relative to RT Start, as RT must begin within 4 weeks after Step 1 registration for RT-alone patients.; Pre-treatment assessments with a 'no more than X days prior to Step 1 registration' window are assumed to occur on the latest possible day within that window (e.g., Day -28 - (X-1)).; Radiation fractions are assumed to occur 5 days a week (Monday-Friday), starting on Day 0.; Weekly H&P/AE evaluations and 'Last Week' serum/plasma/urine collections during RT are assumed to coincide with RT treatment days and are categorized as core_treatment due to tie-breaker precedence.; Follow-up visits at 'End of RT' are assumed to coincide with the last RT treatment day and are categorized as core_treatment due to tie-breaker precedence.; Follow-up visits at 6 months and 12 months are assumed to occur on Day 180 and Day 365 respectively from the start of RT.; For follow-up visits, if multiple activities occur on the same day, the highest priority category is chosen (labs > clinic_visits)."
38483412,ARM II (HYPORT),intervention,2,23,25,26,26,27,0,23,25,25,25,25,0,0,0,0,0,0,1,0,0,1,1,2,1,0,0,0,0,0,N/A (radiation therapy),Radiation therapy for 25 fractions (approx. 5 weeks); ADT allowed for no more than 6 months (not explicitly scheduled as contact days beyond initial administration).,"Pre-treatment assessments (imaging, H&P, labs, questionnaires), daily radiation fractions (Mon-Fri) for 5 weeks, and scheduled follow-up visits at 6 and 12 months from start of RT.","RT Start is considered Day 0 (C1D1).; Step 1 Registration is assumed to occur on Day -28 relative to RT Start, as RT must begin within 4 weeks after Step 1 registration for RT-alone patients.; Pre-treatment assessments with a 'no more than X days prior to Step 1 registration' window are assumed to occur on the latest possible day within that window (e.g., Day -28 - (X-1)).; Radiation fractions are assumed to occur 5 days a week (Monday-Friday), starting on Day 0.; Weekly H&P/AE evaluations and 'Last Week' serum/plasma/urine collections during RT are assumed to coincide with RT treatment days and are categorized as core_treatment due to tie-breaker precedence.; Follow-up visits at 'End of RT' are assumed to coincide with the last RT treatment day and are categorized as core_treatment due to tie-breaker precedence.; Follow-up visits at 6 months and 12 months are assumed to occur on Day 180 and Day 365 respectively from the start of RT.; For follow-up visits, if multiple activities occur on the same day, the highest priority category is chosen (labs > clinic_visits)."
38499457,Pracinostat + AZA,intervention,1,12,32,56,80,112,0,11,29,50,71,99,1,0,1,3,4,6,0,0,1,2,4,6,0,1,1,1,1,1,28,"until disease progression, relapse, or non-manageable toxicity","Screening (1 day); Cycle 1 (Day 0, 1, 2, 3, 4, 5, 6, 14, 21); Cycle 2 (Day 28, 29, 30, 31, 32, 33, 34, 49); Subsequent Odd Cycles (Day 1, 2-7, 21); Subsequent Even Cycles (Day 1, 2-7, 21). Cycle 1 Day 0, 1, 2, 3, 4, 5, 6, 14 are core_treatment. Cycle 1 Day 21 is clinic_visits. Cycle 2 Day 28, 29, 30, 31, 32, 33, 34 are core_treatment. Cycle 2 Day 49 is imaging_diagnostics. Subsequent Odd Cycles Day 1, 2-7 are core_treatment. Subsequent Odd Cycles Day 21 is labs. Subsequent Even Cycles Day 1, 2-7 are core_treatment. Subsequent Even Cycles Day 21 is imaging_diagnostics.","AZA administration schedule is 7 days (Days 1-7) per cycle, as it is the standard schedule and the 5-2-2 schedule is only 'if unable to accommodate'.; ""Day 21-26"" visits are assumed to occur on Day 21 for calculation purposes, as it is the earliest day in the specified window.; Pracinostat/placebo administration is considered an in-person contact day only on Cycle 1 Day 1, Cycle 1 Day 3, Cycle 1 Day 15, and Cycle 2 Day 1, as explicitly stated on page 15 that study personnel must administer it on these days for PK/ECG. On all other days, it is assumed to be self-administered at home and thus not a contact day.; Sub-study Pracinostat/AZA PK sampling (IN SELECTED SITES ONLY) is counted for all patients to provide a conservative estimate of maximum contact days.; End of Treatment and Long-Term Follow-up visits are assumed to fall outside the 12-month window (Day 0 to Day +365) if treatment continues for 12 months, as per the protocol's average treatment duration and follow-up definitions."
38499457,Placebo + AZA,control,1,12,32,56,80,112,0,11,29,50,71,99,1,0,1,3,4,6,0,0,1,2,4,6,0,1,1,1,1,1,28,"until disease progression, relapse, or non-manageable toxicity","Screening (1 day); Cycle 1 (Day 0, 1, 2, 3, 4, 5, 6, 14, 21); Cycle 2 (Day 28, 29, 30, 31, 32, 33, 34, 49); Subsequent Odd Cycles (Day 1, 2-7, 21); Subsequent Even Cycles (Day 1, 2-7, 21). Cycle 1 Day 0, 1, 2, 3, 4, 5, 6, 14 are core_treatment. Cycle 1 Day 21 is clinic_visits. Cycle 2 Day 28, 29, 30, 31, 32, 33, 34 are core_treatment. Cycle 2 Day 49 is imaging_diagnostics. Subsequent Odd Cycles Day 1, 2-7 are core_treatment. Subsequent Odd Cycles Day 21 is labs. Subsequent Even Cycles Day 1, 2-7 are core_treatment. Subsequent Even Cycles Day 21 is imaging_diagnostics.","AZA administration schedule is 7 days (Days 1-7) per cycle, as it is the standard schedule and the 5-2-2 schedule is only 'if unable to accommodate'.; ""Day 21-26"" visits are assumed to occur on Day 21 for calculation purposes, as it is the earliest day in the specified window.; Pracinostat/placebo administration is considered an in-person contact day only on Cycle 1 Day 1, Cycle 1 Day 3, Cycle 1 Day 15, and Cycle 2 Day 1, as explicitly stated on page 15 that study personnel must administer it on these days for PK/ECG. On all other days, it is assumed to be self-administered at home and thus not a contact day.; Sub-study Pracinostat/AZA PK sampling (IN SELECTED SITES ONLY) is counted for all patients to provide a conservative estimate of maximum contact days.; End of Treatment and Long-Term Follow-up visits are assumed to fall outside the 12-month window (Day 0 to Day +365) if treatment continues for 12 months, as per the protocol's average treatment duration and follow-up definitions."
38531002,Pazopanib (Arm A),intervention,2,8,13,20,28,36,0,0,0,0,0,0,1,3,4,5,6,8,1,2,6,12,19,25,0,3,3,3,3,3,28,"13 cycles (364 days) or until progression, followed by long-term follow-up. Calculations are for the treatment period and EoT within 365 days.","Based on Table 7.1 'Clinical Parameters' with weekly BP in C1, Day 1 and Day 15 visits for subsequent cycles, and quarterly imaging/clinical tumor assessments. Screening visits occur prior to Day 0. End of Treatment visit occurs at the end of 13 cycles.","Randomization is not counted as a separate contact day; Cycle 1 Day 1 (C1D1) is the anchor (Day 0).; All procedures marked with 'X' in Table 7.1 'Clinical Parameters' are considered in-person contact days unless explicitly stated as phone/home activities.; Visits labeled 'PRN' (as needed) for INR, aPTT, Brain MRI, and Bone scan are excluded, except for initial screening Brain MRI and Bone scan which are explicitly listed as 'Prior to Randomization' assessments.; Baseline ECG, Chest CT, Abdomen/pelvic CT/MRI, Brain MRI, and Bone scan are assumed to occur on one dedicated screening day (imaging_diagnostics).; All other baseline labs (Urinalysis, CBC, Blood Chemistries, Pregnancy test, Research Blood) and clinic visits (H&P, ECOG PS, BP, Clinical Tumor Assessment) are assumed to occur on a separate screening day (labs, due to precedence).; Pill Count/Diary is considered part of a clinic visit for review.; PK blood draw on C2D1 is assumed to occur on the same day as other C2D1 assessments, with the highest priority category applied.; The 'Every 3 months' imaging/Clinical Tumor Assessment visits are considered distinct from 'Day 1' or 'Day 15' cycle visits unless they fall on the same nominal date.; The End of Treatment (EoT) visit (approx. Day 364) and the last 3-month imaging visit (approx. Day 360) are counted as separate days, as consolidation is not explicitly mandated by footnote 15.; All arms (Pazopanib and Placebo) have identical visit schedules."
38531002,Placebo (Arm B),control,2,8,13,20,28,36,0,0,0,0,0,0,1,3,4,5,6,8,1,2,6,12,19,25,0,3,3,3,3,3,28,"13 cycles (364 days) or until progression, followed by long-term follow-up. Calculations are for the treatment period and EoT within 365 days.","Based on Table 7.1 'Clinical Parameters' with weekly BP in C1, Day 1 and Day 15 visits for subsequent cycles, and quarterly imaging/clinical tumor assessments. Screening visits occur prior to Day 0. End of Treatment visit occurs at the end of 13 cycles.","Randomization is not counted as a separate contact day; Cycle 1 Day 1 (C1D1) is the anchor (Day 0).; All procedures marked with 'X' in Table 7.1 'Clinical Parameters' are considered in-person contact days unless explicitly stated as phone/home activities.; Visits labeled 'PRN' (as needed) for INR, aPTT, Brain MRI, and Bone scan are excluded, except for initial screening Brain MRI and Bone scan which are explicitly listed as 'Prior to Randomization' assessments.; Baseline ECG, Chest CT, Abdomen/pelvic CT/MRI, Brain MRI, and Bone scan are assumed to occur on one dedicated screening day (imaging_diagnostics).; All other baseline labs (Urinalysis, CBC, Blood Chemistries, Pregnancy test, Research Blood) and clinic visits (H&P, ECOG PS, BP, Clinical Tumor Assessment) are assumed to occur on a separate screening day (labs, due to precedence).; Pill Count/Diary is considered part of a clinic visit for review.; PK blood draw on C2D1 is assumed to occur on the same day as other C2D1 assessments, with the highest priority category applied.; The 'Every 3 months' imaging/Clinical Tumor Assessment visits are considered distinct from 'Day 1' or 'Day 15' cycle visits unless they fall on the same nominal date.; The End of Treatment (EoT) visit (approx. Day 364) and the last 3-month imaging visit (approx. Day 360) are counted as separate days, as consolidation is not explicitly mandated by footnote 15.; All arms (Pazopanib and Placebo) have identical visit schedules."
38552197,Atezolizumab in combination with Cabozantinib,intervention,3,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,21,until progression,Screening (3 days) followed by treatment every 21 days (Day 1 of cycle).,"Screening activities are grouped into 3 distinct in-person days: one for consent/H&P/PROs, one for all blood/urine labs, and one for imaging/diagnostic biopsy.; Optional visits (e.g., optional RBR blood samples) are excluded. Diagnostic tumor biopsy at screening is counted as an in-person day due to the 'X' in the schedule.; Treatment is assumed to continue for the full 12 months (up to Day 365) for calculation purposes, as per the 'until progression' rule. This results in 18 cycles within the 12-month window.; All Day 1 of cycle visits are considered a single contact day. Since an IV infusion (Atezolizumab) occurs on Day 1 of each cycle, these days are categorized as 'core_treatment' due to priority, subsuming any other assessments (labs, vital signs, physical exam, PROs, ECG, tumor assessments) performed on the same day.; The first dose of Cabozantinib (oral) on Day 1 of Cycle 1 is administered in the clinic on the same day as Atezolizumab infusion. Subsequent doses are self-administered at home and are not counted as contact days.; Tumor response assessments (imaging) are scheduled every 6 weeks for the first 48 weeks. These assessments fall on the same days as treatment infusions (Day 0, 42, 84, 126, 168, 210, 252, 294, 336) and therefore do not add additional contact days, with the day categorized as 'core_treatment'.; ECG assessments are performed on Day 1 of Cycles 1-5 (Day 0, 21, 42, 63, 84). These fall on core treatment days.; TSH assessments are performed on Day 1 of Cycles 1, 5, 9, 13, 17 (Day 0, 84, 168, 252, 336). These fall on core treatment days.; The '30 Days after Final Dose' post-treatment follow-up visit and any subsequent survival follow-up visits fall outside the 12-month window if treatment continues for the full 12 months, and are therefore not included in the 12-month count."
38552197,Docetaxel monotherapy,control,3,2,5,9,13,18,0,2,5,9,13,18,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,21,until progression,Screening (3 days) followed by treatment every 21 days (Day 1 of cycle).,"Screening activities are grouped into 3 distinct in-person days: one for consent/H&P/PROs, one for all blood/urine labs, and one for imaging/diagnostic biopsy.; Optional visits (e.g., optional RBR blood samples) are excluded. Diagnostic tumor biopsy at screening is counted as an in-person day due to the 'X' in the schedule.; Treatment is assumed to continue for the full 12 months (up to Day 365) for calculation purposes, as per the 'until progression' rule. This results in 18 cycles within the 12-month window.; All Day 1 of cycle visits are considered a single contact day. Since an IV infusion (Docetaxel) occurs on Day 1 of each cycle, these days are categorized as 'core_treatment' due to priority, subsuming any other assessments (labs, vital signs, physical exam, PROs, ECG, tumor assessments) performed on the same day.; Tumor response assessments (imaging) are scheduled every 6 weeks for the first 48 weeks. These assessments fall on the same days as treatment infusions (Day 0, 42, 84, 126, 168, 210, 252, 294, 336) and therefore do not add additional contact days, with the day categorized as 'core_treatment'.; ECG assessments are performed on Day 1 of Cycles 1-5 (Day 0, 21, 42, 63, 84). These fall on core treatment days.; TSH assessments are performed on Day 1 of Cycles 1, 5, 9, 13, 17 (Day 0, 84, 168, 252, 336). These fall on core treatment days.; The '30 Days after Final Dose' post-treatment follow-up visit and any subsequent survival follow-up visits fall outside the 12-month window if treatment continues for the full 12 months, and are therefore not included in the 12-month count."
38648575,Irinotecan Liposome Injection (ONIVYDE®),intervention,1,7,15,28,41,54,0,3,7,13,20,26,1,1,1,1,1,1,0,3,7,14,20,27,0,0,0,0,0,0,28,until progression,"Screening (Day -X to -1); Cycle 1: Day 0 (C1D1), Day 1 (PK), Day 7 (C1D8), Day 14 (C1D15), Day 21 (C1D22), Day 28 (C2D1), Day 35 (C1D36); Subsequent Cycles (every 28 days): Day X (C D1), Day X+14 (C D15), Day X+28 (C D29); Tumor/QoL every 6 weeks; Biobanking at 6 and 12 weeks; 30-day Follow-up (Day +30).","The 'Screening Visit' column in Table 3 represents one in-person contact day, encompassing all procedures marked with an 'X' in that column. Randomization is considered a procedure within this single screening visit day.; Treatment duration is assumed to be 'until progression' for calculation purposes, as stated in the protocol.; Cycle length for Irinotecan Liposome Injection is 28 days, with treatment administered on Day 1 and Day 15 of each cycle.; PK samples on C1D1 include a 24-hour post-infusion sample, which falls on Day 1 (Day +1 from C1D1), counted as a separate lab day.; ECG assessments beyond screening (C1D1, D8, D15) are assumed to be for Part 1 only, as per footnote 12, and thus not counted for Part 2 arms unless explicitly stated as required for Part 2.; Tumor assessments and QoL questionnaires occur every 6 weeks from C1D1. If these coincide with a treatment day, the day is categorized as 'core_treatment'. If they coincide with a lab day (e.g., C1D8, C1D22, C1D36), the day is categorized as 'imaging_diagnostics' due to precedence.; Biobanking samples are collected at 6 and 12 weeks. If these coincide with a treatment day, the day is categorized as 'core_treatment'. If they coincide with an imaging_diagnostics day, the day is categorized as 'imaging_diagnostics'. If they coincide with a labs day, the day is categorized as 'labs'.; The 30-day follow-up visit is considered an in-person contact day.; Long-term follow-up for OS is explicitly stated as potentially remote (phone, email, or clinic visit), making in-person attendance optional, so it is not counted as an in-person contact day.; COVID-19 temporary measures allowing remote or local lab alternatives are noted but the primary schedule in Table 3 is followed for mandated in-person visits, as these are not explicitly optional or non-contact in the main schedule."
38648575,IV Topotecan,control,1,9,31,55,80,109,0,6,25,45,65,90,1,0,0,0,0,0,0,3,6,10,15,19,0,0,0,0,0,0,21,until progression,"Screening (Day -X to -1); Cycle 1: Day 0-4 (C1D1-5), Day 7 (C1D8), Day 14 (C1D15); Subsequent Cycles (every 21 days): Day X (C D1-5), Day X+14 (C D15); Tumor/QoL every 6 weeks; Biobanking at 6 and 12 weeks; 30-day Follow-up (Day +30).","The 'Screening Visit' column in Table 4 represents one in-person contact day, encompassing all procedures marked with an 'X' in that column. Randomization is considered a procedure within this single screening visit day.; Treatment duration is assumed to be 'until progression' for calculation purposes, as stated in the protocol.; Cycle length for IV Topotecan is 21 days, with treatment administered on Day 1-5 of each cycle, as stated in the text (Page 11, 33). The 'Topotecan Administration (5 consecutive days)' row in Table 4, which shows 'X' for C1D1, D8, D15, D22, D29, is considered contradictory to the text and is overridden by the text's explicit '5 consecutive days, every 3 weeks'.; Tumor assessments and QoL questionnaires occur every 6 weeks from C1D1. If these coincide with a treatment day, the day is categorized as 'core_treatment'. If they coincide with a lab day (e.g., C1D8, C1D15), the day is categorized as 'imaging_diagnostics' due to precedence.; Biobanking samples are collected at 6 and 12 weeks. If these coincide with a treatment day, the day is categorized as 'core_treatment'. If they coincide with an imaging_diagnostics day, the day is categorized as 'imaging_diagnostics'. If they coincide with a labs day, the day is categorized as 'labs'.; The 30-day follow-up visit is considered an in-person contact day.; Long-term follow-up for OS is explicitly stated as potentially remote (phone, email, or clinic visit), making in-person attendance optional, so it is not counted as an in-person contact day.; COVID-19 temporary measures allowing remote or local lab alternatives are noted but the primary schedule in Table 4 is followed for mandated in-person visits, as these are not explicitly optional or non-contact in the main schedule."
38683596,Aspirin 300 mg daily x 5 years,intervention,1,0,0,1,1,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,180,5 years or until progression,"One screening visit, followed by 6-monthly visits during 5 years of treatment, and then annual follow-up visits (beyond 12 months window).","The 'Prior to Registration/Randomization' column in the Study Calendar (Page 10) represents a single in-person screening visit.; Procedures listed under 'For patients who agree to participate' at 'Baseline (After agreement to participate, prior to drug start date)' (Page 10, 12, 13) occur on the same day as the 'Prior to Registration/Randomization' visit.; Day 0 (start of treatment) involves daily oral medication taken at home, with no mandated in-person contact on Day 0 itself.; The 'Every 6 months from start of study treatment' visits occur at nominal Day 180, Day 360, Day 540, Day 720, Day 900, Day 1080, Day 1260, Day 1440, and Day 1620 relative to Day 0.; The 'At End of protocol Treatment' visit occurs at Day 1825 (5 years after Day 0).; The 'Evaluation of Disease Recurrence or new invasive disease' is considered a clinical assessment (clinic_visits) as per Section 11.1, which states PET scans may be performed at investigator discretion but do not meet criteria for recurrence determination.; Patient Medication Log return and Lifestyle/Fatigue/Uniscale assessments are considered clinic_visits.; Tissue collection (for future analysis, not for treatment delivery) is categorized as imaging_diagnostics. Blood and urine collections are categorized as labs.; The schedule is identical for both arms."
38683596,Placebo daily x 5 years,control,1,0,0,1,1,2,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,2,180,5 years or until progression,"One screening visit, followed by 6-monthly visits during 5 years of treatment, and then annual follow-up visits (beyond 12 months window).","The 'Prior to Registration/Randomization' column in the Study Calendar (Page 10) represents a single in-person screening visit.; Procedures listed under 'For patients who agree to participate' at 'Baseline (After agreement to participate, prior to drug start date)' (Page 10, 12, 13) occur on the same day as the 'Prior to Registration/Randomization' visit.; Day 0 (start of treatment) involves daily oral medication taken at home, with no mandated in-person contact on Day 0 itself.; The 'Every 6 months from start of study treatment' visits occur at nominal Day 180, Day 360, Day 540, Day 720, Day 900, Day 1080, Day 1260, Day 1440, and Day 1620 relative to Day 0.; The 'At End of protocol Treatment' visit occurs at Day 1825 (5 years after Day 0).; The 'Evaluation of Disease Recurrence or new invasive disease' is considered a clinical assessment (clinic_visits) as per Section 11.1, which states PET scans may be performed at investigator discretion but do not meet criteria for recurrence determination.; Patient Medication Log return and Lifestyle/Fatigue/Uniscale assessments are considered clinic_visits.; Tissue collection (for future analysis, not for treatment delivery) is categorized as imaging_diagnostics. Blood and urine collections are categorized as labs.; The schedule is identical for both arms."
38833658,Arm A: Lenvatinib Plus Pembrolizumab Treatment,intervention,1,4,8,14,21,28,0,3,7,13,20,27,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,28,until progression,"Screening (Day -28 to -1). Treatment cycles (28-day): C1D1, C1D8, C1D15, then D1 and D15 of subsequent cycles (C2-C26). Imaging on Screening, Day 56, 112, 168, 224, 280, 336. Pembrolizumab on D1 of odd cycles. Lenvatinib dispensing/return on D1 and D15 of every cycle.","Cycle length is 28 days for all cycles.; Treatment continues until progression, so we assume it continues for the full 12-month period for counting purposes.; Screening procedures are consolidated into 1 contact day within the screening window (Day -28 to Day -1).; The 'Telephone Contact Visit' on C1D8 is considered a non-contact day as per the rule 'NOT a contact day – Tele-visits, phone calls'. However, other procedures scheduled on C1D8 (e.g., Vital Signs) make it an in-person clinic_visits day.; For 'Pembrolizumab administration', the 'X' marks in the Schedule of Events table (D1 of odd cycles: C1, C3, C5, C7, C9, C11, C13) are followed, which results in administration every 56 days. This overrides the general 'Q6W' (every 42 days) statement in the protocol summary and drug description, and the complex note for cycles >=7, as the table provides the specific visit schedule.; Lenvatinib Dispensing and Lenvatinib Container Returned are considered in-person core_treatment days on D1 and D15 of every cycle, as indicated by 'X' marks and notes 'Dispensed every 2 weeks' and 'Container should be returned every 2 weeks'.; Archival or Newly Obtained Tissue Collection is considered an imaging_diagnostics day as it's a diagnostic biopsy for eligibility/biomarker assessment.; ePROs are considered in-person clinic_visits days as the note states 'ePROs should be performed... prior to drug administration' and 'ePRO collection is required at D1 and D15 of C1 through C3 and then D1 of C4 through C12 and then D1 of every other cycle thereafter...'.; For procedures with '#' (e.g., Directed Physical Exam, Hematology and Chemistry, Urine Dipstick on D15 every 8 weeks starting from C3), these additional D15 visits are counted as contact days."
38833658,Arm B: Regorafenib Treatment,control,1,4,8,14,21,28,0,1,1,1,1,1,1,1,2,4,7,9,0,1,4,8,12,17,0,1,1,1,1,1,28,until progression,"Screening (Day -28 to -1). Treatment cycles (28-day): C1D1, C1D8, C1D15, then D1 and D15 of subsequent cycles (C2-C26). Imaging on Screening, Day 56, 112, 168, 224, 280, 336. Regorafenib administration only on C1D1.","Cycle length is 28 days for all cycles.; Treatment continues until progression, so we assume it continues for the full 12-month period for counting purposes.; Screening procedures are consolidated into 1 contact day within the screening window (Day -28 to Day -1).; The 'Telephone Contact Visit' on C1D8 is considered a non-contact day as per the rule 'NOT a contact day – Tele-visits, phone calls'. However, other procedures scheduled on C1D8 (e.g., Vital Signs) make it an in-person clinic_visits day.; For 'Regorafenib Administration', only C1D1 is marked with an 'X' and the note states 'The C1D1 dose must be given to the participant at the site.' This implies subsequent doses are taken at home and there are no other in-person core_treatment days for Regorafenib administration/dispensing/return.; Archival or Newly Obtained Tissue Collection is considered an imaging_diagnostics day as it's a diagnostic biopsy for eligibility/biomarker assessment.; ePROs are considered in-person clinic_visits days as the note states 'ePROs should be performed... prior to drug administration' and 'ePRO collection is required at D1 and D15 of C1 through C3 and then D1 of C4 through C12 and then D1 of every other cycle thereafter...'.; For procedures with '#' (e.g., Directed Physical Exam, Hematology and Chemistry, Urine Dipstick on D15 every 8 weeks starting from C3), these additional D15 visits are counted as contact days."
38833658,Arm B: TAS-102 Treatment,control,1,3,7,13,20,27,0,3,7,13,20,27,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,28,until progression,"Screening (Day -28 to -1). Treatment cycles (28-day): D1 and D15 of every cycle (C1-C26). Imaging on Screening, Day 56, 112, 168, 224, 280, 336. TAS-102 administration/dispensing/return on D1 and D15 of every cycle.","Cycle length is 28 days for all cycles.; Treatment continues until progression, so we assume it continues for the full 12-month period for counting purposes.; Screening procedures are consolidated into 1 contact day within the screening window (Day -28 to Day -1).; The 'Telephone Contact Visit' is not marked in the table for TAS-102, so it is not counted as an in-person visit.; For 'TAS-102' administration, the 'X' marks in the Schedule of Events table (D1 and D15 of every cycle) are followed, as the note states 'The C1D1 dose must be given to the participant at the site. Participants must return to the site every 2 weeks.' This implies D1 and D15 of every cycle are in-person core_treatment days for administration/dispensing/return.; Archival or Newly Obtained Tissue Collection is considered an imaging_diagnostics day as it's a diagnostic biopsy for eligibility/biomarker assessment.; ePROs are considered in-person clinic_visits days as the note states 'ePROs should be performed... prior to drug administration' and 'ePRO collection is required at D1 and D15 of C1 through C3 and then D1 of C4 through C12 and then D1 of every other cycle thereafter...'.; For procedures with '#' (e.g., Directed Physical Exam, Hematology and Chemistry, Urine Dipstick on D15 every 8 weeks starting from C3), these additional D15 visits are counted as contact days."
38838287,Arm A: NKTR-214 + Nivolumab,intervention,1,5,8,12,16,21,0,2,4,7,9,13,1,0,1,2,4,5,0,3,3,3,3,3,0,0,0,0,0,0,42,maximum 2 years from C1D1 (Arm A); until progression (Arm B),"Screening: 1 day. On-treatment (Cycle=42 days): Cycle 1: Day 1, Day 3, Day 5, Day 8, Day 22. Subsequent Cycles: Day 1, Day 22. Additional imaging visits every 9 weeks (Day 63, 126, 189, 252, 315).","A single screening visit day is counted for all screening procedures marked with 'X' in Table 1.; Oral Hydration Follow-up (X1, X2 in Table 2) is not counted as an in-person contact day as it can be a phone call, unless other procedures mandate an in-person visit on that day.; Body Imaging and Brain Imaging (every 9 weeks) are considered separate in-person contact days, unless they coincide with a scheduled treatment visit. If they coincide, imaging_diagnostics takes precedence.; PK/Biomarker samples (Table 6) are assumed to be collected during scheduled treatment visits (Table 2) or on dedicated PK visit days (C1D3, C1D5, C1D8). They do not add new contact days beyond those specified in the SoE tables, but influence the category.; For Arm B, 'Dispense Study Drug' is considered a core_treatment activity requiring an in-person visit.; For Arm B, 'Pill Diary' review is considered a clinic_visits activity requiring an in-person visit.; Treatment is assumed to continue for the full 12-month period for calculation purposes, despite 'until progression' rule for Arm B and 'maximum 2 years' for Arm A."
38838287,Arm B: Sunitinib or Cabozantinib,control,1,3,6,10,14,19,0,2,4,7,9,13,1,0,1,2,4,5,0,0,0,0,0,0,0,1,1,1,1,1,42,maximum 2 years from C1D1 (Arm A); until progression (Arm B),"Screening: 1 day. On-treatment (Cycle=42 days): Cycle 1: Day 1, Day 8, Day 22. Subsequent Cycles: Day 1, Day 22. Additional imaging visits every 9 weeks (Day 63, 126, 189, 252, 315).","A single screening visit day is counted for all screening procedures marked with 'X' in Table 1.; Oral Hydration Follow-up (X1, X2 in Table 2) is not counted as an in-person contact day as it can be a phone call, unless other procedures mandate an in-person visit on that day.; Body Imaging and Brain Imaging (every 9 weeks) are considered separate in-person contact days, unless they coincide with a scheduled treatment visit. If they coincide, imaging_diagnostics takes precedence.; PK/Biomarker samples (Table 6) are assumed to be collected during scheduled treatment visits (Table 2) or on dedicated PK visit days (C1D3, C1D5, C1D8). They do not add new contact days beyond those specified in the SoE tables, but influence the category.; For Arm B, 'Dispense Study Drug' is considered a core_treatment activity requiring an in-person visit.; For Arm B, 'Pill Diary' review is considered a clinic_visits activity requiring an in-person visit.; Treatment is assumed to continue for the full 12-month period for calculation purposes, despite 'until progression' rule for Arm B and 'maximum 2 years' for Arm A."
38872480,Bevacizumab + Chemotherapy arm,intervention,3,4,7,11,15,20,0,2,5,9,13,18,1,0,0,0,0,0,1,0,0,0,0,0,1,2,2,2,2,2,21,"Chemotherapy (Paclitaxel/Carboplatin) for 6 cycles, Bevacizumab/Placebo for 21 cycles, or until progression/unacceptable toxicity, whichever occurs first. For calculation purposes, maximum duration is assumed.","Screening (3 days: clinic, labs, imaging). Cycle 1: Day 1 (core_treatment), Day 7 (clinic_visits), Day 14 (clinic_visits). Cycles 2-6: Day 1 of each cycle (core_treatment). Cycles 7-18 (within 365 days): Day 1 of each cycle (core_treatment).","Screening procedures are assumed to occur over 3 distinct days: one for clinic/PROs (Day -28), one for labs (Day -21), and one for imaging (Day -14).; Weekly vital signs are only counted as in-person contact days for Cycle 1 (Day 7, Day 14), as per footnote 'e' on page 51.; Radiographic disease assessments (Scans 2-7) follow the schedule described in footnote 'o' on page 52, which clarifies the 'Every 9 weeks' and 'Every 12 weeks' intervals, overriding the 'Every Other Course' checkbox in the table where there was a discrepancy. Specific imaging days are C4D1 (Day 63), C7D1 (Day 126), C8D1 (Day 147), C12D1 (Day 231), C16D1 (Day 315), C20D1 (Day 399).; All Day 1 visits for cycles involve drug administration (Paclitaxel/Carboplatin for C1-C6, Bevacizumab/Placebo for C2-C22), which is categorized as core_treatment. If other activities (imaging, labs, clinic visits) occur on the same day, core_treatment takes precedence.; PT/INR, aPTT (Xk) is assumed to be a required visit for all patients for safety monitoring before each treatment.; Audiogram (Xm) is assumed to be performed at screening and counted as an imaging_diagnostics day.; Incision checks (Xw) are not counted as universal contact days as they are conditional ('Patients with granulating incisions... require weekly wound examinations until complete closure')."
38872480,Placebo + Chemotherapy arm,control,3,4,7,11,15,20,0,2,5,9,13,18,1,0,0,0,0,0,1,0,0,0,0,0,1,2,2,2,2,2,21,"Chemotherapy (Paclitaxel/Carboplatin) for 6 cycles, Bevacizumab/Placebo for 21 cycles, or until progression/unacceptable toxicity, whichever occurs first. For calculation purposes, maximum duration is assumed.","Screening (3 days: clinic, labs, imaging). Cycle 1: Day 1 (core_treatment), Day 7 (clinic_visits), Day 14 (clinic_visits). Cycles 2-6: Day 1 of each cycle (core_treatment). Cycles 7-18 (within 365 days): Day 1 of each cycle (core_treatment).","Screening procedures are assumed to occur over 3 distinct days: one for clinic/PROs (Day -28), one for labs (Day -21), and one for imaging (Day -14).; Weekly vital signs are only counted as in-person contact days for Cycle 1 (Day 7, Day 14), as per footnote 'e' on page 51.; Radiographic disease assessments (Scans 2-7) follow the schedule described in footnote 'o' on page 52, which clarifies the 'Every 9 weeks' and 'Every 12 weeks' intervals, overriding the 'Every Other Course' checkbox in the table where there was a discrepancy. Specific imaging days are C4D1 (Day 63), C7D1 (Day 126), C8D1 (Day 147), C12D1 (Day 231), C16D1 (Day 315), C20D1 (Day 399).; All Day 1 visits for cycles involve drug administration (Paclitaxel/Carboplatin for C1-C6, Bevacizumab/Placebo for C2-C22), which is categorized as core_treatment. If other activities (imaging, labs, clinic visits) occur on the same day, core_treatment takes precedence.; PT/INR, aPTT (Xk) is assumed to be a required visit for all patients for safety monitoring before each treatment.; Audiogram (Xm) is assumed to be performed at screening and counted as an imaging_diagnostics day.; Incision checks (Xw) are not counted as universal contact days as they are conditional ('Patients with granulating incisions... require weekly wound examinations until complete closure')."
38889373,Amcenestrant (SAR439859) plus palbociclib,experimental,3,3,6,9,12,15,0,2,4,7,10,13,1,0,0,0,0,0,1,1,2,2,2,2,1,0,0,0,0,0,28,until progression,"Screening (Day -28, Day -7, Day -1). Treatment cycles (28 days): C1D1, C1D15, C2D1, C2D15, then D1 of subsequent cycles (C3D1, C4D1, etc.).","Screening period is assumed to involve 3 distinct contact days: Day -28 for initial diagnostic imaging/labs/clinic visits, Day -7 for follow-up labs, and Day -1 for randomization and final checks.; Fresh tumor biopsy at screening is assumed not to be required (conservative estimate).; DXA scan at screening is assumed to be required if not done recently.; Goserelin administration is assumed to apply to the participant for the calculation, adding a core_treatment day on D1 of each cycle.; Treatment is assumed to continue until Day +365 (12 months) for the purpose of calculating contact days within the fixed time windows, as the protocol states 'until progression' with a median duration of 33 months. Therefore, End of Treatment (EOT) and Post-Treatment Follow-up visits are not included in the 12-month window.; All 'X' marks in the Schedule of Activities (SoA) table are considered in-person contact days unless explicitly noted as optional or remote.; Drug administration (Amcenestrant, Palbociclib, Letrozole, Goserelin) is considered a core_treatment contact day only on D1 of each cycle when dispensed/administered at the clinic. Daily oral intake at home is not a contact day.; For days with multiple procedures, the tie-breaker precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to assign the day to a single primary category."
38889373,Letrozole plus palbociclib,control,3,3,6,9,12,15,0,2,4,7,10,13,1,0,0,0,0,0,1,1,2,2,2,2,1,0,0,0,0,0,28,until progression,"Screening (Day -28, Day -7, Day -1). Treatment cycles (28 days): C1D1, C1D15, C2D1, C2D15, then D1 of subsequent cycles (C3D1, C4D1, etc.).","Screening period is assumed to involve 3 distinct contact days: Day -28 for initial diagnostic imaging/labs/clinic visits, Day -7 for follow-up labs, and Day -1 for randomization and final checks.; Fresh tumor biopsy at screening is assumed not to be required (conservative estimate).; DXA scan at screening is assumed to be required if not done recently.; Goserelin administration is assumed to apply to the participant for the calculation, adding a core_treatment day on D1 of each cycle.; Treatment is assumed to continue until Day +365 (12 months) for the purpose of calculating contact days within the fixed time windows, as the protocol states 'until progression' with a median duration of 33 months. Therefore, End of Treatment (EOT) and Post-Treatment Follow-up visits are not included in the 12-month window.; All 'X' marks in the Schedule of Activities (SoA) table are considered in-person contact days unless explicitly noted as optional or remote.; Drug administration (Amcenestrant-matching placebo, Letrozole, Palbociclib, Goserelin) is considered a core_treatment day only on D1 of each cycle when dispensed/administered at the clinic. Daily oral intake at home is not a contact day.; For days with multiple procedures, the tie-breaker precedence (core_treatment > imaging_diagnostics > labs > clinic_visits) was applied to assign the day to a single primary category."
38942046,Arm A: Perioperative Nivolumab,intervention,2,3,5,9,13,15,0,2,4,7,11,11,2,0,0,1,1,2,0,1,1,1,1,2,0,0,0,0,0,0,28,"1 neoadjuvant dose + 9 adjuvant doses (9 months), followed by long-term follow-up.","Screening (2 days), C1D1 Nivolumab (Day 1), Pre-Surgery (Day 10), Surgery (Day 15), Adjuvant Nivolumab (9 doses q28 days from Day 43 to Day 267), Week 20 Assessment (Day 140), Week 40 Assessment (Day 280), Within 6 Weeks after Final Treatment (Day 300).","Randomization is Day 0.; Neoadjuvant Nivolumab (C1D1) is administered on Day 1 (anchor).; Nephrectomy is performed on Day 15 (within 7-28 days of C1D1).; The first Adjuvant Nivolumab dose is administered on Day 43 (4 weeks post-nephrectomy).; Subsequent Adjuvant Nivolumab doses are administered every 28 days.; Baseline assessments (H&P, labs, imaging, QOL, etc.) are performed on one day in the screening window.; Mandatory biopsy (if no prior biopsy) is a separate day in the screening window.; Pre-surgery labs/assessments are performed on one day prior to surgery.; Week 20, Week 40, and 'Within 6 Weeks after Final Treatment' visits are distinct assessment days, not overlapping with nivolumab administration days.; Optional visits (e.g., optional bone imaging, clinically indicated EKG) are excluded.; Telephone calls and survival follow-up are not counted as in-person contact days.; Pregnancy testing is considered an in-person lab visit when listed in the table."
38942046,Arm B: Observation,control,1,2,4,6,7,8,0,1,1,1,1,1,1,0,1,2,3,4,0,1,2,3,3,3,0,0,0,0,0,0,,"Observation after nephrectomy, followed by long-term follow-up.","Screening (1 day), Pre-Surgery (Day 25), Surgery (Day 30), Within 6 Weeks after Surgery (Day 60), Week 12 Assessment (Day 84), Week 15 Assessment (Day 105), Week 20 Assessment (Day 140), Week 30 Assessment (Day 210), Week 40 Assessment (Day 280).","Randomization is Day 0.; Nephrectomy is performed on Day 30 (within 8 weeks of randomization).; Baseline assessments (H&P, labs, imaging, QOL, etc.) are performed on one day in the screening window.; Optional visits (e.g., optional bone imaging, clinically indicated EKG, optional biopsy) are excluded.; Pre-surgery labs/assessments are performed on one day prior to surgery.; Telephone calls and survival follow-up are not counted as in-person contact days.; Pregnancy testing is considered an in-person lab visit when listed in the table.; The CT/MRI scan schedule for Arm B follows the table entries (Week 12, 20, 30, 40, 54) rather than footnote 4 on page 66, which appears to be a general guideline for follow-up imaging."
